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Abstract
Inflammatory bowel disease (IBD) is a chronic disease with unknown aetiology. The two most prevalent types
of IBD are Crohn’s disease and ulcerative colitis which, given their similarities, are often difficult to distin-
guish. Their chronic characteristics, along with a high risk of complications (including relapses, surgeries and
disabling, among others) make it essential to develop accurate prediction models. The different published stud-
ies, developed to improve the prognosis, have been struggling as they show heterogeneous results, likely the
result of using different methodologies and/or applying different criteria for patient selection and evaluation.
In addition, predicting the prognosis is a task of considerable uncertainty, so the development of predictive
models also requires research. These can be based on different factors, namely genetic, serologic, clinical and
demographical, but the latter two are probability the easiest to use since they are faster to collect. Thus, it
has become vital to identify and evaluate these clinical and demographic factors.
This work has three objectives: summarize the evidence regarding IBD outcomes and risk factors, identify
and assess risk factors for identified outcomes, and develop and validate prognostic models for those outcomes,
based on the identified factors.
In order to identify factors associated with the prognosis, systematic reviews and meta-analysis for Crohn’s
disease and ulcerative colitis were developed. Factors such as young age at diagnosis, perianal disease, initial
use of steroids for the first flare and ileocolic disease location were identified as independent factors for dis-
abling disease in Crohn’s patients. Concerning ulcerative colitis, male gender, non-smoking habits, extensive
disease, need for corticosteroids and hospitalization were associated with colectomy. In order to identify and
assess risk factors for outcomes of Crohn’s disease, an observational study, using an independent cohort of
patients, was conducted. We have studied the impact of demographical and clinical factors (such as the
timing of therapeutics strategies) on disabling disease and reoperation. Early surgery or immunosuppression
seem to not prevent global disabling disease, but an early start of immunosuppression by itself is associated
with fewer surgeries and should be considered in daily practice as a preventive strategy. Nonetheless, within
surgical patients, an early surgery (within six months after diagnosis) can prevent disabling events, and the
introduction of immunosuppressive medication more than one month after the initial surgery seems to increase
the likelihood of needing further surgeries. The third objective of this thesis is to develop and validate prog-
nostic models for the identified outcomes. Two main paths of work have been followed for modelling predictive
classifiers, one based on Bayesian networks and the other on decision trees. Bayesian network models achieved
high area under the curve (AUC) for disabling disease and reoperation, and were included in an online tool,
allowing the application of the classifier at bedside. Risk matrices - based on age at diagnosis, perianal disease,
disease aggressiveness and early therapeutic decisions - exhibited also good performance for the most impor-
tant prognostic criteria: high positive post-test odds for disabling disease and low negative post-test odds for
reoperation. The risk matrices seem also easily applicable as bedside clinical tools that can help physicians
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during therapeutic decisions in early disease management. In the second path, decision trees were able to
predict disabling, surgery and reoperation with high AUC, and were shown to be a valid and useful approach
to depict outcome risks. The defined cut-off risk levels expressed high odds for a positive test for disabling,
while excluding surgery and reoperation with low odds for a negative test.
In conclusion, clinical and demographical factors should be used more frequently in the prognosis of IBD
as they are easier to collect than serologic or genetic ones. Factors such as age at diagnosis, behavior, perianal
disease, and location are important predictors for negative outcomes and should, as soon as possible, be known.
Concerning interventions, immunosuppression, as the first therapy after diagnosis, is effective in preventing
future surgeries, being its efficiency higher upon an early start. On the other hand, patients undergoing an
early surgery after diagnosis have an increased tendency to be re-operated, even with a concomitantly early
start of immunosuppression therapy. Given this, predictive models for CD prognosis could enhance the initial
approach and, therefore, improve the clinical outcome.
Resumo
A doenc¸a inflamato´ria intestinal (DII) e´ uma doenc¸a cro´nica e com etiologia desconhecida. As duas formas
mais prevalentes de DII sa˜o a doenc¸a de Crohn e a colite ulcerosa que, dadas as suas semelhanc¸as, sa˜o muitas
vezes dif´ıceis de distinguir. As suas caracter´ısticas cro´nicas, acumuladas com um grande risco de complicac¸o˜es
(nomeadamente recidivas, cirurgias e doenc¸a incapacitante, entre outras), tornam imprescind´ıvel o desen-
volvimento de modelos de progno´stico. Os estudos desenvolvidos no intuito de melhorar esse progno´stico
teˆm apresentado resultados muito d´ıspares, fruto provavevelmente da utilizac¸a˜o de diferentes metodologias e
crite´rios de selec¸a˜o e avaliac¸a˜o utilizados. Para ale´m disso, a previsa˜o do progno´stico reveste-se de elevada
incerteza, pelo que o desenvolvimento de modelos preditivos requer tambe´m uma investigac¸a˜o mais aprofun-
dada. Os modelos podem ser baseados em diferentes fatores, nomeadamente gene´ticos, serolo´gicos, cl´ınicos e
demogra´ficos, sendo estes u´ltimos mais fa´ceis de usar, uma vez que sa˜o mais facilmente recolhidos tornando-se
assim vital a sua identificac¸a˜o e utilizac¸a˜o mais frequente.
Este trabalho tem treˆs objetivos: o primeiro, resumir a evideˆncia no que diz respeito aos factores de risco
na DII, identificar e avaliar fatores de risco para diferentes outcomes, e desenvolver e validar modelos de
progno´sticos para os outcomes utilizados, com base nos fatores identificados.
Com o objectivo de identificar os fatores associados ao progno´stico, foram realizadas duas reviso˜es sis-
tema´ticas e meta-ana´lise para a doenc¸a de Crohn e colite ulcerosa. Fatores como idade ao diagno´stico menor
que 40 anos, doenc¸a perianal, uso inicial de corticostero´ides durante a primeira reca´ıda e doenc¸a ileoco´lica
foram identificados como fatores de risco independentes para a doenc¸a incapacitante nos pacientes com
doenc¸a Crohn. No que diz respeito a` colite ulcerosa, foram associados com a colectomia o sexo masculino,
na˜o-fumadores, doenc¸a extensa, necessidade de corticostero´ides e de hospitalizac¸a˜o . A fim de identificar e
avaliar os fatores de risco na doenc¸a de Crohn, foi realizado um estudo observacional, utilizando uma coorte
independente de pacientes, foi realizado. Foi tambe´m estudado o impacto de fatores demogra´ficos e cl´ınicos
(como o tempo de introduc¸a˜o de terapeˆuticas farmacolo´gicas) na doenc¸a incapacitante e na reoperac¸a˜o. A
cirurgia precoce ou imunossupressa˜o parece na˜o prevenir a doenc¸a incapacitante, mas um in´ıcio precoce da
imunossupressa˜o, por si so´, esta´ associado a menos cirurgias e devera´ ser considerado na pra´tica dia´ria como
uma estrate´gia preventiva. No entanto, em pacientes ciru´rgicos, uma cirurgia precoce (nos primeiros seis
meses apo´s o diagno´stico) pode prevenir a doenc¸a incapacitante. Por outro lado a introduc¸a˜o de imunos-
supressores um meˆs apo´s a cirurgia inicial parece aumentar o risco de reoperac¸a˜o. O terceiro objetivo desta
tese e´ desenvolver e validar modelos de progno´stico para os outcomes identificados. Foram efetuadas duas
abordagens na modelac¸a˜o: uma baseada em redes Bayesianas e a outra em a´rvores de decisa˜o. Os modelos
baseados nas redes Bayesianas apresentaram AUC elevadas tanto para a doenc¸a incapacitante como para a re-
operac¸a˜o, tendo sido inclu´ıdos numa ferramenta online, que permite a aplicac¸a˜o diretamente na pra´tica cl´ınica.
As matrizes de risco - com base na idade ao diagno´stico, a doenc¸a perianal, comportamento da doenc¸a e as
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deciso˜es terapeˆuticas precoces - exibiram tambe´m um bom desempenho para os crite´rios de progno´stico mais
importantes: elevados odds po´s-teste positivos para a doenc¸a incapacitante e baixos odds po´s-teste negativos
para a reoperac¸a˜o. As matrizes de risco podem ser facilmente aplica´veis como ferramentas cl´ınicas podendo
ajudar os cl´ınicos durante as deciso˜es terapeˆuticas com efeitos no percurso da doenc¸a. Na segunda abordagem,
as a´rvores de decisa˜o foram, tambe´m, capazes de prever doenc¸a incapacitante, a cirurgia e reoperac¸a˜o com
valores altos de AUC, tendo sido mostrado que as a´rvores de decisa˜o sa˜o uma abordagem va´lida e u´til. Mais
uma vez, para a doenc¸a incapacitante foram obtidos valores altos de odds po´s-teste positivos e valores baixos
de odds po´s-teste negativos para a cirurgia e reoperac¸a˜o.
Em conclusa˜o, fatores cl´ınicos e demogra´ficos devem ao ser usados com mais frequeˆncia no progno´stico da
DII, uma vez que sa˜o mais fa´ceis e baratos de recolher do que os serolo´gicos ou gene´ticos. Fatores como idade
ao diagno´stico, comportamento da doenc¸a, doenc¸a perianal, e localizac¸a˜o da doenc¸a sa˜o importantes preditores
de maus outcomes e devem, logo que poss´ıvel, ser conhecidos. No que diz respeito a intervenc¸o˜es precoces, a
imunossupressa˜o, como primeira abordagem da doenc¸a, e´ eficaz na prevenc¸a˜o de futuras cirurgias. Por outro
lado, os pacientes submetidos a uma cirurgia precoce teˆm uma maior tendeˆncia para serem reoperados, mesmo
com um in´ıcio precoce da imunossupressa˜o. Perante isto, modelos preditivos para o progno´stico na doenc¸a de
Crohn poderiam reforc¸ar a abordagem inicial a` doenc¸a e, consequentemente, melhorar o seu resultado cl´ınico.
1. Outline

1. Outline
Although based on several different studies, this thesis conveys a consolidated message which is organized
into several chapters.
Chapter 2 presents an introduction on inflammatory bowel disease (IBD) and clinical decision support.
Also presented are the main statistical concepts of Bayesian networks, decision trees, and different valida-
tion methodologies.
Chapter 3 synthetizes the aim and specific objectives of this thesis.
Chapters 4, 5 and 6 present the main results of the different studies developed to achieved the three main
objectives of the thesis.
Chapter 4 presents a synthesis of the main evidence, published in the literature, regarding outcomes and
risk factors for Crohn’s disease and ulcerative colitis.
Chapter 5 presents original cohort studies developed to identify and assess risk factors for Crohn’s disease.
Chapter 6 presents the development and validation of predictive models for Crohn’s disease prognosis, taking
into account the outcomes defined in Chapter 4 and some of the risk factors found in Chapter 5.
Chapter 7 presents a brief discussion and some recommendations for the future of Crohns disease prog-
nosis.
Appendix A and B include preliminary papers presented at two editions of an international symposium
on computer-based medical systems, where the Bayesian network prognostic models were first studied and
discussed.
Appendix C presents a screenshot and example of use of the online tool developed to allow the applica-
tion of the Bayesian network classifier at bedside.
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2.1 Inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic disease which involves all or part of the digestive tract. The
most frequent diseases are Crohn’s disease (CD) and ulcerative colitis (UC) [Devlin and Panaccione, 2010].
Ulcerative colitis might affect only the large intestine and can be classified according to its location and severity.
The extent of the disease can be classified according to the Montreal classification [Dignass et al., 2012] into
three categories presented in Table 2.1.
Table 2.1: Classification of Montreal - Extent of ulcerative colitis.
Extent Description
E1: Ulcerative proctitis involvement limited to the rectum
(that is, proximal extent of inflammation is
distal to the rectosigmoid junction)
E2: Left side UC (distal UC) involvement limited to a proportion
of the colorectum distal to the splenic flexure
E3: Extensive UC (pancolitis) involvement extends proximal to splenic flexure
Concerning severity, and using the Montreal classification [Satsangi et al., 2006], patients can be classified
into five categories presented in Table 2.2.
Crohn’s disease might affect both the large and the small intestine, being a transmural disease, afecting
not only the mucosa but also the deeper layers [Latella et al., 2009, Devlin and Panaccione, 2010], being the
ileum and colon the most commonly affected areas. The disease can also be classified according to location,
behavior and age at diagnosis according to the Montreal classification [Dignass et al., 2010] as presented in
Table 2.3.
The symptoms of the disease can be mild or severe depending of the severity of the disease. The main
symptoms include diarrhoea, fever and fatigue, abdominal pain, blood in stool, reduction of appetite and conse-
quently weight loss. These symptoms are common in the two inflammatory bowel diseases and, because of that,
many times the differential diagnosis is very difficult to establish [Latella et al., 2009, Cosnes et al., 2002]. The
diagnosis is made based on blood tests, endoscopic procedures (colonoscopy, sigmoidoscopy, upper endoscopy,
capsule endoscopy or double-balloon endoscopy) and imaging procedures (x-ray, computerized tomography
scan or magnetic resonance imaging).
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Table 2.2: Classification of Montreal - Severity of ulcerative colitis.
Severity Description
S0: Clinical remission Asymptomatic
S1: Mild UC Passage of 4 fewer stools/day (with or without blood),
absence of any systemic illness, and
normal inflammatory markers (ESR)
S2: Moderate UC Passage of more than 4 stools per day
but with minimal signs of systemic toxicity
S3: Severe UC Passage of least 6 blood stools/day
Pulse rate of at least 90 beats/min
Temperature of at least 37.5
Haemoglobin of least 10.5g/100ml
ESR of at less than 30 mm/h
Table 2.3: Montreal classification for Crohn’s disease
Age at diagnosis
A1 <=16 years
A2 17-40 years
A3 >40 years
Location
L1 Ileal
L2 Colonic
L3 Ileocolonic
L4
Behavior
B1 Non-Stricturing/penetrating
B2 Stricturing
B3 Penetrating
p Perianal disease2
1 L4 is a modifier that can be added to L1-L3
when concomitant upper gastrointestinal disease is present.
2 ”p” is added to B1-B3 when concomitant perianal disease is present.
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The cause of IBD remains unknown but some hypotheses were already raised: heredity - patients having
relatives with the disease have a higher probability of developing the disease - and immune system malfunction.
It is also believed that the interaction between genetic and environment factors may play a role in the aetiology
of the disease. Factors such as stress and diet were considered possible causes for the disease but, in current
days, as far as knowledge has advanced, it is known that these factors aggravate the disease but do not cause
it [Latella et al., 2009, Cosnes et al., 2002]. Nonetheless, some factors have already being identified as risk
factors for developing IBD [Cosnes et al., 2011] - Table 2.4.
Table 2.4: Risk factors for developing IBD
Factors Highest risk
Age Before 30 years old
Ethnicity White race
Family history Relatives with disease
Smoking habits Cigarette smoking
Nonsteroidal anti-inflammatory medications Increase the risk of disease or
worse the disease
Place you live Patient in urban area or
industrialized country
IBD is a long course disease and can occur at any time of life, but about 80% of the diagnoses are
made during the second and third decade of life [Vatn, 2009, Cosnes et al., 2011]. The clinical course is
characterized by intermittent recurrences, and approximately 50% of patients have a mild course of the
disease with a low prevalence of hospitalizations and other complications. The remaining patients have a
more aggressive course and could require a more aggressive intervention, namely surgery [Cosnes et al., 2002,
Vatn, 2009]. Being a chronic disease - for which medical, therapeutically and surgical therapies are not
curative - patients need medical appoitments and may require hospital admission frequently. These factors
create uncertainty about the future of patients with reflection in family relationship, professional and social
life [Fauci et al., 2009, Baumgart and Sandborn, 2007]. The classical approach for IBD was to control the
symptoms and only recently the target changed into an increase of the quality of life, reducing hospitalizations
and surgeries so as to minimize the effects of the disease on daily activity, working capacity and the course
of the disease [Devlin and Panaccione, 2010]. The course of the disease has become of particular importance
since medical therapeutics can change the history of the disease, in particular with the introduction of biological
therapy [Vermeire et al., 2007, Van Assche et al., 2010, Cosnes, 2009]. This way, identifying good prognostic
models based on genetic/serological or clinical/demographic factors has been the focus of recent literature.
However, the latter option seems more appealing since they are probability easier and faster to use since the
data can be collected during daily clinical practice [Louis et al., 2010].
2.1.1 IBD in Portugal
In Portugal, only in the 80’s were the first studies on the prevalence of CD made. Tavarela Veloso et al.
presented in 1989 the first study for CD, with a cohort of patients between 1975 and 1988. This study was
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based on clinical, radiological, endoscopical and histological data collected in several hospitals, presenting
a prevalence of CD of 9.9 patients / 100000 inhabitants [Tavarela Veloso and Carvalho, 1989]. Some years
later, Shivananda et al. developed an European multicentric prospective study, between 1991 and 1993, which
included results for Portugal where the incidence rate ranged between 4.4 patients / 100000 inhabitant-years
(in Braga) and 2.6 patients / 100000 inhabitant-years (in Almada), in the only two regions included in the
study due to the nature of the study [Shivananda et al., 1996]. In 2009, Magro et al. developed a cross-
sectional study to apply Montreal Classification to a large cohort of Portuguese patients with 5 or more years
of the disease. In this work, it was possible to characterize patients from Portugal: 44% male, most of
the patients between 17 and 40 years-old at diagnosis and with a median of 10 years (IQR 7-16) with the
disease. Around 60% of the patients had a B1 phenotype in the first year and 34% presented ileal disease.
Concernig severity, a minority if patients (less than 10%) did not receive steroids, immunossuppresants or
were submitted to abdominal surgery.Twenty-seven percent of patients became steroid-dependent and 49%
of then required immunosuppressants with or without biologic treatment [Magro et al., 2009]. In 2010, a
pharmaco-epidemiological study approach to estimate the prevalence of the disease was published, where data
from anti-inflammatory drugs consumption between 2003 and 2007 was used. The prevalence of CD increased
from 42 (in 2003) to 71 patients / 100000 inhabitants (in 2007). Prevalence was always higher in women than
men while, concerning age, the prevalence was higher in the 17-39 stratum (121 patients/100000 inhabitants)
[Azevedo et al., 2010]. In 2014, the ECCO-EpiCom group conducted a new study where the incidence of the
disease was shown to increase since the study of Shivananda, reaching an incidence rate of 7.0 patients /
100000 inhabitant-years, in the Vale do Sousa hospital [Burisch et al., 2014].
For ulcerative colitis (UC), the first study for an estimate of the prevalence of the disease was also
made by Tavarela Veloso in 1995, a retrospective study which also included patients between 1975 and
1988 [Tavarela Veloso, 1995]. The estimated prevalence was 13.6 patients / 100000 inhabitants. Portuguese
hospitals also collaborated with the EC-IBD study developed by Shivananda et al. with only two centers:
one in the north of Portugal (Porto and Braga) and the other in the south (Lisboa and Almada). The in-
cidence ranged between 1.7 and 5.5 patients / 100000 inhabitant-years, for south and north, respectively
[Shivananda et al., 1996]. In 2009, Portela et al. developed a cross-sectional study to apply Montreal Classi-
fication in a large group of patients . Portuguese patients were more male (44%), with more left side colitis
(52%), a median age at diagnosis was 38 years-old (±15) and with a median of 8(±8) years with the disease.
The main complaints were rectal bleeding, diarrhea and abdominal pain. Sevem percent had family history
of IBD and 8% were active smokers, 16% former smokers and 76% never smoked. Salicylates were used in
almost 98% of the patients and in 38% were the only drug used in treatment. Sixty percent had taken steroids
at least once, 14% immunosuppressors and 1% biologic agents. Concernig surgery arroud 5% of patietns were
submitted to surgery mostly due to an acute severe flare or chronic relapsing disease [Portela et al., 2010]. In
order to better estimate the prevalence of UC, the 2010 pharmaco-epidemiological study , using data from
anti-inflammatory drugs consumption between 2003 and 2007, estimated an increase in UC prevalence from 43
to 73 patients / 100000 inhabitants. Prevalence was also always higher in women than men while, concerning
age, the prevalence was higher for the 40-64 stratum (99 patients / 100000 inhabitants) [Azevedo et al., 2010].
In 2014, the ECCO-EpiCom group study presented an incidence of UC of 3.9 patients / 100000 inhabitant-
years [Burisch et al., 2014].
A national study on the prevalence and incidence of both ulcerative colitis and Crohns disease is required,
to better assess the need and impact of different early approaches, prognostic models, and patient follow-up
at a national level.
10
2.2. CLINICAL DECISION
2.2 Clinical decision
A clinical decision tool, as defined by Wyatt and Liu [Wyatt and Liu, 2002], is: ”any type of mechanical, paper,
or electronic aid that collects or processes data from an individual patient and generates a specific output that
aids clinical decision”. In this way, clinical decision tools are a kind of clinical decision support developed for a
healthcare professional involved in patient care [Teich et al., 2005]. The definition of clinical decision support
tools is nowadays a very important topic as they provide help in the diagnosis, prognosis or even treatment
decisions [Lucas et al., 2004]. The interaction with the user can be classified according to three categories -
presented in Table 2.5 - and different users also imply different usage risks - Table 2.6 [Musen et al., 2006].
Table 2.5: Classification of clinical decision support according interaction
Level
Passive help in decision making but without recommendation
or suggestions
Active with suggestions and/or explicit actions
Cooperative allowing the user to modify or redefine the recommendation
or decision
Table 2.6: Classification of different usage risk for clinical decision support
Level
Low if the user is a health care professional, hence providing
knowledgeable control
High if the user is a patient or the general public
Very high if no human user is in control
In clinical decision it is absolutely necessary the use of all available evidence, which includes the physicians´
personal experience, the aggregate evidence included in quality clinical research and, not less important, the
values, needs and expectations of each patient [Sackett et al., 1996]. But all these data and information come
with uncertainty: uncertainty in the observed patients (information collected from a sample), uncertainty in
collected data (precision or random error, and validity or systematic errors), uncertainty in the applied meth-
ods (data processing and data analysis, confounding bias), uncertainty in the chosen knowledge representation
(level of abstraction), uncertainty in the generalization procedure (from a model to each patient) and, finally,
uncertainty in the actual decision applied to the patient. But in what way can we help the decision making?
The crucial step is formalizing the uncertainly in order to reduce it [Rodrigues, 2016]. Therefore, it is necessary
to use robust methods which can comply with this concept.
Traditionally, in prognostic or diagnostic models, support systems are based in logistic or linear regression
[Campbel, 2001, Lucas, 2004]. These techniques have the advantage of being easily interpretable from the
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clinical point of view, having nonetheless a poor graphical representation. The nature of biomedical data
requires the application of techniques that go beyond traditional biostatistics [Lucas, 2004] , such as Bayesian
networks (which allow the computation of posterior probabilities) [Darwiche, 2010] or decision trees (whose
estimates are computed strictly from the proportions in the sample) [Breiman et al., 1984]. Both techniques
have an intuitive graphical representation for the user without losing the necessary formalism to clinical rea-
soning.
For learning these methods it is important to follow several steps, which include selection of relevant
variables, identification of variables interaction, validation of the model and sensitivity analysis. In each of
them it is necessary to take into account the knowledge of experts, the evidence in the literature and not least
important the patient data [Lucas et al., 2004, Lucas, 2004].
2.2.1 Bayesian network
Contrary to the common frequentist statistical inference, which gives us confidence intervals and hypothesis
testing theory, Bayesian statistical approaches compute the probability that the hypothesis is true, updating
the prior probability about the hypothesis with the new incoming available data [Petrie and Sabin, 2009]. In
medical diagnosis problems, it is common to calculate estimates such as prevalence (prev) of the disease (prior
probability) and sensitivity (sens) or specificity (spec) of a diagnostic test, equivalent to the conditional proba-
bility of positive/negative test given the presence/absence of disease - e.g sens = p(+|D) = P (+,D)/P (D).
But in daily routine what is important to be calculated is the probability of having a disease given a posi-
tive/negative test. This value is the positive/negative predictive value (posterior probability) and can be easily
calculated using Bayes theorem:
p(D|+) = p(+,D) ∗ p(D)
p(+)
(2.1)
with
p(+) = p(+|D) ∗ p(D) + p(+| ∼ D) ∗ p(∼ D) (2.2)
where D is the disease outcome and + is the observation of a positive test. Given the usual information
available for the diagnostic test and the disease, this equation could be re-written as:
p(D|+) = sens ∗ prev
sens ∗ prev + (1− spec) ∗ (1− prev) (2.3)
For example, considering a disease with a prevalence of 1%, and a test with 99% sensitivity and 60% specificity,
the question is what is the probability of having the disease given a positive test? If we apply the previously
presented Bayes theorem to calculate p(D|+), i.e. the positive predictive value, we obtain the following
posterior probability:
p(D|+) = 0.001 ∗ 0.99
0.001 ∗ 0.99 + 0.99 ∗ 0.40 = 0.02 (2.4)
showing that the probability of disease has increased to 2% after the observation of a positive test. Graphically,
this association can be visualized as a directed graph, as depicted in Figure 2.1.
But, usually, a disease does not have only one symptom or observable expression. So it is necessary to
develop models which allow the presence of many characteristics that could explain the outcome. If we have
a patient with two tests (symptoms) and we want to compute the updated posterior probability of having a
disease, the graphical model needs to be extended as in Figure 2.2.
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Figure 2.1: Graphical probabilistic model for representation of a diagnostic test
Using the same factorization as before the p(D,+1,+2) is calculated as follows:
p(D|+1,+2) = p(D,+1,+2)p(+1,+2)
= p(+1|D)∗p(+2 |D)∗p(D)p(+1|D)∗p(+2 |D)∗p(D)+p(+1|∼D)∗p(+2 |∼D)∗p(∼D) (2.5)
Again this equation could be re written using the measures calculated for both tests and the information
about the prevalence of the disease:
p(D|+1,+2) = sens1 ∗ sens2 ∗ prev
sens1 ∗ sens2 ∗ prev + (1− spec1) ∗ (1− spec2) ∗ (1− prev) (2.6)
With more than two tests (variables) the problem becomes more complex and requires robust algorithms to
deal with all the involved data, but the formalism lingers.
Figure 2.2: Graphical probabilistic model for representation of two diagnostic tests
Given its graphical representation and statistical foundations, this modelling is known as Bayesian net-
works [Darwiche, 2010]. Generically, a Bayesian network represents a joint distribution of a set of variables,
specifying the independence assumption between each pair of variables. This dependence is representing by
a direct acyclic graph, where each variable is represented by a node. An arc in the network shows that the
descendant variable is conditionally dependent of the ascendant node [Mitchell, 1997]. This representation
of knowledge includes two distinct models: a qualitative model, which represents the relationships among
variables, and a quantitative model, the joint probability distribution represented by the conditional proba-
bilities (further explained). The simpler Bayesian network is the nave Bayes (NB) - Figure 2.3. This model
assumes that all variables are independent among themselves, and conditionally independent given the out-
come [Domingos and Pazzani, 1997].
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Figure 2.3: Qualitative model for Na¨ıve Bayes
In order to give expression to the relations among variables it is important to define the quantitative model,
i.e. the joint probability of the variables which can be computed using the following equation:
p(V1, ...Vn) =
n∏
i=1
p(Vi|Pai) (2.7)
where V1, ..., Vn are a set of variables and Pairepresents the set of ascendant nodes of i. For simple
networks, this joint probability is easily computed. For the example in Figure 2.3 the joint probability for the
outcome y is given by:
p(Y,A,B,CD) = p(Y ) ∗ p(A|Y ) ∗ p(B|Y ) ∗ p(C|Y ) ∗ p(D|Y ) (2.8)
But in real world variables are not independent, rather related among them. To allow such interaction, Fried-
man et al. [Friedman et al., 1997] developed an adaptation of nave Bayes: the Tree Augmented Nave Bayes
(TAN), an example of which is represented in Figure 2.4. The TAN classifier model includes two assumptions:
1) all explanatory variables are conditioned by the outcome, i.e. all will directly influence the outcome during
inference; and 2) an optional additional dependence is allowed for each variable, i.e. each variables effect
might be adjusted by one additional covariable [Huang et al., 2002]. From those, the method allows learning
the network structure from the data [Lucas, 2004, Mitchell, 1997] aiming at finding the structure that best
fits the available data and which may provide the best classifier for the designated outcome.
For this example, the joint probability has now the following formulation:
p(Y,A,B,C,D) = p(Y ) ∗ p(A|Y ) ∗ p(B|Y ) ∗ p(C|Y ) ∗ p(D|Y,C) (2.9)
Figure 2.4: Qualitative model of a TAN Classifier
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Several different topologies and learning algorithms exist, but the TAN has given solid evidence of provid-
ing sound classifiers [Dias et al., 2014, Sakellaropoulos and Nikiforidis, 2000] and knowledge representations
in clinical settings.
Bayesian approaches have an extreme importance in clinical problems, since they provide a qualitative
and quantitative perspective. Additionally, they take into account prior knowledge, making data analysis an
update processing of prior knowledge with observed evidence [Lucas, 2004], making it a very useful tool in the
practice of evidence-based medicine.
2.2.2 Decision tree
A decision tree is a formal knowledge model which uses a divide-and-conquer strategy to solve decision prob-
lems. A complex problem is divided in simpler problems to which the same strategy is applied, recursively.
The solution of sub-problems can afterwards be combined, in the form of a tree, to produce the solution of the
original problem. One advantage of this approach relates with its capacity to divide the instance space into
disjoint subspaces, possibly adjusting different models to each subspace. As other knowledge models, decision
trees are commonly handcrafted by experts. But this idea of defining subspaces allows the rising of automatic
methods to induce the trees from data, and is the basis of all algorithms behind decision tree induction, such
as: ID3 [Quinlan, 1986], which can use the entropy or the information gain to choose the best variable to be
selected at each node; CART [Breiman et al., 1984], which uses the entropy (a negative sum of logarithmic
proportions) to choose the best variable to be selected at each node; or CHAID [Kass, 1980], which uses a
chi-squared test, with Bonferroni correction, instead.
Formally, a decision tree is a direct acyclic graph where each node has exactly one ascendant, wherein each
node could be a splitting node or a leaf node (an example is presented in figure 2.5). In splitting nodes, a
conditional test is applied based on the values of a single variable (selected for this node). In leaf nodes, the
outcome variable within the instance subspace, defined by ascendant splits, is inspected to form a decision
(usually, the majority class within the corresponding subspace is used as predicted class).
Figure 2.5: Decision tree example (adapted from [Gama et al., 2012])
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Figure 2.5 represents an example of a decision tree and the correspondent split in the space of variables
x1 and x2. Each node of the tree corresponds to a subspace defined by the variables. The areas defined by
the leaves of the tree are mutually exclusive and the union of these areas is the entire instance space. This
way defined, each path traversing the tree defines a decision rule (e.g. if x1 < a1 <x1 and then C1).
2.2.3 Methods of validation
After the development of any model, it is necessary to estimate the performance of the model. In fact, the
generalising ability of the model is related to its capacity to predict cases on an independent sample of new
data [Hastie et al., 2001]. Therefore, the aim of this approach is to estimate the validity of the model by
assessing the expected error associated to it. There are many methods to estimate this validity, as presented
as follows:
Independent external sample to use an independently collected sample of data and compute the predictive
error in it;
Holdout to divide the data into two samples: one used for building the model and the other to compute the
predictive error;
Cross-validation to divide the sample into k exclusive sets of equal size (folds) and assess validity in k models,
each built with k-1 folds and tested in the remaining fold, with the error estimated as the mean of all k
error estimates - this is usually repeated several times to improve the precision of the error estimates;
Leave-one-out a special case of cross-validation, where k=n, with n being the number of cases in the sample.
In classification problems, the most common procedure to validate the models is the confusion matrix
which allows the comparison between the result of the model (prediction) and the real result - Table 2.7. This
matrix allows also the computation of many other measures, commonly used in diagnostic studies - Table 2.8.
Table 2.7: Diagnostic testing confusion matrix
Real
Positive Negative Total
Result of test
Positive TP FP TP+FP
Negative FN TN FN+TN
Total TP+FN FP+TN n
TP: True positive, TN: True negative,
FP: False positive, FN: false negative
Many classifiers (likewise, diagnostic tests) provide a continuous result rather than a class outcome. For
these, if no cut-off is previously defined (which can translate a continuous value into a class outcome), another
way to evaluate classifiers is to construct and analyse a receiver operating characteristics curve (ROC), which
assesses the discriminative power of the models. This curve allows the visualization of the relation between
sensitivity and specificity of the model, for each possible cut-off value, enabling either the selection of an op-
timal (according to the study aims, as described further down) cut-off point or the evaluation of the classifier
as a whole - Figure 2.6. Having into account the expected prevalence of the outcome and the impact of a
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Table 2.8: Descriptions of measures which can be calculated from the confusion matrix (using the diagnostic
testing metaphor)
Measure Acronym Description Formula
Pre-test probability pretest Prevalence TP/n
Pre-test odds pretest odds pretest/(1− pretest)
Accuracy acc Proportion of cases (TP + TN)/n
correctly classified
Sensitivity sens Proportion of patients
with the disease TP/(TP + FN)
who had a positive test
Specificity spec Proportion of patients
without the disease TN/(TN + FP )
who had a negative test
Positive PPV Proportion of patients
predictive value with positive test TP/(TP + FP )
who actually have the disease
Negative NPV Proportion of patients
predictive value with negative test TN/(TN + FN)
who actually
do not have the disease
Positive LR+ Ratio between the probability
likelihood ratio that a test is positive
in disease patients sens/(1− spec)
and the probability
that test is positive
in non-disease patients
Negative LR- Ratio between the probability
likelihood ratio that a test is negative
in disease patients (1− sens)/spec
and the probability
that test is negative
in non-disease patients
Positive Odds of disease after pretest odds ∗ LR+
post-test odds a positive test
Negative Odds of disease after pretest odds ∗ LR−
post-test odds a negative test
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positive/negative prediction, the cut-off can be chosen following either a rule-in approach (aiming at a high
positive predictive value) or a rule-out approach (aiming at a high negative predictive value) instead of the
balanced approach where both sensitivity and specificity are optimized together.
Figure 2.6: Examples of ROC curves of different quality models.
Associated with this representation is the computation of the Area Under the Curve (AUC). This metric
varies between 0 and 1 and can be interpreted as the probability that the model would rank a randomly chosen
positive case higher than one other randomly chosen negative case.
2.2.4 From modeling to bedside
The application of classifiers to actual patients creates the need to translate the resulting probabilities of the
outcome into an actionable decision. Therefore, the visualization of modeling results is of major importance
to enable their use at bedside; possible means include:
• The classifier result (either a continuous value, such as a probability, or a class outcome) can be directly
shown to the human and interpreted as extra evidence to be combined with other sources of evidence
for the actual patient;
• Graphical models (such as Bayesian networks and decision trees) allow a deeper understanding of the
relations among factors and can even allow a cooperative interaction with the human (e.g. to assess the
impact of different observed signs or symptoms in the classifiers result);
• By defining risk matrices, which create subgroups of patients with similar characteristics (usually based
upon 2 to 4 variables) for which risk estimates are presented; the human user can then easily allocate
the patient to one of the subgroups and use the aggregated risk estimate as evidence in their decision
making process. In order to choose which variables should define the subgroups in a risk matrix, different
methods can be used to assess factor relevance, or they can be chosen by clinical relevance.
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3. Objectives
This thesis has three main goals:
Goal 1: Evidence (Chapter 4)
The first aim of this thesis is to summarize the evidence regarding Crohn’s disease and ulcerative
colitis outcomes and corresponding associated factors, limited to clinical and demographical data.
Goal 2: Classification (Chapter 5)
The second aim of this thesis is to identify and assess risk factors for outcomes identified in Goal
1 for Crohn’s disease, using an independent cohort of patients.
Goal 3: Prediction (Chapter 6)
The third aim of this thesis is to develop and validate prognostic models for outcomes identified
in Goal 1, with risk factors isolated in Goals 1 and 2.
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4. Evidence
The first aim of this thesis is to summarize the evidence regarding Crohn’s disease and ulcerative colitis
outcomes and corresponding associated factors, limited to clinical and demographical data. Factors such as
age at diagnosis, perianal disease, initial use of steroids and disease location were identified as independent
factors of disabling disease for Crohn’s patients. Concerning ulcerative colitis, gender, smoking habits, disease
extent, need for corticosteroids and hospitalization were associated with colectomy.
Two studies were conducted:
Prognostic factors for disabling Crohn’s disease: a systematic review and meta-analysis.
World Journal of Gastroentereology 19(24): 3866-71, 2013.
Cla´udia Camila Dias, Pedro Pereira Rodrigues, Altamiro da Costa Pereira, Fernando Magro
Clinical Predictors of colectomy in patients with ulcerative colitis: systematic review and meta-
analysis of cohort studies.
Journal of Crohn’s and Colitis, 9(2): 156-163, 2015
Cla´udia Camila Dias, Pedro Pereira Rodrigues, Altamiro da Costa Pereira, Fernando Magro
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4.1 Prognostic factors for disabling Crohn’s disease: a systematic
review and meta-analysis
World Journal of Gastroentereology 19(24): 3866-71, 2013.
Cla´udia Camila Dias, Pedro Pereira Rodrigues, Altamiro da Costa Pereira, Fernando Magro
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Abstract
AIM: To identify demographic and clinical factors asso-
ciated with disabling Crohn’s disease (CD).
METHODS: A systematic review and meta-analysis 
of observational studies, focusing on the factors that 
can predict the prognosis of different outcomes of CD 
was undertaken. PubMed, ISI Web of Knowledge and 
Scopus were searched to identify studies investigat-
ing the above mentioned factors in adult patients with 
CD. Studies were eligible for inclusion if they describe 
prognostic factors in CD, with inclusion and exclusion 
criteria defined as follows. Studies with adult patients 
and CD, written in English and studying association 
between clinical factors and at least one prognosis out-
come were included. Meta-analysis of effects was un-
dertaken for the disabling disease outcome, using odds 
ratio (OR) to assess the effect of the different factors in 
the outcome. The statistical method used was Mantel-
Haenszel for fixed effects. The 16-item quality assess-
ment tool (QATSDD) was used to assess the quality of 
the studies (range: 0-42). 
RESULTS: Of the 913 papers initially selected, sixty 
studies were reviewed and three were included in the 
systematic review and meta-analysis. The global QA-
TSDD scores of papers were 18, 21 and 22. Of a total 
of 1961 patients enrolled, 1332 (78%) were classified 
with disabling disease five years after diagnosis. In two 
studies, age at diagnosis was a factor associated with 
disabling disease five years after diagnosis. Individu-
als under 40 years old had a higher risk of developing 
disabling disease. In two studies, patients who were 
treated with corticosteroids on the first flare developed 
disabling disease five years after diagnosis. Further, 
perianal disease was found to be relevant in all of the 
studies at two and five years after diagnosis. Finally, 
one study showed localization as a factor associated 
with disabling disease five years after diagnosis, with 
L3 being a higher risk factor. This meta-analysis showed 
a significantly higher risk of developing disabling dis-
ease at five years after initial diagnosis among patients 
younger than 40 years of age (OR = 2.47, 95%CI: 
1.74-3.51), with initial steroid treatment for first flare 
(OR = 2.42, 95%CI: 1.87-3.11) and with perianal dis-
ease (OR = 2.00, 95%CI: 1.41-2.85).
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CONCLUSION: Age at diagnosis, perianal disease, ini-
tial use of steroids and localization seem to be indepen-
dent prognostic factors of disabling disease.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Crohn’s disease (CD) occurs in equal proportion in both 
genders and its incidence has been growing worldwide 
in the last decades[1]. CD is a disabling disease affecting 
psychological, familial, and social dimensions of  life[2]. 
Therefore, the need to develop a specific instrument 
able to evaluate disabilities and identify specific fac-
tors as predictors is paramount. This is particularly true 
since in the last decades the medical treatment options 
have been dramatically changed. Other strategies are 
now approaching, namely accelerate step-up and top-
down treatment[3]. The top-down strategy is based on 
the very early use of  intensive therapy (immunosuppres-
sants and/or biologics) to maintain a good quality of  life 
from the first flare-up of  the disease and prevent any ir-
reversible consequences[3]. Therefore, it is now crucial to 
identify simple clinical criteria at diagnosis to predict CD 
outcome. This work aims to systematically review the 
evidence with respect to predictive clinical prognostic 
factors for CD.
MATERIALS AND METHODS
A systematic review and meta-analysis of  observational 
studies focusing on the factors that can predict the prog-
nosis of  different outcomes of  CD was undertaken. The 
methodology included the definition of  eligibility crite-
ria, search strategies, study selection and characteristics, 
outcome measures, quantitative data synthesis and sen-
sitivity analysis, methodological quality of  studies, and 
statistical data analysis.
Eligibility criteria 
Studies that described prognostic factors in CD were 
eligible for inclusion. The criteria for inclusion were 
studies with adult patients and CD written in English 
and studying association between clinical factors and dis-
abling disease. Studies not in English, without available 
abstract, with genetic or serologic factors, biomarker 
studies, or those addressing diagnosis or quality of  life 
were excluded.
Search strategy 
The main method to search for the eligible articles was 
a broad literature search using PubMed with the follow-
ing keywords and MeSH terms: “crohn disease”[MeSH 
Terms] OR “crohn”[All Fields] AND predictor [All Fields] 
OR predictors [All Fields] OR predict [All Fields] OR “prog-
nostic factor” [All Fields] OR “prognostic factors” [All Fields]. 
Literature searches were also undertaken in Scopus data-
base and ISI Web of  Knowledge using the same search 
keywords: crohn disease AND (predictors OR predict OR prog-
nostic factors).
Study selection 
The studies were screened and selected by two reviewers. 
First, all titles and abstracts were read and the inclusion 
and exclusion criteria were applied. Second, the reviewers 
read the full text of  all papers considered for inclusion 
after abstract selection, again applying the inclusion and 
exclusion criteria.
Study characteristics 
The following properties of  each study were recorded: 
total number of  patients, prognostic variables, and per-
centage of  patients with disabling disease. 
Outcome measures 
The aim of  the study is to assess prognostic factors to 
predict disabling CD. 
Methodological quality of included studies 
The 16-item quality assessment tool (QATSDD), devel-
oped by Higgins et al[4], was used to assess the quality of  
the included studies. This tool includes 16 items, scored 
between 0 and 3, and can be applied to different types of  
studies using different approaches. However, two of  the 
items were not evaluated as they only address qualitative 
studies, hence we only considered a maximum score of  42.
Statistical analysis
Statistical evidence of  effects is presented as described 
in the original studies. Meta-analysis of  effects was un-
dertaken for the disabling disease outcome using odds 
ratio (OR) to assess the effect of  the different factors in 
the outcome. The statistical method used was Mantel-
Haenszel for fixed effects. All included estimates are 
recomputed from original articles descriptions, potentially 
resulting in slightly different values. All reported P-values 
are 2-sided with a significance level of  5%. Statistical het-
erogeneity was assessed with the I2 statistic; values higher 
than 50% indicate a substantial level of  heterogeneity
[5]. 
RevMan v5.1 (The Nordic Cochrane Center, The Cochrane 
Collaboration, 2011) was used to calculate OR and 95%CI 
for disabling disease and to derived forest plots showing 
the results of  individual studies and pooled analysis.
RESULTS
Search and study selection 
A total of  913 articles were identified using the search 
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strategy. After reading all titles and abstracts, 853 articles 
were excluded (Figure 1). Sixty studies were reviewed 
in detail and three articles were included in the study. 
A new search of  the literature focused on the outcome 
was made in order to find other papers that could have 
been missed by the generic search. The global QATSDD 
scores ranged between 18 and 22.  The main characteris-
tics of  the studies are summarized in Table 1.
Predicting factors of disabling disease 
Beaugerie et al[6] and Loly et al[7] define disabling disease by 
the presence of  at least one of  the following criteria: two 
steroid courses required and/or steroid dependency; fur-
ther hospitalization after diagnosis for flare up or compli-
cations of  the disease; chronic symptoms (diarrhea with 
nocturnal and/or urgent stools, intensive abdominal pain 
due to intestinal obstruction, fever, fatigue attributable 
to the disease); joint pain; painful uveitis or pyoderma 
gangrenous for 12 mo within the five year study; immu-
nosuppressive therapy and intestinal resection or surgical 
operation for perianal disease. Yang et al[8] defined CD 
as disabling if  patients satisfy at least one of  the follow-
ing criteria: require two or more steroids courses and/or 
steroid dependency; need immunosuppressive therapy; 
intestinal resection or surgical operation for perianal dis-
ease and hospitalization after diagnosis for the treatment 
of  acute exacerbation, or complication of  the disease.  
According to Beaugerie et al[6], 957 of  1123 patients 
(85.2%) were classified with disabling disease. With a 
sample of  361 patients, Loly et al[7] found 209 patients 
(57.9%) with disabling disease, while Yang et al[8] found 
80.2% of  207 patients with disabling disease five years 
after diagnosis, and 71% of  patients already had disabling 
disease two years after diagnosis. 
Different factors were found that could predict dis-
abling disease, namely age at diagnosis, use of  steroids, 
perianal disease, and localization.
Age at diagnosis
Beaugerie et al[6] found age at diagnosis as a factor associ-
ated with disabling disease. Patients less than 40 years old 
had a higher risk of  developing disabling disease than 
older patients (OR = 2.1, 95%CI: 1.3-3.6) five years after 
the diagnosis. Yang et al[8] also showed that patients under 
40 had a higher risk of  developing disabling disease (OR 
= 3.56, 95%CI: 1.74-7.30).
Results of  studies comparing younger patients (under 
40) with older patients (over 40) are shown in Figure 2A. 
A fixed effects model shows that younger patients had a 
higher risk of  disabling disease five years after diagnosis 
(OR = 2.47, 95%CI: 1.74-3.51). There was no evidence 
of  statistical heterogeneity among the studies (I2 = 26%).
Steroids for treatment of first flare 
Both Beaugerie et al[6] and Loly et al[7] show patients who 
had initial requirement of  steroids for treating the first 
flare had a higher risk of  developing disabling disease 
five years after diagnosis when compared to those who 
did not require treatment (OR = 3.1, 95%CI: 2.2-4.4 
and OR = 1.7, 95%CI: 1.02-2.7, respectively). Yang et al[8] 
found similar results two years after diagnosis (OR = 2.142, 
95%CI: 1.068-4.298). 
Results of  these different studies comparing patients 
with and without steroid requirement treatment are pre-
sented in Figure 2B. A fixed effects model shows that pa-
tients with steroid treatment had a higher risk of  disabling 
913 studies selected by queries
60 studies considered for full text analysis
2 not accessed
3 studies included
3 disabling
7 not in English
853 excluded by title and abstract analysis
   75 children
   144 no Crohn's disease
   42 without abstract
   592 without clinical factors
48 excluded by full text analysis
   3 without clinical factors
   45 not about disabling disease
Figure 1  Flowchart of the selection process for this meta-analysis.
Table 1  Characteristics of the studies
Ref. Country Sample size (n ) Type of study Disabling Follow-up (yr) Factor QATSDD
Beaugerie et al[6] France 1123 Retrospective 85.2% 5 Age (under 40 yr) 22
Steroids for 1st flare
Perianal disease
Loly et al[7] Belgium 361 Retrospective 57.9% 5 Steroids for 1st flare 18
Perianal disease
L3
Yang et al[8] China 207 Retrospective 71.0% 2 Steroids for 1st flare 21
Perianal disease
80.2% 5 Age (under 40 yr)
QATSDD: Sixteen-item quality assessment tool.
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disease five years after diagnosis (OR = 2.41, 95%CI: 
1.87-3.10). Significant heterogeneity was found among the 
studies (I2 = 66%). Nevertheless, all studies found a higher 
risk of  disabling disease for patients on steroids.
Perianal disease 
In all three studies, patients with perianal disease had a 
higher risk of  developing disabling disease five years after 
diagnosis when compared to patients without perianal 
disease: Beaugerie et al[6] (OR = 1.8, 95%CI: 1.2-2.8), Loly 
et al[7] (OR = 2.6, 95%CI: 1.4-5.1), Yang et al[8] (two years 
after diagnosis) (OR = 5.433, 95%CI: 1.585-18.620).
The comparison between patients with and without 
perianal disease is shown in Figure 2C. A fixed effects 
model shows the presence of  perianal disease as a high 
risk of  disabling disease five years after diagnosis (OR = 
2.00, 95%CI: 1.41-3.85). There was no evidence of  statis-
tical heterogeneity among the studies (I2 = 48%).
Localization 
One study associated disabling disease to the localization 
of  the disease. In this study, patients with L3 localiza-
tion had a higher risk of  developing disabling disease five 
years after the diagnosis (OR = 1.74, 95%CI: 1.06-2.8)
[7]. 
DISCUSSION
CD is a chronic disease with no known medical or surgical 
cure, requiring several appointments and hospitalizations 
for those afflicted. There are several reasons stressing the 
importance of  prognostic factors: (1) Recent available 
drugs, namely anti-tumour necrosis factor (TNF), having 
the potential of  inducting mucosal healing and prolonged 
clinical remission; (2) Mucosal healing has been consid-
ered a therapeutic goal; and (3) Early therapeutic interven-
tions are followed by a better outcome. Therefore, it is 
imperative that therapeutic options are optimized.
The present systematic review and meta-analysis pre-
sented some of  the factors that could help clinicians iden-
tify risk groups for disabling CD. Age, perianal disease, 
the use of  steroids and localization were all associated 
with disabling disease. Although other markers can help 
clinicians to predict disease course of  CD, namely genetic, 
serologic and endoscopic findings, we limited this meta-
analysis to demographic and clinical characteristics due to 
feasibility to apply at diagnosis at the bedside.
Three studies address disabling disease and used si-
milar definitions, although in Yang et al[8] the presence of  
chronic symptoms like diarrhea, fever, fatigue, was not 
Age below 40 40 yr or above Odds ratio Odds ratio
Study or subgroup Events Total Events Total Weight M-H, fixed, 95%CI M-H, fixed, 95%CI
Beaugerie et al [6] 839 966 118 157 79.0% 2.18 [1.45, 3.28]
Yang et al [8] 131 152 35 55 21.0% 3.56 [1.74, 7.30]
Total (95%CI) 1118 212 100.0% 2.47 [1.74, 3.51]
Total event 970 153
Heterogeneity: χ 2 = 1.36, df  = 1 (P  = 0.24, I2 = 26%)                                                                             0.1   0.2      0.5     1      2         5     10
Test for overall effect: Z  = 5.06 (P  < 0.00001)                                                                                             40 yr or above     Age below 40 yr
A
Yes No Odds ratio Odds ratio
Study or subgroup Events Total Events Total Weight M-H, fixed, 95%CI M-H, fixed, 95%CI
Beaugerie et al [6] 623 684 334 439 46.5% 3.21 [2.28, 4.52]
Loly et al [7] 95 145 114 215 40.5% 1.68 [1.09, 2.60]
Yang et al [8] 61 71 105 136 13.0% 1.80 [0.83, 3.93]
Total (95%CI) 900 790 100.0% 2.41 [1.87, 3.10]
Total event 779 553
Heterogeneity: χ 2 = 5.85, df  = 2 (P  = 0.05, I2 = 66%)                                                                             0.1   0.2      0.5     1      2         5     10
Test for overall effect: Z  = 6.78 (P  < 0.00001)                                                                                                     No                       Yes
B
Yes No Odds ratio Odds ratio
Study or subgroup Events Total Events Total Weight M-H, fixed, 95%CI M-H, fixed, 95%CI
Beaugerie et al [6] 252 281 705 842 73.4% 1.69 [1.10, 2.58]
Loly et al [7] 50 65 159 296 26.6% 2.87 [1.54, 5.34]
Total (95%CI) 346 1138 100.0% 2.00 [1.41, 2.85]
Total event 302 864
Heterogeneity: χ 2 = 1.91, df  = 1 (P  = 0.17, I2 = 48%)                                                                               0.05      0.2           1            5        20
Test for overall effect: Z  = 3.87 (P  = 0.0001)                                                                                                         No                       Yes
C
Figure 2  Predictor of disabling disease. A: Age at diagnosis as a predictor of disabling disease; B: The use of steroids for treatment of the first flare as a predictor 
of disabling disease; C: Perianal disease as a predictor of disabling disease.
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considered. All studies were retrospective and the num-
ber of  patients in each study ranged from 207 to 1123[6,8]. 
It was clear that a large number of  patients had disabling 
disease (range: 59%-81%), which gives an indication of  
the severity of  the disease. Moreover, the study with the 
highest percentage of  disabling disease included the least 
amount of  defining characteristics
[8]. Our meta-analysis 
showed that patients under 40 years old and patients 
with an initial requirement of  steroids, or patients with 
perianal disease had a higher risk of  having disabling dis-
ease five years following initial diagnosis. These results 
are in line with the three studies used in the meta-analy-
sis[6-8]. Although the definition of  disabling disease in Yang 
et al[8] is slightly different, this study had a lower weight in 
the final result of  the meta-analysis, hence limiting the pos-
sible bias. Even though the effect of  age at diagnosis was 
clear in the meta-analysis; further studies are necessary to 
better assess relative CD risk, including an evaluation of  
more patients diagnosed after the age threshold. We call 
into question some of  the recent points included in dis-
ability definition, namely steroids following the first flare, 
the need for immunosuppressants, and surgery. The per-
centage of  patients treated with steroids in the first flare 
(65%) in Beaugerie et al[6] was very similar to the percent-
age of  patients who received steroids within in the first 
year of  disease in the North-European population-based 
study, however this only reflects the step-up strategy, and 
the population on immunosuppressants was very low[9]. 
Markowitz et al[10] showed children requiring steroids for 
the treatment of  the first flare-up that a very early use 
of  6-Mercaptopurine was associated with steroid sparing 
and a more favorable clinical outcome in the 18-mo pe-
riod following diagnosis. Similar results were observed in 
those treated with anti-TNF in the first two years of  dis-
ease[11]. Finally, the role of  early surgery in limiting ileal 
disease with regard to CD prognosis is also debatable. In 
conclusion, the risk factors analyzed in this meta-analysis 
should be considered when new scores or approaches 
are taken concerning risk factors in CD outcome, par-
ticularly when more early therapeutic approaches are im-
minent.
The QATSDD scale, developed by Sirriyeh et al[5], allows 
the comparison of  the quality of  the included papers even 
when their designs are different. The included papers con-
sistently presented low quality scores, especially considering 
the representativeness of  the sample and the absence of  a 
critical discussion of  strengths and limitations. 
The results of  this study may need further confirma-
tion due to the small number of  reviewed studies and 
their low quality (maximum QATSDD score of  22 out 
of  42). Nevertheless, this work presents a step-forward 
in the definition of  clinical predictors for disabling CD, 
exposing their relevance and impact in disease prognosis. 
In summary, this review and meta-analysis showed that 
age, perianal disease and the use of  steroids are associated 
with disabling disease. The use of  these factors in build-
ing predictive models for CD prognosis could enhance the 
initial clinical approach, and therefore improve the clinical 
outcome of  patients with severe disease. However, more 
elaborate and precise definitions of  disabling and severe dis-
ease are needed.
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Abstract
Introduction: Colectomy is a major event that may significantly affect the outcome of ulcerative 
colitis (UC) in terms of both quality of life and mortality. This paper aims to identify clinical 
prognostic factors that may be significantly associated with this event.
Methods: PubMed, ISI Web of Knowledge and Scopus were searched to identify studies 
investigating the association between clinical factors in adult patients with UC and studied events. 
The clinical factors evaluated in this meta-analysis were gender, smoking habits, disease extent, 
use of corticosteroids, and episodes of hospitalization.
Results: Of the 3753 initially selected papers, 20 were included. The analysis showed a significantly 
lower risk of colectomy for female patients (odds ratio [OR] 0.78 [95% CI 0.68, 0.90]) and for smoking 
patients (OR 0.55 [0.33, 0.91]), and a higher risk for patients with extensive disease (OR 3.68 [2.39, 
5.69]), for patients who took corticosteroids at least once (OR 2.10 [1.05, 4.22]), and for patients who 
were hospitalized (OR 4.13 [3.23, 5.27]).
Conclusion: Gender, smoking habits, disease extent, need for corticosteroids, and hospitalization 
were all significantly associated with UC prognosis. These results may clarify the relative influences 
of these and other prognostic factors in the natural course of the disease and therefore help 
improve the management approach, thus improving the follow-up of patients.
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1. Introduction
Ulcerative colitis (UC) has a heterogeneous course. It is a chronic disease 
in which activity has been described as mild, moderate, or severe, based 
on how many of the following symptoms are present: bloody diar-
rhea, abdominal cramps, and fever.1 Medical treatment and surgery are 
the two possible treatment options. The primary goal of medical treat-
ment is to reduce symptoms, but nowadays it is also aimed at clinical, 
endoscopic, and histologic remission. Surgery is limited to refractory 
patients and to those with dysplasia or carcinoma.2,3 Therefore, it is 
now crucial to define clinical criteria at diagnosis to help predict UC 
outcome. Demographic and clinical characteristics are also important 
since they are easy to use and have been consistently associated with 
the disease course.4 This work aims to systematically review the evi-
dence with respect to predictive clinical prognostic factors for UC.
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2. Materials and Methods
A systematic review and meta-analysis of observational studies 
focusing on the factors that can predict different outcomes of ulcera-
tive colitis was undertaken. Eligible studies were identified through 
an electronic search of bibliographic databases until October 2013 
(Medline through PubMed, ISI Web of Knowledge and Scopus data-
bases). The method included the definition of eligibility criteria, 
search strategies, study selection and characteristics, outcome meas-
ures, quantitative data synthesis and sensitivity analysis, methodo-
logical quality of studies, and statistical data analysis.
2.1 Eligibility criteria
Observational studies describing prognostic factors in UC were eli-
gible for inclusion. The criteria for inclusion were: (1) adult patients 
with UC; and (2) written in English and studying associations 
between clinical factors and colectomy. This meta-analysis was lim-
ited to clinical factors because they are easy to apply in predictive 
models of outcome. Genetic, serologic, and biomarker studies were 
excluded because they are not universally used and are useful tools 
at only some centers. The only exception was C-reactive protein 
(CRP), to enhance the comprehensiveness of the analysis. We there-
fore tried to analyze predictive tools applicable at the bedside by 
all physicians. Studies not in English, without an available abstract, 
studying only genetic or serologic factors, biomarker studies (with 
exception of CRP), or those addressing diagnosis or quality of life 
were excluded. Furthermore, clinical trials were also not used since 
they often did not contain sufficient information to determine risk 
factors associated with our outcome.
2.2 Search strategy
To gather a more sensitive set of data, we defined a search query with 
several outcomes, looking to capture studies that, although focused 
on other outcomes, might provide useful information regarding 
colectomy as well. A literature search was therefore performed using 
PubMed with the following keywords and MeSH terms: ‘(‘colitis, 
ulcerative’[MeSH Terms] OR (‘colitis’[All Fields] AND ‘ulcerative’[All 
Fields]) OR ‘ulcerative colitis’[All Fields]) AND (‘Prognosis’[Mesh] 
OR prognostic[All Fields] OR factor[All Fields] OR predictor[All 
Fields]) AND (‘corticoids’[All Fields] OR ‘steroids’[MeSH 
Terms] OR ‘steroids’[All Fields] OR ‘colectomy’[MeSH Terms] 
OR ‘colectomy’[All Fields] OR ‘recurrence’[MeSH Terms] OR 
‘recurrence’[All Fields] OR ‘relapse’[All Fields])’. Literature searches 
were also undertaken in the Scopus database and the ISI Web of 
Knowledge using the same search keywords: (‘ulcerative colitis’ 
AND (‘prognostic’ OR ‘factor’ OR ‘predictors’) AND (‘corticoids’ 
OR ‘steroids’ OR ‘colectomy’ OR ‘relapse’)).
2.3 Study selection and data collection process
The studies were screened and selected by two reviewers. First, all 
titles and abstracts were read and the inclusion and exclusion cri-
teria were applied. Second, the reviewers read the full text of all 
papers considered for inclusion after abstract selection, again apply-
ing the inclusion and exclusion criteria. The following properties of 
each study were recorded: location and type of study, total number 
of patients, characteristics of included patients, definitions of out-
comes, and clinical or demographic factors. Quality was assessed 
using a qualitative classification of the risk of bias. We used a four-
item classification based on the MOOSE5 and STROBE6 checklists. 
The items were chosen based on the factors that can incorporate 
bias, i.e., inclusion and exclusion criteria, justification of the cohort 
(eligibility criteria, sources and methods of selecting participants, 
and methods used to describe follow-up), disease assessment (if UC 
was evaluated or self-reported), and outcome adjustments for poten-
tial confounders.
2.4 Predictors of UC
The predictors evaluated were: gender, disease extent, smoking hab-
its, hospitalization at any time, use of corticoids (oral or intrave-
nous) at any time, and CRP.
2.5 Outcome measures
The main endpoint of this study was colectomy at any time dur-
ing the disease course. Whenever possible, subgroup analysis was 
focused on (1) colectomy due to nonresponse to treatment or within 
1 year after diagnosis, and (2) colectomy during the disease course.
2.6 Quantitative data synthesis and sensitivity 
analysis
Statistical evidence of effects is presented as described in the original 
studies. We compared the groups using random effects meta-analysis 
weighted by the inverse of variance to estimate the odds ratio (OR) 
and 95% confidence interval (95% CI). Raw data were first converted 
to the OR using classic methods. When raw data were not available 
we used the hazard ratio (HR) in the analysis. All included estimates 
were recomputed from descriptions given in the original articles, 
which might result in slightly different values. All reported p-values 
are two-sided with a significance level of 5%. Statistical heterogeneity 
was assessed with the I2 statistic; values higher than 50% indicate a 
substantial level of heterogeneity.7 Review Manager v5.1 was used to 
calculate ORs and 95% CIs. Sensitivity analysis, to evaluate the weight 
of each study in the heterogeneity analysis, was performed to assess 
robustness of findings.
3. Results
3.1 Search and study selection
A total of 3753 articles were identified using the search strategy. 
After reading all titles and abstracts, 3634 articles were excluded 
(mostly because they did not address UC or the studied clinical fac-
tors). The reasons for exclusion are shown in Figure 1. One hun-
dred nineteen studies were reviewed in detail and 20 articles were 
included.
3.2 Description of studies
Of the total of 20 studies showing clinical factors for colec-
tomy,8–27 12 were conducted in Europe,10,11,15–17,20,22–27 six in North 
America,8,9,12,13,18,19 and two in Asia. Their main characteristics are 
summarized in Table  1. All had suitable inclusion and exclusion 
criteria, five did not clearly justify the cohort or disease assess-
ment,13,17,18,22,23 and one did not adjust the outcome for possible con-
founders.28 The highest risks of bias were found for these unadjusted 
outcomes (Figure 2). Concerning publication bias, funnel plots were 
derived and did not reveal any obvious asymmetric tail other than 
some possible bias in disease extent, as shown later in this article 
(Figure 8). Also, sensitivity analysis did not show significant changes 
in the results for any of the outcomes.
3.3 Colectomy
Colectomy was studied as an outcome in 20 studies.8–27 Different fac-
tors were found that could predict colectomy, namely gender, extent 
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Table 1. Characteristics of the included studies.
Study Location/type of study No. of patients Patient characteristics Factor Colectomy
Ananthakrishnan (2009)8 North America 246 All Gender 11%
Retrospective Disease extent
Smoking
Hospitalization
Ananthakrishnan (2010)9 North America 15 142 All Gender 2.4%
Retrospective Disease extent
Desmond (2012)10 Europe 424 All Gender 6.8%
Prospective Disease extent
 Hospitalization 15.8%
Ho (2004)11 Europe 167 All Gender 40%
Retrospective Disease extent
Smoking
Corticosteroids
CRP
Nguyen (2006)12 North America 23 389 Age 5–80 years at UC diagnosis Gender 10.3/1000 hospital 
days
Retrospective
Hefti (2009)13 North America 561 Minimum of 7 years of UC, no colec-
tomy, and at least one colonoscopy
Disease extent 17%
Retrospective Corticosteroids
Shiga (2010)14 Asia 296 With at least 1 year of treatment and 
without colectomy 1 month after 
treatment (no response)
Gender 14.5%
Disease extent
CRP
Solberg (2009)15 Europe 519 All Gender 9.8%
Disease extent
Smoking
Triantafillidis (1998)16 Europe 413 All Gender 16.7%
Retrospective Disease extent
Hoie (2007)17 Europe 781 All Gender 8.7%
Retrospective Smoking
Samuel (2013)18 North America 369 All Gender 13.1%
Retrospective
Targownik (2012)19 North America 3752 At least 25 years of follow-up Gender 7.5%
Retrospective Hospitalization
Ferrante (2008)20 Europe 81 Refractory UC; first infusion with 
infliximab before November 2006
Corticosteroids –
Retrospective CRP
Kuriyama (2006)21 Asia 981 All Gender 9%
Disease extent
Molnar (2011)22 Europe 183 Severe exacerbation of UC requiring 
parenteral corticosteroid therapy
Disease extent 25%
Retrospective
Ho (2006)23 Europe 86 All with information on 2 databases Gender
Disease extent
Smoking
Travis (1996)24 Europe 49 All CRP 19%
Prospective
Oussalah (2010)25 Europe
Retrospective 191 All patients who received at least 1 
infliximab infusion
CRP 18.8%
Lindgren (1998)26 Europe
Retrospective 97 Patients with acute attacks CRP 34%
Henriksen (2008)27 Europe
Prospective 454 All CRP
of disease, smoking habits, hospitalization, and the need for corti-
costeroids at any time during the course of UC. The random effects 
model showed that female patients had a lower risk of colectomy 
(OR 0.78 [95% CI 0.68, 0.90]) and there was no evidence of statisti-
cal heterogeneity (I2 = 49%) Figure 3. Regarding disease extent and 
colectomy risk, ten cohorts were found. The random effects model 
showed that patients with extensive disease had a higher risk of 
colectomy (OR 3.68 [95% CI 2.39, 5.69]); however, significant het-
erogeneity was found among them (I2 = 67%) Figure 4. Concerning 
smoking habits, the random effects model showed that patients who 
smoked had a lower risk of colectomy (OR 0.55 [95% CI 0.33, 
0.91]), with no significant heterogeneity (I2 = 0%) Figure 5.
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Patients hospitalized at any time had a higher risk of colec-
tomy (OR 4.13 [95% CI 3.23, 5.27]) and there was no evidence 
of statistical heterogeneity (I2  =  0%) Figure  6. An association 
between the use of corticosteroids and colectomy was found in 
four studies. Patients who took corticosteroids (oral or intrave-
nous) at any time had a higher risk of colectomy (OR 2.10 [95% 
CI 1.05, 4.22]); however, significant heterogeneity was found 
(I2 = 54%) Figure 7.
Subgroup analysis was performed on the outcome, addressing 
colectomy due to nonresponse to treatment or within 1 year after 
diagnosis, and colectomy during the disease course. This analysis 
was done only for gender, disease extent, and smoking because the 
number of studies did not allow any conclusion to be drawn for the 
remaining factors. For gender (Figure 3), disease extent (Figure 4), 
and smoking habits (Figure 5), no significant differences were found 
in those receiving surgery within the first year after diagnosis or 
thereafter.
In the evaluation of CRP as a predictive factor for colectomy, 
seven papers showed different types of risk estimation, heteroge-
neity in the time of CRP measurement, and different cut-offs for 
risk assessment, making aggregation impossible. In three studies 
the median or mean CRP level was not given,14,20,25 the median was 
given in one work,11 and the mean with standard deviation was 
given in two24,26; moreover, the assay for CRP measurement was 
not given in any study, which made it difficult to draw any relevant 
conclusion. In all but one study14 there was a trend for high rates 
of colectomy in those with a high CRP. Ho et al.11 provided a risk 
index to aid the identification of patients who did not respond to 
treatment (and were submitted to colectomy), with higher CRP 
levels in nonresponders (6.9 versus 3.9 mg/L, p < 0.02), although 
Shiga et al.14 reported that CRP was not associated with a risk of 
colectomy, either at diagnosis (HR 0.93 [95% CI 0.86, 1.02]) or 
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In
cl
us
io
n 
an
d 
ex
cl
us
io
n 
cr
ite
ri
a
Ju
st
ifi
ca
tio
n 
co
ho
rt
D
is
ea
se
 a
ss
es
sm
en
t
O
ut
co
m
e 
aj
us
tm
en
ts
Anathakrishnan2010
Desmond2012
Ferrante2008
Hefti2009
Henriksen2008
Ho2004
Ho2006
Hoie2007
Kuryama2006
Lindgren1998
Molnar2007
NGuyen2006
Oussalah2010
Samuel2013
Shiga2010
Solberg2009
Targownik2012
Travis1996
Triantafillidis1998
Figure 2. Summary of risk of bias.
3753 studies selected by queries
119 studies considered for full text analysis
20 studies included
7 not accessed
9 not in English
83 excluded by full text analysis
34 without clinical factors
49 other outcome
3634 Excluded by title and abstract analysis
266 children
2250 no UC
57 without abstract
1061 without clinical factors
Figure 1. Study selection.
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4 weeks after the first induction therapy (HR 1.15 [95% 0.82, 
1.62]). Patients who required colectomy24 had higher values of 
CRP at admission than other patients (mean [sd] 116 [102] versus 
43 [25] mg/L). Lindgren et al.26 also identified CRP (on the third 
day of hospitalization) ≥25 mg/L as a predictor of colectomy, in 
the first 30 days of hospitalization, and colectomized patients had 
a higher value of CRP (on day third day after treatment) than 
other patients (36.3 versus 18.0 mg/L, p = 0.007). One year after 
diagnosis, patients with CRP ≥10 mg/L had a higher risk of colec-
tomy in the following 4 years (OR 3.0 [95% CI 1.1, 7.8]).27 At the 
time of infliximab induction, two studies showed an association 
between high CRP values and the risk of colectomy, one at CRP 
Study or Subgroup
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Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 = 0% 
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Figure 4. Disease extent as a predictor of colectomy.
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Figure 3. Gender as a predictor of colectomy.
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≥10 mg/L (HR 5.11 [95% CI 1.77, 14.76])25 and the other at CRP 
≥5 mg/L (HR 14.5 [95% CI 2.0, 108.6]).20
4. Discussion
There are several reasons for the importance of prognostic factors: 
(1) recently available drugs, namely anti-tumor necrosis factor have 
the potential to induce mucosal healing and prolonged clinical remis-
sion; (2) mucosal healing has been considered a therapeutic goal; 
and (3) early therapeutic interventions are followed by a better out-
come.29 The need to develop a specific clinical tool able to evaluate 
disabilities and identify specific factors as predictors is paramount. 
Therefore, the clinical risk factors analyzed in this meta-analysis 
should be considered when new scores or approaches are developed 
to assess the outcome of UC.
Here we show some of the features that could help clinicians 
to identify risk groups for UC. This is a step forward in the defini-
tion of predictors for UC, revealing their applicability and impact 
on disease prognosis, namely the risk of colectomy. Gender, dis-
ease extent, hospitalization, the need for corticosteroids, smoking 
habits, and CRP were associated with colectomy. Although other 
markers can help clinicians to predict the disease course of UC, 
namely genetic, serologic, and endoscopic findings, we limited this 
meta-analysis to demographic and clinical characteristics because 
of the feasibility of their assessment at diagnosis and at the bed-
side. Regarding CRP, the different types of risk estimation used 
and inadequate information about the method of measurement 
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Figure 5. Smoking habits as a predictor of colectomy.
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Figure 7. Use of the corticosteroids as a predictor of colectomy.
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Figure 6. Hospitalization as a predictor of colectomy.
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did not allow aggregation. However, there was a trend toward 
a risk of colectomy in patients with high CRP levels. The most 
relevant risk finding in this analysis was extensive disease and hos-
pitalization and, in the opposite sense, smoking habits. Subgroup 
analysis showed that colectomy predictors were the same when 
the population was stratified by colectomy due to nonresponse to 
treatment at diagnosis or within 1 year after diagnosis, and colec-
tomy during disease course. Gender, disease extent, and smoking 
remained associated factors, strengthening their value in predic-
tive models.
We tried to evaluate more than one hospitalization per year 
and repeated flares requiring steroids as markers of chronic mor-
bidity; however, there was too little information in the studies 
for an aggregated analysis. It was also not possible to study the 
roles of other clinical and demographical variables, such as age 
at diagnosis, because data were not available or could not be 
aggregated due to the different measures used. Furthermore, it 
was impossible to analyze several clinical trials in UC because 
the outcome (colectomy) was not stratified in terms of gender, 
disease extent, smoking habits, hospitalization, and the need for 
corticosteroids.
The overall quality of the included studies was good; however, 
we found outcome adjustment deficiencies in four of them. The main 
limitation found in our meta-analysis was the heterogeneity and the 
different approaches used. To better assess the effect of heterogene-
ity on our results, sensitivity analysis was performed; it showed little 
change in outcomes, thus supporting the robustness of our findings. 
However, these aspects should be taken into account in the analysis 
of our results and conclusions.
In summary, this review and meta-analysis showed that clinical 
findings such as gender, disease extent, smoking habits, hospitaliza-
tion, and the need for corticosteroids are associated with the prog-
nosis UC, namely the risk of colectomy. The use of these parameters 
in building predictive models for UC prognosis could enhance the 
clinical approach and thus improve the clinical outcome of patients 
with severe disease.
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The second aim of this thesis is to identify and assess risk factors for outcomes identified in Goal 1 for
Crohn’s disease, using an independent cohort of patients. In this chapter we study the impact of demogra-
phical and clinical factors (such as the timing of therapeutics strategies). Early surgery or immunosuppression
seem to not prevent global disabling disease, an early start of immunosuppression by itself is associated with
fewer surgeries and should be considered in daily practice as a preventive strategy. Although, within surgical
patients, an early surgery (within six months after diagnosis) can prevent disabling events, and the introduc-
tion of immunosuppressive medication more than one month after the initial surgery seems to increase the
likelihood of needing further surgeries.
Two studies were conducted:
The impact of early surgery and immunosuppression on Crohn’s disease disabling outcomes.
(Inflammatory Bowel Diseases, 23 (2):289-297, 2017)
Fernando Magro, Cla´udia Camila Dias, Rosa Coelho, Paula Moura Santos, Samuel Fernandes, Cidalina Cae-
tano, Aˆngela Rodrigues, Francisco Portela, Ana Oliveira, Paula Ministro, Euge´nia Cancela, Ana Isabel Vieira,
Rita Barosa, Jose´ Cotter, Pedro Carvalho, Isabelle Cremers, Daniel Trabulo, Paulo Caldeira, Artur Antunes,
Isadora Rosa, Joana Moleiro, Paula Peixe, Rita Herculano, Raquel Gonc¸alves, Bruno Gonc¸alves, Helena Tavares
Sousa, Lu´ıs Contente, Henrique Morna , Susana Lopes on behalf of GEDII
The timing of early therapeutics strategies has a significante impact on the Crohn’s disease prog-
nosis
(submitted, 2016)
Cla´udia Camila Dias, Samuel Fernandes, Francisco Portela, Paula Ministro, Diana Martins, Paula Sousa, Paula
Lago, Isadora Rosa, Lu´ıs Correia, Paula Moura Santos Fernando Magro on behalf GEDII
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5.1 The impact of early surgery and immunosuppression on Crohn’s
disease disabling outcomes.
Inflammatory Bowel Diseases, 23 (2):289-297, 2017
Fernando Magro, Cla´udia Camila Dias, Rosa Coelho, Paula Moura Santos, Samuel Fernandes,
Cidalina Caetano, Aˆngela Rodrigues, Francisco Portela, Ana Oliveira, Paula Ministro, Euge´nia
Cancela, Ana Isabel Vieira, Rita Barosa, Jose´ Cotter, Pedro Carvalho, Isabelle Cremers, Daniel
Trabulo, Paulo Caldeira, Artur Antunes, Isadora Rosa, Joana Moleiro, Paula Peixe, Rita Hercu-
lano, Raquel Gonc¸alves, Bruno Gonc¸alves, Helena Tavares Sousa, Lu´ıs Contente, Henrique Morna
, Susana Lopes on behalf of GEDII
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ORIGINAL ARTICLE
Impact of Early Surgery and Immunosuppression on Crohn’s
Disease Disabling Outcomes
Fernando Magro, MD, PhD,1,2 Cláudia C. Dias, MSc,3,4 Rosa Coelho, MD,5 Paula M. Santos, MD,6
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Background and Aims: The definition of early therapeutic strategies to control Crohn’s disease aggressiveness and prevent recurrence is key to
improve clinical practice. This study explores the impact of early surgery and immunosuppression onset in the occurrence of disabling outcomes.
Methods: This was a multicentric and retrospective study with 754 patients with Crohn’s disease, who were stratified according to the need for an early
surgery (group S) or not (group I) and further divided according to the time elapsed from the beginning of the follow-up to the start of immunosup-
pression therapy.
Results: The rate of disabling events was similar in both groups (S: 77% versus I: 76%, P ¼ 0.700). The percentage of patients who needed surgery
after or during immunosuppression therapy was higher among group S, both for first surgeries after the index event (38% of groups S versus 21% of
group I, P , 0.001) and for reoperations (38% of groups S versus 12% of group I, P , 0.001). The time elapsed to reoperation was shorter in group I
(HR ¼ 2.340 [1.367–4.005]), stratified for the onset of immunosuppression. Moreover, reoperation was far more common among patients who had a late
start of immunosuppression (S36: 50% versus S0–6: 27% and S6–36: 25%, P , 0.001) and (I36: 16% versus I0–6: 5% and I6–36: 7%, P , 0.001).
Conclusions: Although neither early surgery nor immunosuppression seem to be able to prevent global disabling disease, an early start of
immunosuppression by itself is associated with fewer surgeries and should be considered in daily practice as a preventive strategy.
(Inflamm Bowel Dis 2017;23:289–297)
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C rohn’s disease (CD) is an idiopathic, chronic, and transmuralinflammatory process that can affect the entire gastrointesti-
nal tract, from the mouth to the anus. It is characterized by a remit-
ting and relapsing course and can cause digestive damage and loss
of function, thus being considered as a disabling condition over
time.1,2 Treatment of CD has evolved over the past few years with
the appearance of anti–tumor necrosis factor a (anti-TNF a)
agents and the development of new drugs, such as anti-integrin
antibodies (natalizumab and vedolizumab), and a monoclonal
antibody against interleukin-12 and interleukin-23 (ustekinu-
mab).3,4 These therapies have considerably advanced the treat-
ment of CD and have improved the likelihood of inducing and
maintaining clinical remission.5 In addition, a significant reduc-
tion in the rate of early intestinal surgery has been described and
associated with the increased use of thiopurines.6 Nonetheless, the
impact of these therapeutic changes in the paradigms that guide
CD treatment remains poorly known.1
Surgery is nowadays considered as an option when medical
therapy fails; conversely, in the past decades, surgery was an
important step in CD treatment, with more than 40% of the
patients being submitted to at least one disease-related abdominal
surgery, most of them in the first year of the disease course.6 More
recently, Peyrin-Biroulet et al1 described a cumulative risk of 40%
to 55% to undergo surgery in the initial 10 years after diagnosis.
Surgical laparoscopic approaches became increasingly common
and have low complication and conversion rates, decreased mor-
bidity, and reduced costs.7,8 Although laparoscopy can be used
safely even in those with recurrent diseases, it did not seem to
decrease the risk of recurrence.9
The concept of “disabling disease” in inflammatory bowel
disease was introduced by Beaugerie10 in 2006 and further
explored by Loly et al11 in 2008. These authors defined disabling
disease by the presence of at least one of the following criteria: 2
steroid courses required and/or steroid dependency; further hos-
pitalization after diagnosis or complications of the disease;
chronic symptoms; immunosuppressive therapy; and intestinal
resection or surgical operation for perianal disease. In 2011, Yang
et al12 used a similar disabling definition but without the inclusion
of chronic symptoms (diarrhea, fever, fatigue, etc.). Currently,
there is no consensus regarding the definition of disabling disease;
in fact, “disabling” is a dynamic concept that necessarily changes
with the evolution of medical techniques and the different strate-
gies followed to achieve disease control.
This study aimed to identify the impact of 2 different
therapeutic approaches to CD—early surgery and/or immunosup-
pression—on disease outcomes, namely disabling events and the
need for further surgeries.
METHODS
This was a nationwide, multicentric, and retrospective
study. Patients with CD from 14 Portuguese inflammatory bowel
disease referral centers were consecutively included. The inclu-
sion criteria were as follows: (1) a definitive diagnosis of CD; (2)
more than 3 years of follow-up; and (3) aged older than 18 years.
The entire population was split into 2 groups: patients who
underwent an early surgery (i.e., within the initial 6 months after
diagnosis) before starting any immunosuppressive therapy (group
S)—for these patients, the index event was the first surgery; and
patients who started immunosuppression before any surgery
(group I)—for these patients, the index event was the diagnosis.
These 2 groups were further stratified by the time of the introduc-
tion of immunosuppressive medication after the index event:
within the initial 6 months (very early introduction), between
the 6th and the 36th month, and after the 36th month (late intro-
duction). Being an observational study, these groups reflected the
different clinical approaches motivated by the aggressiveness of
the disease.
Demographic and clinical information was collected for each
patient, including date of birth, date of CD diagnosis, presence of
perianal disease, and smoking habits. Age at diagnosis, disease
location, and phenotype were classified according to the Montreal
classification.13 The date of the first abdominal surgery and the total
number of surgeries during the follow-up period were also col-
lected, as was data concerning therapy (type and onset date).
Steroid use was classified into 6 categories: never exposed to the
drug, 1 steroid course per year, 2 or more steroids courses per year,
1 course every 3 years, steroid dependence, or steroid refractori-
ness. The definition of steroid dependence was the inability to
reduce steroids below the equivalent of 10 mg/d prednisolone
within 3 months of starting steroids without recurrent active disease
or disease relapse within 3 months of stopping steroids. Steroid
resistance was defined as the presence of active disease despite
a prednisolone dose of up to 0.75 mg$kg21$d21 over a period of
4 weeks.14 The number of hospital admissions directly related to
CD and the appearance of clinical events after the index episode
(fistula, abscess, stenosis, perforation, or anal disease) and the time
point at which they occurred were also collected. The concept of
global disabling disease was defined by the presence of one of the
following criteria: more than 1 abdominal surgery or 2 hospital
admissions in the follow-up period; more than 2 courses of steroids
per year, steroid dependence or steroid refractoriness; need to
switch the initial immunosuppressor or anti-TNF a; and the appear-
ance of new clinical events after the index episode (fistula, abscess,
stenosis, perforation, or anal disease).15 All data were collected
from a web database, and the investigators reviewed all the missing
data and discrepancies. The study was monitored by the national
coordinator of the Portuguese IBD group (GEDII).
Statistical Analysis
Categorical variables were described through absolute (n)
and relative (%) frequencies, and continuous variables were
described by their median, minimum, and maximum. Hypotheses
were tested regarding the distribution of continuous variables with
nonnormal distribution using the nonparametric Mann–Whitney
and Kruskal–Wallis tests, depending on the nature of the hypoth-
esis. When testing a hypothesis regarding categorical variables,
a chi-square test or a Fisher’s exact test was used, as appropriate.
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usage of anti-TNF or steroids (Table 3). However, there were
significant differences concerning age at diagnosis (P ¼ 0.028),
phenotype (P ¼ 0.016), and smoking habits (P ¼ 0.021).
Analyzing the occurrence of disabling events from a global
perspective, there were no significant differences between the
subgroups defined by the immunosuppression onset (Table 3).
However, on analyzing the disabling criteria in an individual
manner, there were statistical differences concerning the events
of “surgery, hospital admissions, events,” “surgery and/or hospital
admission,” and the occurrence of anal and stenosis events (see
Table S1, Supplemental Digital Content 1, http://links.lww.com/
IBD/B432). In what comes to the need for a first surgery after
immunosuppression therapy, there was a borderline significant
trend for an increase when the immunosuppression was initiated
later (P ¼ 0.053). This same trend became significant when con-
sidering reoperations only (P ¼ 0.001).
After adjusting the results for all the other variables,
there was no difference between the time-defined
subgroups regarding occurrence of disabling disease (I6–36:
OR ¼ 1.063 [0.562–2.011] and I36: OR ¼ 1.078
[0.617–1.866]). However, differences were found concerning
disease location (L2: OR ¼ 2.023 [1.204–3.397] and L3: OR
¼ 4.819 [2.622–8.859], using L1 as reference) and behavior
(B2: OR ¼ 2.023 [1.204–3.397] and B3: OR ¼ 4.819
[2.622–8.859], using B1 as reference). Concerning reopera-
tion, patients with structuring or penetrating behavior pre-
sented a higher risk (B2: OR ¼ 12.003 [3.975–36.242] and
B3: OR ¼ 10.436 [3.518–30.963], using B1 as reference), as
did those who had a later onset of immunosuppression (I36:
OR ¼ 3.090 [1.158–8.272], using I0–6 as reference) (see
Table S3, Supplemental Digital Content 3, http://links.lww.
com/IBD/B432).
TABLE 1. Baseline Characteristics of Patients with CD
Total (n ¼ 754) Surgery (S) (n ¼ 244) Immune (I) (n ¼ 510) P,a Global
Sex, n (%) 0.905
Male 367 (48) 118 (48) 249 (48)
Age at diagnosis, yr, n (%) ,0.001
A1: #16 67 (9) 6 (2) 61 (22)
A2: 17–40 551 (73) 180 (74) 371 (73)
A3: .40 136 (18) 58 (24) 78 (15)
Location, n (%) 0.365
L1: Ileon 353 (47) 123 (51) 230 (45)
L2: colonic 43 (6) 13 (5) 30 (6)
L3: ileocolonic 357 (47) 107 (44) 250 (49)
Upper tract involvement L4, n (%) 94 (12) 19 (8) 75 (15) 0.008
Behavior, n (%) ,0.001
B1: nonstricturing/nonpenetrating 239 (32) 21 (9) 218 (43)
B2: stricturing 247 (33) 108 (44) 139 (27)
B3: penetrating 268 (35) 115 (47) 153 (30)
Perianal disease, n (%) 207 (27) 55 (23) 152 (30) 0.041
Smoking habits, n (%) 0.903
Never smoke 298 (53) 70 (53) 228 (52)
Smoker 144 (25) 34 (26) 110 (25)
Exsmoker 125 (22) 27 (21) 98 (23)
Follow-up time, yr, median (min–max) 11 (3–65) 11 (3–47) 11 (3–65) 0.954
Therapeutics, n (%)
Anti-TNF 194 (29) 102 (41) 120 (24) ,0.001
Steroids 202 (27) 87 (35) 115 (23) ,0.001
Disabling, n (%)
Global 579 (77) 190 (77) 389 (76) 0.770
Surgery after index event 200 (27) 93 (38) 107 (21) ,0.001
Reoperation 152 (20) 93 (38) 59 (12) ,0.001
Total Surgeries/patients — 1.63 0.66
Montreal classification and therapeutics.
aChi-Square test.
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Concerning the comparison of group S versus group I
patients, all variables were entered in the univariate and
multivariate model. On the comparison of patients stratified by
the immunosuppressive therapy onset, smoking habits was not
considered because of an excessive number of missing values.
The time elapsed from the index episode to the appearance
of disabling disease or the need for reoperation was evaluated
using survival analysis. The cumulative probabilities of event-free
survival were estimated using the Kaplan–Meier method consid-
ering the group of patients using log-rank and Breslow tests.
All the reported P values were 2 sided, and P ,0.05 were
considered statistically significant. All data were arranged, pro-
cessed, and analyzed with SPSS v.23.0 (Statistical Package for
Social Sciences).
RESULTS
Population
The studied cohort included 754 patients with CD who
were stratified into 2 groups: group S included patients who were
submitted to an early surgery (within 6 months after diagnosis),
having afterward been enrolled in immunosuppressive therapy at
different time points (n ¼ 244); and group I included patients who
started immunosuppressive therapy at different time points after
diagnosis, but before any surgical procedure (n ¼ 510) (Fig. 1).
The demographic and clinical characteristics of the entire cohort
and the 2 subgroups are shown in Table 1. Forty-eight percent of
all patients were male, and 73% of them were diagnosed between
17 and 40 years of age (A2). Most patients had an ileal or an
ileocolonic location of the disease, and groups S and I were sim-
ilar regarding this aspect (location). Upper tract involvement was
present in 12% of all patients with CD and seemed to be slightly
more frequent in patients from group I (15% versus 8% in group
S, P ¼ 0.008). Perianal disease had a similar pattern, being pres-
ent in 27% of all patients and slightly more frequent among those
belonging to group I (30% versus 23% in group S, P ¼ 0.041).
There were also significant differences concerning the usage of
anti-TNF and steroids. The distribution of phenotypes was bal-
anced, with the exception of a noticeable smaller occurrence of
B1 phenotypes among group S patients. Concerning smoking
habits, there were no differences to report, as most patients in
both groups have never smoked.
To further analyze these patients having into consideration
the time elapsed from the index event to the start of immunosup-
pression therapy, both groups were stratified into 3 different
categories: 0 to 6 months, 6 to 36 months, and later than 36
months (Fig. 1).
Surgery Group (Group S)
Concerning group S, there were no differences among
patients with different immunosuppression starting points in what
comes to sex, age at diagnosis, location, upper gastrointestinal
involvement, perianal disease, smoking habits, and anti-TNF
usage (Table 2). There was, however, significant differences con-
cerning steroid intake and the Montreal classification phenotype.
The occurrence of disabling events was similar among
these time-defined groups (P ¼ 0.372) (Fig. 2). The absence of
significant differences was maintained when analyzing the dis-
abling criteria in an individual manner (see Table S1, Supplemen-
tal Digital Content 1, http://links.lww.com/IBD/B432). However,
the need for a reoperation was far more common among patients
who had a late start of immunosuppression (50% for S36 versus
27% and 25% for S0–6 and S6–36, respectively, P , 0.001).
After adjusting for all the other variables, there was no
difference between the 3 time-defined groups in what comes to the
occurrence of disabling disease (S6–36: odds ratio [OR] ¼ 0.776
[0.314–1.919] and S36: OR ¼ 1.559 [0.701–3.466], using S0 as
reference), but patients with perianal disease had an overall higher
risk of facing disabling disease (OR ¼ 2.814 [1.074–7.372]). Con-
cerning reoperation, the group S36 had a higher risk of recurrence
(OR ¼ 2.413 [1.168–4.986]), as did patients with a stricturing
phenotype (OR ¼ 3.642 [1.029–12.897]) (see Table S2, Supple-
mental Digital Content 2, http://links.lww.com/IBD/B432).
Immunosuppression Group (Group I)
On stratifying patients in group I according to the time
point at which they started the immunosuppression therapy, one
could not find differences among the 3 groups concerning sex,
disease location, perianal disease, upper tract involvement, and
FIGURE 1. Stratification of patients in the groups.
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Group S Versus Group I
Comparing the groups S and I in what concerns the 2
outcomes addressed in this study, one can see that there was
a significant difference among the number of surgeries but no
difference among the occurrence of disabling events (Table 1). In
fact, global disabling disease was present in 77% of all patients
enrolled and was similar between the 2 groups (77% versus 76%,
P ¼ 0.770). However, the need to undergo surgery after or during
immunosuppression therapy was higher among group S patients,
either comparing the frequency of first surgeries (38% of groups S
patients versus 21% of group I patients, P , 0.001) or that of
reoperations (38% of groups S patients versus 12% of group I
patients, P , 0.001).
On stratifying the patients of both groups according to the
time elapsed to the onset of the immunosuppressive therapy, an
interesting trend emerges: although the need for a surgery
increases with time in a similar fashion among patients belonging
to groups I and S (Tables 2 and 3), the total number of surgeries
has a dissimilar distribution (Table 1). In fact, the total number of
patients undergoing surgery is higher in group S patients when
compared with group I. Consequently, the overall average of
surgeries is 1.63/patient and 0.66/patient in the groups S and I,
respectively.
After adjusting the results for all the other variables, there
were no differences between the 2 groups (S and I) in what
concerns the occurrence of disabling disease (OR ¼ 0.830
[0.465–1.481]). Nevertheless, female patients (OR ¼ 1.636
[1.069–2.504]), patients with colonic disease (OR ¼ 3.235
[1.019–10.269]), and patients with a B2 (OR ¼ 2.162
[1.282–3.645]) or a B3 (OR ¼ 4.046 [2.287–7.157]) behavior
TABLE 2. Characteristics of Patients with CD with Surgery in the First 6 Months After Diagnosis
S0–6 (n ¼ 59) S6–36 (n ¼ 60) S36 (n ¼ 125) Pa
Sex, n (%) 0.426
Male 27 (45) 30 (51) 69 (55)
Age at diagnosis, yr, n (%) 0.147
A1: #16 3 (5) 1 (2) 2 (2)
A2: 17–40 42 (71) 39 (65) 99 (79)
A3: .40 14 (24) 20 (33) 24 (19)
Location, n (%) 0.081
L1: Ileon 24 (40) 34 (58) 65 (62)
L2: colonic 6 (10) 0 (0) 7 (6)
L3: ileocolonic 30 (50) 25 (42) 52 (42)
Upper tract involvement L4, n (%) 5 (9) 6 (10) 8 (7) 0.740
Behavior, n (%) 0.023
B1: nonstricturing/nonpenetrating 8 (13) 0 (0) 13 (11)
B2: stricturing 22 (37) 26 (43) 60 (49)
B3: penetrating 30 (50) 35 (57) 50 (41)
Perianal disease, n (%) 13 (22) 13 (22) 29 (23) 0.983
Smoking habits, n (%) 0.345
Never smoke 1 (100) 21 (60) 48 (51)
Smoker 0 (0) 5 (14) 29 (31)
Exsmoker 0 (0) 9 (26) 18 (19)
Follow-up time, yr, median (min–max) 6 (3–15) 7 (3–47) 16 (4–40) ,0.001
Therapeutics, n (%)
Anti-TNF 23 (38) 28 (47) 51 (41) 0.628
Steroids 1 (2) 25 (41) 61 (49) ,0.001
Disabling, n (%) [95% CI]
Global 45 (75) [69%–80%] 44 (72) [66%–78%] 101 (81) [77%–85%] 0.372
Reoperation 16 (27) [21%–33%] 15 (25) [19%–31%] 62 (50) [45%–54%] 0.001
Montreal classification and therapeutics.
S0–6, patients with surgery in the first 6 months after diagnosis and imunossupression in the first semester after surgery; S6–36, patients with surgery in the first 6 months after diagnosis
and imunossupression between 6 and 36 months after surgery; S36, patients with surgery in the first 6 months after diagnosis and imunossupression 36 months after surgery.
aChi-square test.
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presented a higher risk of facing disabling disease. Concerning
reoperation, the group I had a lower risk of recurrence (OR ¼
0.197 [0.117–0.330]), whereas B2 and B3 phenotype presented an
increased risk (B2: OR ¼ 8.911 [3.737–21.250] and B3: OR ¼
7.701 [3.281–18.072]) (see Table S4, Supplemental Digital Con-
tent 4, http://links.lww.com/IBD/B432).
The analyses of time disabling disease, adjusted to all
variables, revealed that female patients and penetrating phenotype
had a higher risk of disabling disease (HR ¼ 1.127 [1.004–1.607]
and HR ¼ 1.547 [1.132–2.114], respectively), whereas no differ-
ences were found between the 2 groups S and I concerning this
event (HR ¼ 0.928 [0.706–1.220]). Regarding time to reoperation,
smoker patients had a higher risk than nonsmokers (HR ¼ 2.054
[1.169–3.610]), and patients from the group I had also a higher risk
than those of group S (HR ¼ 2.340 [1.367–4.005]) (Table 4).
DISCUSSION
This study was a national, retrospective, and observational
one, which means that the therapeutic choices were performed
exclusively by each physician involved according to their practice
and best judgment. Patients with CD with at least 3 years of
follow-up and subjected to immunosuppression therapy at some
point within the 36 months after the index event (diagnosis or
early surgery after diagnosis) were consecutively enrolled, and
there was no intervention whatsoever from the researchers before
or during patients’ treatment. This study aimed at understanding
whether different therapeutic options, namely early surgery and/or
immunosuppression onset, had an impact on patients’ outcomes
concerning disabling events and further need for surgery. The
rationale for the stratification based on the option for an early
surgery is supported by the fact that resection is supposed to
eliminate disease burden, as if there was a reset of CD in these
patients. It is also important to emphasize the need to perform
studies in the real world, i.e., involving heterogeneous patient
populations with varying disease characteristics, as in the restric-
tive design of controlled trials, a number of factors influencing
outcomes may remain unidentified and unrecognized.16
Our study shows that disabling events occur in 77% of the
population and are not different between the 2 therapeutic groups
analyzed. Moreover, the option for an early surgery (after diagnosis
and before immunosuppressive treatment) does not decrease the
likelihood of needing a second surgery. In fact, the need for
reoperation in patients from group S was significantly higher than
the need for a surgery (for the first time or as a reoperation) in
patients belonging to group I. When we adjusted the results for all
variables (sex, age at diagnosis, behavior, upper track involvement,
and perianal disease), group I has a lower risk of recurrence (OR ¼
0.197 [0.117–0.330]). Moreover, the total number of surgeries/
patient is higher in the group S (1.63) than in group I (0.66).
Nevertheless, and despite the different surgical rates, both groups
presented the same tendency, i.e., an increase in the need for sur-
geries with the increment in the time elapsed between the index
event and the beginning of immunosuppressive therapy.
The importance of early therapies to prevent the recurrence
of the disease in patients with CD is a cornerstone study subject.
In this context, De Cruz et al17 analyzed a cohort of 174 post-
operative patients with CD divided into active care (colonoscopy
at 6 months after resection and consequent medication adjust-
ment, if needed) and standard care. Their results demonstrated
that treatment according to clinical risk of recurrence with an early
colonoscopy for assessment and treatment step-up was better than
conventional drug therapy alone for prevention of postoperative
CD recurrence.17 Our study had a different rationale and different
endpoints and was consolidated in a different background—the
impact of early strategies in the prevention of disabling events.
FIGURE 2. Proportion and 95% confidence interval (95% CI) of disabling disease (left) and reoperation (right) for 3 times of immunosuppression for
2 main groups (surgery and immunosuppression).
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However, both studies are comparable in the way that both
acknowledge the importance of an early intervention (either treat-
ment adjustment after a colonoscopy or an early immunosuppres-
sion start) for the CD control and patients’ management.
The concept of disabling disease in inflammatory bowel
disease was introduced by Beaugerie.10 In this work, we have
chosen to use a more strict definition of this concept by applying
precise criteria: abdominal surgery, hospital admissions, course of
steroids/year, steroid dependence or refractoriness, need to switch
immunosuppressors or anti-TNF, and the appearance of new clin-
ical events (abscesses, fistula, anal disease, and stenosis). This
change was motivated by the new tendency to prescribe immu-
nosuppressive drugs early after diagnosis, within a window of
disease opportunity, instead of using it as “the end of route.”15
The 77% rate of disabling disease reported here is similar to that
of previous studies18 and is in accordance with the known aggres-
siveness of CD.
At this point, it is important to clarify that the disabling
events analyzed were not considered a proxy of disability: this last
concept refers to a decrement in functioning and conveys the
result of an interaction between health conditions and their
context, including personal and environmental factors.19 In fact,
we aimed at analyzing the occurrence and timeline distribution of
a series of events considered to be disabling after different ther-
apeutic approaches, instead of obtaining an overall disability
assessment.
Surgery tends to be delayed for as long as possible by
patients, physicians, and even surgeons. As a consequence,
TABLE 3. Characteristics of Patients with CD with Imunossupression After Diagnosis
I0–6 (n ¼ 103) I6–36 (n ¼ 131) I36 (n ¼ 276) P,a Global
Sex, n (%) 0.426
Male 27 (45) 30 (51) 69 (55)
Age at diagnosis, yr, n (%) 0.028
A1: #16 12 (12) 16 (12) 33 (12)
A2: 17–40 83 (80) 85 (65) 203 (74)
A3: .40 8 (8) 30 (23) 40 (14)
Location, n (%) 0.063
L1: Ileon 45 (44) 69 (53) 116 (42)
L2: colonic 3 (3) 11 (8) 16 (6)
L3: ileocolonic 55 (53) 51 (39) 144 (52)
Upper tract involvement L4, n (%) 22 (22) 16 (12) 37 (13) 0.089
Behavior, n (%) 0.016
B1: nonstricturing/nonpenetrating 52 (51) 65 (50) 101 (37)
B2: stricturing 30 (29) 29 (22) 80 (29)
B3: penetrating 21 (20) 37 (28) 95 (34)
Perianal disease, n (%) 30 (29) 37 (28) 85 (31) 0.866
Smoking habits 0.021
Never smoke 48 (68) 66 (54) 114 (47)
Smoker 11 (15) 26 (21) 73 (30)
Exsmoker 12 (17) 30 (25) 56 (23)
Follow-up time, yr, median (min–max) 6 (3–36) 8 (3–25) 16 (4–65) ,0.001
Therapeutics
Anti-TNF 28 (27) 31 (24) 61 (22) 0.583
Steroids 28 (27) 30 (23) 57 (21) 0.397
Disabling, n (%) [95% CI]
Global 75 (73) [69%–77%] 98 (75) [71%–79%] 216 (78) [75%–80%] 0.487
Surgery after index event 19 (18) [14%–22%] 27 (21) [28%–25%] 80 (29) [26%–32%] 0.053
Reoperation 5 (5) [3%–7%] 9 (7) [5%–9%] 45 (16) [14%–18%] 0.001
Montreal classification and therapeutics.
I0–6, patients with immunosuppression in the first 6 months after diagnosis; I6–36, patients with immunosuppression between 6 and 36 months after diagnosis; I36, patients with
immunosuppression in the after 36 months after diagnosis.
aChi-square test.
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patients often come to surgery very late, with advanced or
complicated diseases. Longitudinal studies suggested that patients
spend a quarter (24%) of their disease course in medical
remission, 41% in postoperative remission, and a further quarter
(27%) with mild disease.20,21 In the study of Aracari et. al,22
involving 207 patients with ileocecal CD at their first resection,
83 underwent surgery at the diagnosis (early surgery), whereas
124 were submitted to surgery 54 months (min–max: 1–438) after
(late surgery). Margagnoni et al23 stated that early surgery (within
3 years after diagnosis) was associated with a longer postoperative
course free from clinical recurrence when compared with late
surgery, but not with reoperation, and despite higher rates of ileal
and complicated disease in patients with early limited surgery, the
overall need for steroids during follow-up was lower. Early sur-
gery has been shown to represent a valid alternative to medical
therapy, particularly in patients with isolated stenotic ileocecal
CD. Still, Jess et al25 reported that the rate of early surgery (in
the first year after diagnosis) has fallen from 35% (1962–1987) to
12% (2003–2004). In between these time points, there was a sig-
nificant change in patient management, with an increased and
earlier use of immunosuppression and biological therapies. Our
study supports this trend and highlights the importance of early
immunosuppression, as this therapy appears to be more efficient
in the prevention of surgeries than early surgery, although neither
of them can prevent disabling. In a similar study by the GETAID
group, early aggressive therapy with AZA within the initial 6
months after diagnosis was equally effective as conventional man-
agement in increasing time of clinical remission assessed by tri-
mesters during 36 months.26
Overall, the studied groups were well balanced concerning
most variables analyzed. However, one may notice that there are
differences among the disease phenotype when comparing groups
S and I and the different immunosuppression onset timings. In this
regard, it is important to emphasize the observational nature of
this study, which precludes the formation of homogeneous
groups. As groups were formed retrospectively taking into
consideration the clinical decisions regarding therapy, it is rational
to expect different levels of disease severity as a mere reflection of
the different therapeutic approaches. We believe that these
differences have a reduced impact in the final analysis, as they
were mostly concerned with the variation in the distribution of the
less aggressive form of the disease. Moreover, it is important to
highlight that there were no differences in disease location
between the compared groups (either defined by the therapeutic
approach or by the onset of the immunosuppressive therapy). This
is particularly important because a recent article reporting the
TABLE 4. Cox Regression for Time to Disabling or Time to Reoperation
Disabling Reoperation
HR (95% CI) P HR (95% CI) P
Sex, n (%)
Female 1.127 (1.004–1.617) 0.046 1.453 (0.889–2.375) 0.136
Age at diagnosis, yr, n (%)
A1: $16 Ref
A2: 17–40 0.715 (0.486–1.052) 0.089 0.540 (0.217–1.347) 0.186
A3: .40 0.804 (0.503–1.285) 0.362 0.339 (0.114–1.005) 0.051
Location, n (%)
L1: Ileon Ref Ref
L2: colonic 1.197 (0.682–2.099) 0.041 0.364 (0.083–1.595) 0.180
L3: ileocolonic 0.938 (0.732–1.202) 0.744 0.624 (0.383–1.015) 0.057
Upper tract involvement L4, n (%) 1.212 (0.898–1.637) 0.209 1.293 (0.521–3.207) 0.579
Behavior, n (%)
B1: nonstricturing/nonpenetrating Ref Ref
B2: stricturing 1.302 (0.951–1.781) 0.099 2.247 (0.856–5.896) 0.100
B3: penetrating 1.547 (1.132–2.114) 0.001 2.363 (0.904–6.178) 0.079
Smoking habits
Never smoke Ref Ref
Smoker 1.073 (0.811–1.421) 0.621 1.497 (0.859–2.609) 0.155
Exsmoker 1.085 (0.808–1.458) 0.587 2.054 (1.169–3.610) 0.012
Perianal disease, n (%) 1.325 (1.018–1.726) 0.037 1.020 (0.589–1.767) 0.943
Therapeutic
Surgery Ref
Immunosuppression 0.928 (0.706–1.220) 0.592 2.340 (1.367–4.005) 0.002
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largest genotype–phenotype association study ever performed in
inflammatory bowel diseases highlighted the role of disease
location as an intrinsic aspect of a patient’s disease, in part
genetically determined.27 In fact, and after correcting for disease
location and age at diagnosis, there was little or no genetic
association with disease behavior, which tends to change dra-
matically over time.
The authors are aware of the possible limitations of the
present work including (1) the retrospective nature of the study
that, although addressed as far as possible with the adjusted
regression methods, may have led to a biased underestimation of
the protective effect of surgery for disabling disease; (2) the
timing of the surgery in the surgical groups was determined by the
clinical presentation and not by a physician’s strategic decision
because most of the patients were operated because of acute
abdomen, abscesses, or acute symptoms; and (3) different medical
and surgical strategies during the follow-up period. However, we
tried to limit these drawbacks by (1) monitoring the inclusion with
a data entry monitor; (2) defining the inclusion and exclusion
criteria well at the beginning of the study; and (3) creating
a web platform for the purpose of the study, which automatically
sent missing data reports.
Overall, this study shows that neither early surgery nor
early immunosuppression can prevent the occurrence of disabling
events in patients with CD. However, immunosuppression as the
first therapy after diagnosis is effective in preventing future
surgeries, being its efficiency higher with an earlier start.
However, patients undergoing an early surgery after diagnosis
have an increased tendency to be reoperated, even with a con-
comitantly early start of immunosuppression therapy.
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Abstract  	
Backgroud: Crohn’s disease (CD) is an auto-inflammatory disease 
characterized by several relapses and abdominal surgery is a therapeutic 
option often followed by physicians for CD management. This study aims to 
determine the effect of the timing of the first surgical intervention on patients’ 
prognosis. 
Methods: This manuscript describes a retrospective analysis of a multicentric 
cohort involving 767 CD patients. Data on the disease characteristics, 
development and need for interventions was collected and determine the 
significant predictors for disabling disease and reoperation 
Results: Disabling disease affected 75% of all patients and  33% needed 
reoperation. The Odds Ratios (OR) of being affected by disabling disease was 
higher when patients had colonic disease (2.615 [1.125-0.078], upper tract 
involvement [2.593 [1.125-6.078]] and a longer time elapsed from diagnosis to 
first surgery (13-36 months: 2,754[1.538-4.934] and >36 months: 2.114 
[1.318-3.235]). On the other hand, the need to undergo further surgical 
interventions was significantly increased in patients with severe CD 
phenotypes (B2:3.090 [1.601-5.964] and B3: 2.440 [1.283-4.640]) , perianal 
disease (2.143 [1.428-3.217] and that those medicated with AZA (2.070 
[1.251-3.425]) or anti-TNF (2.253 [1.522-3.334]) more than one month after 
the initial surgery. 
Conclusions: The timing of therapeutic strategies affects the CD outcomes. 
Whereas an early surgery (within six months after diagnosis) can decrease the 
occurrence of disabling events, the introduction of immunosuppressive 
medication more than one month after the initial surgery seems to increase the 
likelihood of needing further surgeries. 
 
Keywords: Disabling disease, reoperation, Crohn’s disease 
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Introduction 
 
Crohn’s disease (CD) is a chronic auto-inflammatory disease that can 
affect any part of the gastrointestinal tract, and is characterized by frequent 
relapses (1). So far, there is no definitive treatment for CD: current therapies 
are meant to alleviate the symptoms and to improve patients’ quality of life (2).  
Among these therapies, bowel surgery appears as an almost inevitable 
option: approximately 50% of patients undergo surgery within the first 10 
years after diagnosis (3,4), whereas a total of 80% is estimated to need 
surgery at some time during the entire course of the disease (5,6).  Surgery 
has an obvious important impact in patients’ quality of life, and is also known 
to play a role in the disease outcomes afterwards, namely disabling disease 
and recurrence. Recurrence is extremely frequent and, according to the 
literature, affects 40% to 80% of CD patients (7,8). Information on the 
proportion of patients experiencing disabling disease is more variable, as the 
notion of “disabling” is rather dynamic and has been changing over the years 
with the introduction of new therapies and a better management of CD. This 
concept was initially introduced by Beaugerie et al. in 2006 (9) and Loly et al. 
in 2008 (10), who performed an evaluation of the disease’s impact according 
to measurable clinical criteria. Those studies reported a proportion of 
disabling disease of 85% and 58%, respectively. Five years after the initial 
study, Yang et al. (11) reported a new analysis that settled the proportion of 
patients with disabling disease at 80%. Following the new strategies for 
disease control meanwhile established, this study used a slightly different 
definition of disabling disease.  
As mentioned previously, surgery in CD patients impacts not only their 
quality of life, but also the likelihood of experiencing certain outcomes 
afterwards. For that reason, it is important to characterize the several 
variables associated to surgery and the specific ways in which they affect the 
course of the disease. This work aimed specifically at identifying the effect of 
the timing of the initial surgery (i.e., the time elapsed from diagnosis to the first 
surgery) on two important CD outcomes, the occurrence of disabling events 
and the need for further surgeries.  
 
 
Material and Methods  
This was consisted in a retrospective multicentric cohort analysis of 767 CD 
patients being followed prospectively by six physicians attending at different 
hospitals. The patients’ inclusion criteria were: 1) a definitive diagnosis of CD; 
2) at least three years of follow-up; 3) at least one appointment with one of the 
physicians involved in this study between 2014 and 2015; 4) had performed at 
least an X-ray computed tomography (CT) or magnetic resonance imaging 
(MRI) during the follow-up; and 5) the occurrence of a first abdominal surgery 
after the CD diagnosis.  
 
Collected variables  
All variables were prospectively collected from the Portuguese Inflammatory 
Bowel Disease study group (GEDII – Grupo de Estudo de Doenças 
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Inflamatórias Intestinais) database (gediibasedados.med.up.pt) (12). Disease 
location and behavior were classified according to the Montreal criteria (13). 
In what concerns pharmacological therapy, both the nature of the treatment – 
immunosuppression with azathioprine (AZA) or anti-Tumour Necrosis Factor 
α (anti-TNFα) – and its starting timepoint were collected.  
 
Outcomes assessment 
The primary endpoints of the study were the occurrence of disabling disease 
and reoperation. Disabling disease was a composite endpoint defined by the 
presence of at least one of the following criteria: more than one abdominal 
surgery or two hospital admissions in the follow-up period; steroid 
dependence or steroid refractoriness; need for switching the first 
immunosuppressive drug or anti-TNFα; and the appearance of new clinical 
events after the index episode (stenosis, anal disease or penetrating disease). 
Steroid use was classified as dependence or refractoriness. The definition of 
steroid dependence was the inability to reduce steroids below the equivalent 
of 10 mg per day, prednisolone within 3 months of starting steroids without 
recurrent active disease, or disease relapse within 3 months of stopping 
steroids. Steroid resistance was defined as the presence of active disease 
despite a prednisolone dose of up to 0.75 mg.kg−1 per day over a period of 
four weeks (14).  Reoperation was defined as the need for further surgeries 
after an initial one. 
 
Statistical Analyses 
Categorical variables were described through absolute (n) and relative (%) 
frequencies, while continuous variables were described as mean and 
standard deviation, or median, percentiles, and minimum and maximum, 
when appropriate. Hypothesis regarding categorical variables were tested 
using a chi-square test or a Fisher’s exact test, as appropriate.  The time 
elapsed from surgery (index event) to disabling disease or reoperation was 
evaluated using survival analysis. This time frame was either measured 
between surgery and disabling disease or reoperation, or was considered to 
be the last known follow-up time (censored cases). The cumulative 
probabilities of event-free survival were estimated using the Kaplan–Meier 
method considering the group of patients by using LogRank and Breslow 
tests.  
Logistic regression was applied to determine the relationship between clinical 
or demographical factors and the occurrence of disabling disease and 
reoperation. The multivariable analysis included all variables (gender, 
smoking habits, age at diagnosis, location disease, behavior, upper tract 
involvement, perianal disease and time between diagnosis and surgery). For 
reoperation, medical therapies (immunosuppressor and anti-TNF) were also 
included. These variables could not be included in the disabling analysis 
because the disabling definition involved medical therapies. Models were built 
according to the backward stepwise approach.  All reported p-values were 
two-sided, and the significance level was set at 5%. All data were arranged, 
processed and analyzed with SPSS® v.23.0 (Statistical Package for Social 
Sciences). 
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Results 
This study included a total of 767 CD patients who underwent an initial 
bowel surgery after diagnosis. The patients were followed for a median of 15 
(IQR – 9-22) years (Table 1). Most patients were female (53%) and 53% of 
them have never smoked. For 72% of patients the diagnosis was made during 
young adulthood (17-40 years). Isolated colonic location was present in 8% of 
the patients, whereas 11% were reported to have upper tract involvement. 
Concerning behavior, the majority of patients had a severe form of the 
disease – 39% had stricturing and 47% had penetrating disease – whereas 
24% of the patients presented perianal disease. Regarding medical therapy, 
22% and 49% of patients were never treated with AZA and anti-TNF, 
respectively. Most patients that ended up being medicated started the 
treatment more than one month after surgery (43% with AZA and 36% with 
anti-TNF). 
To study the effect of the timing of the first surgical intervention in the 
analyzed outcomes, patients were stratified according to the number of 
months elapsed from diagnosis to that initial surgery: less than 6 months, 7 to 
12 months, 13 to 36 months and more than 36 months. Most patients (45%) 
fell into this last category, whereas for 30% the time interval was less than 6 
months. For 9% and 17% of the patients the time elapsed was 7-12 and 13-36 
months, respectively (Table 1). 
The median (IQR) time to the introduction of AZA and anti-TNF was 65 
months (13-144) and 72 months (30-143), respectively. The number of 
months elapsed from surgery to AZA introduction did not vary with the timing 
of the first surgery (p=0.095) – Fig. 1. On the other hand, the introduction of 
anti-TNF was done later for patients that had an early surgery (less than 6 
months after diagnosis) than for patients that had a late one, more than 36 
months after diagnosis (118 vs. 53 months, p<0.001) - Fig 1. Finally, the 
timing to the first surgery had no significant impact on the proportion of 
patients being medicated with AZA or anti-TNF throughout the follow up (Fig. 
2), with two exceptions: the proportion of patients being treated with AZA 
varied with the time elapsed from the initial surgery in the intervals of 5 to 7 
and 11 to 15 years after diagnosis. 
 
Disabling Disease 
During the follow up period analyzed in this study, 573 (75%) patients 
were considered to have disabling disease (Table 1). The association 
between demographic and clinical variables and the occurrence of events that 
defined the disabling condition is depicted on Table 2: age at diagnosis, upper 
tract involvement, perianal disease and time elapsed from diagnosis to 
surgery were significant. Regarding age at diagnosis, patients that were 
diagnosed as young adults (17-40 years old) were more frequently found to 
have disabling disease (75% vs. 66% without disabling, p=0.002). Moreover, 
the absence of upper tract involvement and perianal disease were statistically 
associated with the group of patients presenting no disabling disease 
(p=0.008 and p<0.001, respectively). Finally, patients that underwent surgery 
later after the diagnosis were found to be associated with disabling disease 
(48% vs. 37% without disabling), whereas those patients with an early surgery 
after diagnosis had a higher proportion of patients without disabling (40% vs. 
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26% with disabling), p=0.001. Accordingly, the cumulative incidence rate of 
disabling disease was lower in the group with early surgery (0-6 months: 
65%), increasing with longer times elapsed from diagnosis to surgery. 
Moreover, when the patients that underwent an early surgery after diagnosis 
reached a status of disabling disease, they did so later than patients that had 
their initial surgery more than 6 months after diagnosis: the median [CI95%] 
was 119 [85-152] for 0-6 months, 84 [57-110] for 7-12 months, 63 [38-87] for 
13-36 months, and 41 [24-57] for >36 months (p<0.001) – ( Fig S1). 
A multivariable logistic regression was performed to determine which 
factors were able to independently predict the occurrence of disabling disease 
in this cohort (Table 3): location, upper tract involvement and time elapsed 
from diagnosis to surgery were the significant variables. The odds ratio (OR) 
of experiencing disabling disease at some time during follow up was 
increased for patients with isolated colonic disease (OR=2.612, CI95% 
[1.125-6.078]), with upper tract involvement (OR=2.593, CI95% [1.125-
6.078]), and with a longer time elapsed from diagnosis to first surgery (13-36 
months: OR=2.754, CI95% [1.538-4.934]; >36 months: OR=2.114, CI95% 
[1.381-3.235]). 
 
Reoperation 
During the follow up period analyzed in this study, 254 (33%) of all patients 
needed to through more than one abdominal surgery (Table 1). The following 
factors were shown to be associated with the need for reoperation: age at 
diagnosis, disease behavior, presence of perianal disease and presence and 
introduction timing of pharmacological therapy (Table 4). As for the 
occurrence of disabling disease, most patients that required reoperation were 
17 to 40 years at the time of diagnosis (79% vs. 69% without reoperation, 
p=0.001). Concerning behavior, patients with a non-structuring/non-
penetrating phenotype required reoperation less often (18% vs. 8% with 
reoperation, p=0.002), as patients without perianal disease (80% vs. 66% with 
reoperation, p<0.001). Finally, the proportion of patients without medication 
was higher among those that had no reoperation (AZA: 24% vs. 18%, anti-
TNF: 55% vs. 37%), whereas the proportion of patients medicated only one 
month after surgery was higher among those that needed reoperation (AZA: 
58% vs. 36%, anti-TNF: 53% vs. 27%), p<0.001 for both cases. There was no 
significant difference in the cumulative incidence rates of reoperation among 
patients with that had their initial surgery at different timings, nor there was 
any difference in the time frame between surgery and reoperation: the median 
[95%CI] was 280 [166-393] for 0-6 months, 214 [159-268] for 7-12 months, 
245 [-],for 13-36 months, and 222[142-301] for >36 months, p=0.303 (Fig S1). 
  The multivariable logistic regression showed that three different 
variables were able to independently predict the occurrence of reoperation: 
behavior, presence of perianal disease and the introduction and timing of the 
pharmacological intervention (Table 4). The ORs of requiring a reoperation at 
some time during the follow up period were increased for patients with more 
severe phenotypes (B2: OR=3.090, CI95% [1.601-5.964] and B3: OR=2.440, 
CI95% [1.283-4.640]), the presence of perianal disease (OR=2.143, CI95% 
[1.428-3.217]) and the introduction of medical therapy more than one month 
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after the initial surgery (AZA: OR=2.070, CI95% [1.251-3.425] and anti-TNF: 
OR=2.253, CI95% [1.522-3.334]). 
 
Discussion  
CD patients are likely to need at least one abdominal surgery during 
the course of the disease. Our hypothesis, addressed in this study, was that 
the time point at which patients were operated had a significant impact on the 
disease’s prognosis, namely concerning the occurrence of disabling disease 
and the need for further surgeries. 
The definition of disabling disease used in this study differed from that 
introduced in 2006 by Beaugerie et al. (9) ,and used by Loly et al. (10) and 
Yang et al. (11) in subsequent studies. Given the current top-down 
therapeutic approaches, the need to start immunosuppressive therapy and 
anti-TNF was not considered to be disabling disease. This was the major 
difference of the disabling definition used in this study compared to previous 
ones, and is an unavoidable consequence of a constantly increasing 
knowledge on the disease, followed by new therapeutic strategies for disease 
control and symptoms management (15–17). Disabling disease is an 
important outcome, as it empowers the physician with a proxy for the severity 
of the disease. Even using an updated and more restrictive definition of 
disabling disease, its estimated rate in this study was 75%, which is similar to 
previous ones. Likewise, disease location, the presence of perianal disease 
and upper tract involvement were also found to be independent predictors of 
disabling disease, as it has been demonstrated in other studies (18). The 
main novelty in this study regarding disabling disease is the realization that 
the time elapsed from diagnosis to an initial surgery is also an independent 
predictor of this outcome: in fact, patients that went through the first surgery 
shortly after diagnosis were less prone to suffer disabling disease during the 
follow-up period.  
Reoperation, i.e., the need to undergo more than one abdominal 
surgery throughout the follow-up period, is a serious and impacting 
complication of CD disease. Multiple risk factors – patient-related, disease-
related and surgery-related – have already been identified and used to predict 
this outcome, but the literature is not consensual on this issue (19) . In our 
study, 33% of all patients needed reoperation, a similar result to that obtained 
in previous ones (20,21). Severe disease phenotypes, presence of perianal 
disease and introduction of pharmacological medication only after surgery 
were found to increase the reoperation risk in a significant fashion. A few 
studies have been published associating the introduction of medical 
therapeutics, namely immunosuppression, with reoperation. 
Immunosuppression was considered to be relevant in the CD management 
particularly when introduced before or after surgery as a prophylactic therapy 
(19). Our study was not entirely conclusive in this regard, but highlighted the 
increased risk for patients beginning medical therapeutics only one month 
after surgery. 
At this point it is important to highlight that, in general, the introduction 
of immunosuppressive therapy (AZA or anti-TNF) was not influenced by the 
time elapsed from diagnosis to first surgery. With the exception of a later 
introduction of anti-TNF in patients that had an early surgery, the time point at 
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which patients underwent their initial surgery had no impact on the moment 
when medication was introduced or on the proportion of patients being 
medicated throughout the follow-up (with two non-relevant exceptions). In 
other words, our results concerning the occurrence of disabling disease and 
need for reoperation were not biased by different therapeutic strategies 
regarding medication. 
This study had a few important strengths that should be acknowledged: 
the cohort under analysis was large, multicentric, thoroughly characterized 
and data was retrieved for a long follow-up period (median 15 years IQR=9-
15). However, a few cautionary notes should also be highlighted: this was a 
retrospective study, and both outcomes were retrospectively defined. 
In conclusion, our study shows that the CD prognosis is influenced not 
only by the patients’ and disease features (disease location and behavior, 
presence of perianal disease and involvement of the upper gastrointestinal 
tract), but also by the timing of the therapeutic strategies followed. In fact, an 
early surgery has a preventive effect on the occurrence of disabling disease, 
whereas the introduction of AZA and anti-TNF more than one month after the 
initial surgery seems to aggravate the risk for reoperation. The important 
clinical impact of these variables support their inclusion in the algorithms 
developed to back the decision-making aiding tools concerning the strategies 
followed for CD management. 
 
Grant Support : This work was funded by GEDII - Grupo de Estudo da 
Doença Inflamatória Intestinal. 
 
Disclosures: Fernando Magro received a fee for presenting from: AbbVie, 
Ferring, Falk, Hospira, PharmaKern, MSD, Schering, Lab. Vitoria, Vifor, 
OmPharma. All others authors: none to declare.  
 
Writing Assistance: Catarina L. Santos for scientific writing assistance. 
 
Author contributions: Dias CC was involved in the conception and design of 
the study, acquisition, analysis and interpretation of data, and was responsible 
for drafting the manuscript; Magro F was involved in the conception and 
design of the study, interpretation of data, and drafting and revising the 
manuscript. All other authors were responsible for data inclusion. All authors 
have read and approved the final manuscript.   
 
Acknowledgments 
The authors would like to acknowledge all investigators at the hospitals who 
provided data for this study, GEDII – Grupo de Estudo da Doença Inflamatória 
Intestinal – for all the support, Sandra Dias for all the help during data 
collection.  
 
 
References 
1.  Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and 
natural history of inflammatory bowel diseases. Gastroenterology. 2011 
May;140(6):1785–94.  
5. CLASSIFICATION
64
	 9	
2.  Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical 
aspects and established and evolving therapies. Lancet. 2007. p. 1641–
57.  
3.  Carter MJ, Lobo AJ, Travis SPL, IBD Section BS of G. Guidelines for 
the management of inflammatory bowel disease in adults. Gut [Internet]. 
2004 Sep;53 Suppl 5:V1–16. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15306569 
4.  Peyrin-Biroulet L, Loftus E V, Colombel J-F, Sandborn WJ. The natural 
history of adult Crohn’s disease in population-based cohorts. Am J 
Gastroenterol [Internet]. 2010;105(2):289–97. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19861953 
5.  Moss AC. Prevention of postoperative recurrence of Crohn’s disease: 
what does the evidence support? Inflamm Bowel Dis [Internet]. 
19(4):856–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23446339 
6.  Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. 
Long-term evolution of disease behavior of Crohn’s disease. Inflamm 
Bowel Dis [Internet]. 2002 Jul;8(4):244–50. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12131607 
7.  Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence 
in 907 patients with primary ileocaecal Crohn’s disease. Br J Surg 
[Internet]. 2000;87(12):1697–701. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11122187 
8.  Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after 
ileocolic resection: endoscopically visualised ileal ulcers preceding 
symptoms. Gut [Internet]. 1992 Mar;33(3):331–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/1568651 
9.  Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J-P, Cosnes J. 
Predictors of Crohn’s disease. Gastroenterology [Internet]. 
2006;130(3):650–6. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16530505 
10.  Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. 
Scand J Gastroenterol [Internet]. 2008 Aug;43(8):948–54. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/19086165 
11.  Yang CH, Ding J, Gao Y, Chen X, Yang Z Bin, Xiao SD. Risk factors 
that predict the requirement of aggressive therapy among Chinese 
patients with Crohn’s disease. J Dig Dis [Internet]. 2011 Apr;12(2):99–
104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21401894 
12.  GEDII Group. GEDII data base. https://gediibasedados.med.up.pt/; 
2016.  
13.  Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, Brant 
SR, et al. Toward an integrated clinical, molecular and serological 
classification of inflammatory bowel disease: report of a Working Party 
of the 2005 Montreal World Congress of Gastroenterology. Can J 
Gastroenterol [Internet]. 2005;19 Suppl A:5A – 36A. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16151544 
14.  Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, 
Colombel JF, et al. The second European evidence-based Consensus 
on the diagnosis and management of Crohn’s disease: Current 
5.2. THE TIMING OF EARLY THERAPEUTICS STRATEGIES HAS A SIGNIFICANT IMPACT
ON THE CROHN’S DISEASE PROGNOSIS
65
	 10	
management. J Crohns Colitis [Internet]. 2010;4(1):28–62. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/21122489 
15.  Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald 
JWD, et al. Treatment of active Crohn’s disease with MLN0002, a 
humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol 
Hepatol [Internet]. 2008;6(12):1370–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18829392 
16.  Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, et 
al. Ustekinumab induction and maintenance therapy in refractory 
Crohn’s disease. N Engl J Med [Internet]. 2012;367(16):1519–28. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/23075178 
17.  Devlin SM, Panaccione R. Evolving Inflammatory Bowel Disease 
Treatment Paradigms: Top-Down Versus Step-Up. Medical Clinics of 
North America. 2010. p. 1–18.  
18.  Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical 
prognostic factors for disabling Crohn’s disease: A systematic review 
and meta-analysis. World J Gastroenterol [Internet]. 2013;19(24):3866–
71. Available from: http://www.wjgnet.com/1007-
9327/pdf/v19/i24/3866.pdf 
19.  Vaughn BP. Prevention of post-operative recurrence of Crohn’s 
disease. World J Gastroenterol [Internet]. 2014;20(5):1147. Available 
from: http://www.wjgnet.com/1007-9327/full/v20/i5/1147.htm 
20.  Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after 
surgery in Crohn’s disease. Relationship to location of disease (clinical 
pattern) and surgical indication. Gastroenterology [Internet]. 1985 
Jun;88(6):1826–33. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/3996839 
21.  Borley NR, Mortensen NJM, Chaudry MA, Mohammed S, Warren BF, 
George BD, et al. Recurrence after abdominal surgery for Crohn’s 
disease: relationship to disease site and surgical procedure. Dis Colon 
Rectum [Internet]. 2002 Mar;45(3):377–83. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12068198 
 
 
 
 
  
5. CLASSIFICATION
66
	 11	
 
  Table 1 - Demographical and clinical variables (n=767) of the cohort 
analysed in this study 
 
 Total 
 n (%) 
Gender   
Male 358 47% 
Female 409 53% 
Smoking habits   
Never smoke 367 53% 
Ex- smoker 155 23% 
Smoker 166 24% 
Age at diagnosis   
A1 - ≥16 years 85 11% 
A2 - 17-40 years 555 72% 
A3 - >40 years 127 17% 
Location   
L1 - Ileon 365 23% 
L2 – Colonic 57 8% 
L3 - IleoColonic 269 39% 
L4 (Upper tract involvement)   
No 647 89% 
Yes 78 11% 
Behavior   
B1 - Non-Stricturing/non-penetrating 105 14% 
B2 - Stricturing 282 39% 
B3 - Penetrating 338 47% 
Perianal disease   
No 580 76% 
Yes 187 24% 
AZA   
No AZA 167 22% 
AZA before and after surgery (<1 month) 108 14% 
Aza only after surgery (>1 month ) 324 43% 
Aza only before surgery 151 20% 
Anti TNF   
No anti TNF 366 49% 
anti TNF before and after surgery (<1 
month) 62 8% 
anti TNF only after surgery (>1 month) 269 36% 
anti TNF only before surgery 53 7% 
Time between diagnosis and surgery   
0-6 months 227 30% 
7-12 months 66 9% 
13-36 months 127 17% 
>36 months 342 45% 
Disabling disease 573 75% 
Reoperation 254 33% 
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Table 2 – Association between disabling disease and demographic/clinical 
aspects. 
 
 Disabling  
 No (n=194,25%) 
Yes 
(n=573,75%) p-value
1 
 n (col 
%) 
(Row 
%) 
n (col  
%) 
(Row 
 %)  
Gender       
0.155 Male 82 42% 23% 276 48% 77% 
Female 112 58% 27% 297 52% 73% 
Smoking habits       
0.805 Never smoke 91 53% 25% 276 54% 75% Ex- smoker 42 24% 27% 113 22% 72% 
Smoker 40 23% 24% 126 24% 76% 
Age at diagnosis       
0.002 A1 19 10% 22% 66 11% 78% A2 127 66% 23% 428 75% 77% 
A3 48 24% 38% 79 14% 62% 
Location       
0.124 L1 103 59% 28% 262 51% 72% L2 10 6% 18% 47 9% 82% 
L3 62 35% 23% 207 40% 77% 
L4       
0.008 No 173 95% 27% 474 88% 73% 
Yes 10 5% 13% 68 12% 87% 
Behavior        
B1 31 17% 30% 74 14% 70% 
0.288 B2 63 34% 22% 219 40% 78% 
B3 89 49% 26% 249 46% 74% 
Perianal disease       
<0.001 No 169 87% 29% 411 72% 71% 
Yes 25 13% 13% 162 28% 87% 
Time between 
diagnosis and surgery 
      
0.001 0-6 months 79 40% 35% 148 26% 65% 7-12 months 19 10% 29% 47 8% 71% 
13-36 months 24 13% 19% 103 18% 81% 
>36 months 72 37% 21% 270 48% 79% 
1Chi-Square test 
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Table 3 – Logistic regression for disabling disease after surgery and 
reoperation. 
 Disabling disease Reoperation 
 OR 95%IC P OR 95%IC P 
Location   0.041    
L1 Ref   - - - 
L2 2.615 1.125-6.078 0.025 - - - 
L3 1.375 0.924-2.047 0.117 - - - 
L4       
No Ref   - - - 
Yes 2.593 1.125-6.078 0.025 - - - 
Behavior      0.003 
B1 - - - Ref   
B2 - - - 3.090 1.601-5.964 0.001 
B3 - - - 2.440 1.283-4.640 0.007 
Perianal disease       
No - - - Ref   
Yes - - - 2.143 1.428-3.217 <0.001 
Time between 
diagnosis and 
surgery 
  
0.001    
0-6 months Ref   - - - 
7-13 months 1.645 0.813-3.331 0.166 - - - 
13-36 months 2.754 1.538-4.934 0.001 - - - 
>36 months 2.114 1.381-3.235 0.001 - - - 
AZA1      0.001 
No AZA - - - Ref   
AZA before and after 
surgery (<1 month) 
- - - 1.263 0.658-2.425 0.482 
AZA only after surgery 
(>1 month ) 
- - - 2.070 1.251-3.425 0.005 
AZA before surgery - - - 0.768 0.399-1.480 0.430 
Anti TNF1 - - -   <0.001 
No anti TNF - - - Ref   
Anti TNF before and 
after surgery (<1 
month) 
- - - 0.855 0.399-1.832 0.687 
Anti TNF only after 
surgery (>1 month) 
- - - 2.253 1.522-3.334 <0.001 
Anti TNF before 
surgery 
- - - 1.315 0.587-2.47 0.506 
Hosmer –Lemshow 0.355 0.435 
Roc  0.633 [0.584-0.682] 0.714 [0.673-0.754] 
1 – AZA and Anti-TNF were not used in regression for disabling disease because 
medical therapeutics is one of the criteria of this outcome 
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Table 4 – Reoperation in patients with abdominal surgery after diagnosis 
(n=767). 
 Reoperation  
 No (n=513,67%) 
Yes 
(n=254,33%) p-value 
 n (col 
%) 
(Ro
w %) 
n (col 
%) 
(Row 
%)  
Gender       
0.194 Male 231 45% 65% 127 50% 35% 
Female 282 55% 69% 127 50% 31% 
Smoking habits       
0.884 Never smoke 249 54% 68% 118 52% 32% Ex- smoker 104 22% 67% 51 23% 33% 
Smoker 109 24% 66% 57 25% 34% 
Age at diagnosis       
0.001 A1 55 11% 65% 30 12% 35% A2 355 69% 64% 200 79% 36% 
A3 103 20% 81% 24 9% 19% 
Location       
0.333 L1 251 55% 69% 114 49% 31% L2 37% 8% 65% 20 9% 35% 
L3 170 37% 63% 99 42% 37% 
L4       
0.402 No 437 90% 68% 210 88% 32% 
Yes 49 10% 63% 29 12% 37% 
Behavior        
B1 86 18% 82% 19 8% 18% 
0.002 B2 178 37% 63% 104 44% 37% 
B3 222 46% 66% 116 48% 34% 
Perianal disease       
<0.001 No 412 80% 71% 168 66% 29% 
Yes 101 20% 54% 86 34% 46% 
Time between 
diagnosis and surgery 
      
0.559 0-6 months 145 28% 64% 82 32% 36% 7-13 months 43 8% 65% 23 9% 35% 
13-36 months 90 18% 71% 37 45% 29% 
>36 months 232 46% 68% 110 44% 32% 
AZA       
<0.001 
No AZA 122 24% 73% 45 18% 27% 
AZA before and after 
surgery (<1 month) 75 15% 69% 33 13% 
31% 
Aza only after surgery 
(>1 month ) 181 36% 56% 143 58% 
44% 
Aza only berore surgery 124 25% 82% 27 11% 18% 
Anti TNF       
<0.001 
No anti TNF 274 55% 75% 92 37% 25% 
Anti TNF before and 
after surgery (<1 month) 50 10% 81% 12 5% 
19% 
Anti TNF only after 
surgery (>1 month) 138 27% 51% 131 53% 
49% 
Anti TNF before surgery 40 8% 76% 13 5% 25% 
1Chi-Square test 
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Fig, 1.  Box plots representing the time elapsed from surgery to introduction of 
AZA (left,p=0.095) and anti-TNF (right, p<0.001), stratified by the timing of the 
first surgery.
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Fig. 2.  Proportion of patients under AZA (up) and anti-TNF (down) therapy 
throughout the follow-up and stratified by the timing of the first surgery.
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Fig. S1. Median time and 95% confidence intervals (bars) of time frame 
between surgery and disabling disease (right) and time frame between 
surgery and reoperation (left), stratified by the timing of the first surgery.
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6. Prediction
The third aim of this thesis is to develop and validate prognostic models for outcomes identified in Goal 1,
with risk factors isolated in Goals 1 and 2. Two main paths of work have been followed for modelling predictive
classifiers, one based on Bayesian networks and the other on decision trees. In the first path, two preparatory
studies, presented in international forums of computer-based medical systems, were developed to a) compare
Bayesian network classifiers with logistic regression (Appendix A), and b) simply assess the classification ability
of the Bayesian network (Appendix B). Then, from the main study, the defined Bayesian models achieved high
AUC for disabling disease and reoperation, and an online tool allows the application of the classifier at bedside
(Appendix C). The risk matrices - based on age at diagnosis, perianal disease, disease aggressiveness and early
therapeutic decisions - exhibited good performance for the most important prognostic criteria: high positive
post-test odds for disabling disease and low negative post-test odds for reoperation. The risk matrices are also
easily applicable as bedside clinical tools that can help physicians during therapeutic decisions in early disease
management. In the second path, decision trees were able to predict disabling, surgery and reoperation with
high AUC, and were shown to be a valid and useful approach to depict outcome risks. The defined cut-off
risk levels had high odds test positivity for disabling, while excluding surgery and reoperation with low odds
test negativity.
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Abstract
Introduction: The establishment of prognostic models for Crohn’s disease [CD] is highly desirable, 
as they have the potential to guide physicians in the decision-making process concerning 
therapeutic choices, thus improving patients’ health and quality of life. Our aim was to derive 
models for disabling CD and reoperation based solely on clinical/demographic data.
Methods: A multicentric and retrospectively enrolled cohort of CD patients, subject to early 
surgery or immunosuppression, was analysed in order to build Bayesian network models and 
 Journal of Crohn's and Colitis Advance Access published January 10, 2017
 by guest on January 11, 2017
http://ecco-jcc.oxfordjournals.org/
Downloaded from 
6.1. DEVELOPMENT AND VALIDATION OF RISK MATRICES FOR CROHN’S DISEASE
OUTCOMES IN PATIENTS SUBMITTED TO EARLY THERAPEUTIC INTERVENTIONS.
79
risk matrices. The final results were validated internally and with a multicentric and prospectively 
enrolled cohort.
Results: The derivation cohort included a total of 489 CD patients [64% with disabling disease and 
18% who needed reoperation], while the validation cohort included 129 CD patients with similar 
outcome proportions. The Bayesian models achieved an area under the curve of 78% for disabling 
disease and 86% for reoperation. Age at diagnosis, perianal disease, disease aggressiveness and 
early therapeutic decisions were found to be significant factors, and were used to construct user-
friendly matrices depicting the probability of each outcome in patients with various combinations 
of these factors. The matrices exhibit good performance for the most important criteria: disabling 
disease positive post-test odds = 8.00 [2.72–23.44] and reoperation negative post-test odds = 0.02 
[0.00–0.11].
Conclusions: Clinical and demographical risk factors for disabling CD and reoperation were 
determined and their impact was quantified by means of risk matrices, which are applicable 
as bedside clinical tools that can help physicians during therapeutic decisions in early disease 
management.
Key Words:  Disabling disease; reoperation; Crohn’s disease; risk matrices
1. Introduction
Crohn’s disease [CD] is a chronic and progressive disease of 
unknown etiology, prone to relapses and disabling events. The 
clinical course is usually characterized by intermittent relapses, 
although half of the patients express a mild disease with low 
propensity to recurrent episodes. On the other hand, the more 
aggressive cases may require surgery.1 As a chronic disease, neither 
treatment nor surgery actually heal the patients, which are usually 
the subject of frequent medical visits and hospitalizations, creating 
an aura of uncertainty surrounding their professional and social 
future that also affects their families.2,3
The new concepts on CD treatment are leaving behind the clas-
sical approach of controlling the disease symptoms—instead, stud-
ies focusing on improvement of quality of life and on the reduction 
of hospitalizations and surgeries are now emerging. Since the treat-
ment schedule clearly affects the disease course, identifying good 
prognostic models based on genetic/serological and clinical/demo-
graphic factors have been a focus of research. The latter option is 
more appealing, as it can be supported by data collected during the 
daily clinical practice.4,5 The identification of clinical criteria that can 
predict CD outcomes at an early phase of the disease is therefore cru-
cial, as it can guide the decision-making process on the therapeutic 
options.
The notion of disabling disease was introduced in 2006 by 
Beaugerie et al.6 Two years later, Lolly et al.7 presented another study 
on this subject. Later, in 2011, Yang et al.8 used a similar definition 
in their study. Currently, and due to the emergence of the above-
mentioned new strategies for disease control, there is no consensus 
regarding the concept of ‘disabling’ in CD.
The studies seeking to identify factors that can improve the 
CD outcomes have conflicting conclusions, as the different cohorts 
yield heterogeneous results due to different methodologies and/or 
different criteria for patient selection and evaluation. Although the 
computation of prognostic models can be considered a crucial step 
towards CD control and management, these are, unfortunately, sel-
dom-addressed topics in the current literature. Moreover, the intri-
cate nature of real-world biomedical data requires the utilization of 
analyses in which complexity goes beyond traditional biostatistics,9 
without losing the necessary formality.10,11
2. Material and Methods
2.1. Derivation and validation cohorts
Data from CD patients being followed by 14 secondary and ter-
tiary care centres was collected in a retrospective fashion [between 
April and December 2013]. Inclusion criteria were defined as fol-
lows: patients aged more than 18 years who had undergone sur-
gery or immunosuppressive therapy in the initial 6 months after 
diagnosis, and who had at least 3 years of follow-up. All data was 
collected through a web database, and all missing data or discrep-
ancies were reviewed by the investigators. The study was moni-
tored by the national coordinator of the Portuguese IBD group 
[GEDII].
The independent validation cohort included patients [from five 
hospitals] who were enrolled in a prospective fashion. Their data 
were registered in a national clinical database [gediibasedados.med.
up.pt] of IBD patients. Inclusion criteria were similar to those used 
in the derivation cohort.
Patients from both cohorts were stratified according to the early 
therapeutic strategies followed by their physicians: Group I patients 
started immunosuppression during the initial 6 months after diag-
nosis [index event] and prior to any surgical procedure; Group S0 
patients underwent a surgical intervention [index event] in the initial 
6 months after diagnosis and had no immunosuppression therapy 
during the known follow-up period; and Group SI patients under-
went a surgical intervention [index event] in the initial 6 months 
after diagnosis and started immunosuppression within the 6 months 
after surgery.
2.2. Clinical and demographic variables
Besides the basic demographic data, clinical information was col-
lected for each patient, including the Montreal classification12 and 
the follow-up data [total number of surgeries and hospitalizations; 
treatment, namely corticoids, immunosuppression or anti-TNF, 
and disease adverse events—stenosis, abscess, perforation and 
anal disease]. Regarding Montreal classification, patients were 
classified according to disease extent, behaviour and age. Steroid 
resistance was defined as the presence of active disease despite a 
prednisolone dose of up to 0.75 mg/kg per day over a period of 
4 weeks.13,14
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2.3. Outcomes analysed
The primary outcome of this study was the occurrence of disabling 
disease, whereas reoperation was studied as a secondary outcome. 
We have defined disabling disease as the occurrence of at least one 
of the following events: one or more surgeries in the first 5 years 
after diagnosis [excluding the index surgery, if applicable]; more 
than one surgery during follow-up [also excluding the index surgery, 
if applicable]; more than two hospitalizations [excluding the index 
episode and hospitalization for infliximab infusion]; at least two 
steroid course requirements per year, steroid dependency and steroid 
refractoriness; need to switch immunosuppression [AZA or MTX], 
and anti-TNF drugs [infliximab or adalimumab]; new events such as 
stenosis, penetrating disease or anal disease. This definition of disa-
bling was determined taking into account the following aspects: [1] 
the introduction of immunosuppression and anti-TNF per se were 
not interpreted as disabling disease based on the development of 
new therapeutic strategies; [2] due to low efficacy of 5-ASA in CD 
patients, many newly diagnosed patients were treated with immu-
nosuppression and anti-TNF; [3] switching treatments was seen as 
disabling and [4] events after the index event were interpreted as 
disabling due to signs of disease progression.
2.4. Statistical analyses
Prognostic models were defined by means of Bayesian networks 
[BNs] built over the set of available variables.15 Bayesian networks 
can be seen as an alternative to logistic regression, where statisti-
cal dependence and independence are not hidden in approximat-
ing weights, but rather explicitly represented by links in a network 
of variables.11 Generally, a Bayesian network represents a joint 
distribution of one set of variables, specifying the assumption of 
independence between them, with the interdependence between vari-
ables being represented by a directed acyclic graph. Each variable 
is represented by a node in the graph, and is dependent on the set 
of variables represented by its ascendant nodes.16 This dependence 
is represented by a conditional probability table that describes the 
probability distribution of each variable, given their ascendant vari-
ables. The Tree Augmented Naïve Bayes [TAN] classifier model, used 
in this study, includes two assumptions: [1] all explanatory variables 
are conditioned by the outcome, i.e. all will directly influence the 
outcome during inference; and [2] an optional additional depend-
ence is allowed for each variable, i.e. each variable’s effect might be 
adjusted by one additional covariable.17 TAN classifiers were built 
from the derivation cohort. Model parameters were validated by 
comparing the AUC in the derivation cohort with those calculated 
from a leave-one-out and a 10 times 2-fold cross-validation [for vari-
ability assessment with independent training and testing], and by an 
independent comparable validation cohort.
The application of the prognostic models generated in this work 
can be visualized by means of [a] an online tool for direct BN infer-
ence [in beta testing phase], and [b] appropriately defined risk matri-
ces. In order to choose which variables should be included in the risk 
matrices, we applied a logistic regression with all independent vari-
ables using the enter method. Variables with statistical significance 
[or with clinical relevance for the course of the disease, e.g. age at 
diagnosis4] were chosen as factors for the matrices. Each cell of the 
matrices represents the marginal posterior outcome probability esti-
mate for that subgroup of patients. The precision of such estimates 
is given by a 95% credible interval, computed from a Monte Carlo 
simulation of one million samples from the derived joint probabil-
ity model [i.e. the BN].18 The risk values in each cell of the matrix 
represent the expected risk for a patient in that subgroup, while the 
credible interval encloses 95% of risk estimates for patients in that 
subgroup [i.e. only 5% of patients in that subgroup have a risk esti-
mate outside the credible interval]. We believe that this approach is 
more interesting from the clinical point of view than the usual one, 
in which a confidence interval [CI] of the expected risk of all patients 
in each subgroup is computed and presented. Since patients with an 
early surgery [Group S] may have either engaged in immunosup-
pression therapy or not [S0 vs. SI], and in order to have an accurate 
prognosis for these patients, the posterior probability P[D|S] and the 
corresponding credible intervals were computed for Groups S0 and 
SI, taking into account the probability of needing immunosuppres-
sive therapy after surgery [Table 1]. The cell risk matrices for Group 
S patients were calculated as follows:
P D | S  = P D | S  x P I | S  + P D | S  x P ~ I | SI 0( ) ( ) ( ) ( ) ( ).
To assess the discriminative ability of the risk matrices for each out-
come, specific cut-off values were chosen after performing a ROC 
analysis of the derivation cohort. For disabling disease, and taking 
into account its expected prevalence and the impact of a positive 
prediction, a rule-in approach was applied aiming at a high positive 
predictive value [~80%]. For reoperation, and taking into account 
its expected prevalence and the impact of a negative prediction, a 
rule-out approach was applied aiming at a high negative predictive 
value [also ~80%]. The thus derived decision rules were then evalu-
ated on both cohorts, estimating sensitivity, specificity, accuracy, the 
predictive values, likelihood ratios, and the post-test odds.
Logistic regression was applied with IBM SPSS v23.0, BN struc-
tures were created with WEKA software,19 posterior probabilities were 
inspected using SamIam software20; the exact inference procedures for 
validation and risk matrices definition were available in R package 
gRain21 using Lauritzen-Spiegelhalter algorithm,22 while ROC curves 
and corresponding AUCs were computed using R package pROC.23
3. Results
3.1. Population characteristics and analysed 
outcomes
The derivation cohort analysed in this study consisted of 489 CD 
patients, of which 46% were male, and 79% were 40 years old or 
younger when diagnosed [Table 2]. Most of the patients had either 
an ileal or an ileocolonic location of the disease, 12% had upper 
tract involvement, and 26% had perianal disease. Disabling disease 
was observed in 64% [CI 95%: 60–68%] of the enrolled patients, 
while 18% [CI 95%: 15–21%] needed reoperation [i.e. more than 
one surgery].
Table 1. Probability of immunosuppression after surgery: P[I|S].
Perianal disease
No Yes
Behaviour
B1 B2 B3 B1 B2 B3
Age at diagnosis
≤40 35% 80% 75% 71% 71% 83%
>40 43% 47% 67% 68% 68% 68%
I = Immunosuppression; S = Surgery.
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This cohort was stratified according to the early therapeutic strat-
egies followed for each patient: Group I consisted of patients who 
started immunosuppression in the initial six months after diagnosis and 
prior to any surgical procedure, and Group S consisted of patients who 
underwent surgery in the initial 6 months following diagnosis. Group 
S was further divided into patients who started immunosuppression 6 
months after the initial surgery [SI], and patients who did not follow 
any immunosuppression therapy during the follow-up time considered 
in this study [S0]. Eighty [16%] patients were in Group S0, 175 [36%] 
in Group SI and 234 [48%] in Group I, and significant differences were 
observed between these groups for all variables accounted for in this 
study, with the exception of gender [Table 2]. Concerning outcome, 
disabling disease occurred most frequently among SI patients [78% of 
SI, 69% of I and 19% of S0, p < 0.001], as did the need for reoperation 
[40% of SI, 3% of I and 15% of S0, p < 0.001].
3.2. Bayesian prognostic models and relevant risk 
factors
In order to unveil the interdependent relationships between the ana-
lysed CD outcomes and the variables considered, BN-based models 
were built for the presence of disabling disease and the need for reop-
eration [Figure 1]. In both cases, patient group was associated [arc 
between variables] with disease behaviour, upper gastrointestinal tract 
location [L4], and age at diagnosis, while location was associated with 
perianal disease. For disabling disease, an association between perianal 
disease and gender was also found, whereas an association between 
gender and upper tract involvement was found for reoperation.
To determine which of the factors listed above were significant and 
should be included in risk matrices, a logistic regression was carried 
out using all the independent variables considered. Those that were 
statistically significant and those that had been shown by previous 
Table 2. Characteristics of the derivation cohort enrolled in this study [n = 489].
Total [n = 489] Group S0 [n = 80] Group SI [n = 175] Group I [n = 234] p-value
1
n [%] n [%] n [%] n [%]
Gender 0.914
Male 225 [46%] 36 [45%] 79 [45%] 110 [47%]
Location <0.001
L1. Ileal 232 [47%] 55 [69%] 95 [54%] 82 [35%]
L2. Colonic 45 [10%] 1 [1%] 4 [2%] 40 [17%]
L3. IleoColonic 212 [43%] 24 [30%] 76 [43%] 112 [48%]
Upper tract involvement [L4] <0.001
Yes 55 [12%] 2 [2%] 11 [6%] 42 [18%]
Disease behaviour <0.001
B1. Non-structuring/non-penetrating 158 [32%] 17 [21%] 14 [8%] 127 [54%]
B2. Structuring 176 [36%] 35 [44%] 80 [46%] 61 [26%]
B3. Penetrating 155 [32%] 28 [35%] 81 [46%] 46 [20%]
Perianal disease 0.001
Yes 125 [26%] 11 [14%] 38 [22%] 76 [32%]
Age at diagnosis <0.001
≤40 years 388 [79%] 48 [60%] 132 [75%] 208 [89%]
>40 years 101 [21%] 32 [40%] 43 [25%] 26 [11%]
Follow-up time, median [IQR] 9[6–14] 13 [8–19] 13 [8–19] 6 [5–10] <0.001
Disabling disease 314 [64%] 15 [19%] 137 [78%] 162 [69%] <0.001
CI 95% [60–68%] [10–28%] [72–84%] [63–75%]
Reoperation 89 [18%] 12 [15%] 70 [40%] 7 [3%] <0.001
CI 95% [15–21%] [7–23%] [33–47%] [0.8–5%]
Total of surgeries [including index] –
None 132 [31%] – – 132 [78%]
1 204 [48%] 68 [85%] 105 [60%] 31 [18%]
2 52 [12%] 9 [11%] 39 [22%] 4 [2%]
3 22 [5%] 1 [1%] 18 [10%] 3 [2%]
4 10 [2%] 1 [1%] 9 [5%] 0 [0%]
5 3 [1%] 1 [1%] 2 [1%] 0 [0%]
6 1 [1%] 0 [0%] 1 [1%] 0 [0%]
9 2 [1%] 0 [0%] 1 [1%] 1 [1%]
Required anti-TNF 176 [37%] 0 [0%] 74 [42%] 102 [45%] <0.001
Steroids 318 [67%] 21 [28%] 105 [63%] 192 [83%] <0.001
 1 cycle/years 57 [29%] 6 [46%] 18 [28%] 33 [28%] 0.670
 ≥2 cycles/year 11 [6%] 0 [0%] 5 [8%] 6 [5%]
 1 cycle for each 3 years 70 [36%] 6 [46%] 24 [37%] 40 [34%]
 Steroid dependent 46 [24%] 1 [8%] 14 [22%] 31 [27%]
 Steroid resistant 11 [6%] 0 [0%] 4 [6%] 7 [6%]
New events
Stenosis 74 [15%] 6 [8%] 43 [25%] 25 [11%] <0.001
Penetrating disease 5 [1%] 2 [3%] 3 [2%] 0 [0%] 0.089
Anal disease 51 [10%] 4 [4%] 25 [14%] 23 [10%] 0.036
1 Chi-Squared test; IQR: interquartile range; 95% CI: 95% confidence interval.
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studies to be important for the outcomes analysed4 were selected and 
included in the final matrices as risk factors: for disabling disease—
age at diagnosis [knowledge from literature], behaviour phenotype 
(B2: OR = 2.359 [1.318–4.22], B3: OR = 2.926 [1.567–5.463]), peri-
anal disease (OR:4.340 [2.399–7.852]), and the therapeutic-defined 
patient group (SI: OR=15.134 [7.483–30.607] and I: OR = 12.797 
[6.128–26.723])—and for reoperation age at diagnosis (A3: 
OR = 0.364 [0.184–0.723]), behaviour phenotype (B2: OR = 6.443 
[2.054–20.206], B3: OR = 4.815 [1.525–15.201]), perianal disease 
(OR: 2.189 [1.144–4.187]) and therapeutic-defined patient group (SI: 
OR = 3.080 [1.500–6.325] and I: OR = 0.204 [0.073–0.571]).
3.3. Risk matrices
The risk matrices convey the risk of each outcome [disabling disease 
and reoperation] stratified by the relevant factors. In the particular 
case of this study, one of the factors considered to be relevant is the 
patient’s group according to the initial therapeutic approaches. In 
this regard, it should be noticed that two of the groups are intimately 
linked: in fact, 52% of the patients [n = 255] were submitted to a 
surgical intervention during the initial six months after diagnosis, but 
only a fraction of those [31%] did not enter into immunosuppressive 
therapy afterwards, yielding Groups SI and S0. Therefore, and in order 
to accurately depict the risk in patients who undertook surgery but 
have not yet started immunosuppression, one has to take into account 
the probability of a patient starting immunosuppression after the ini-
tial surgery, i.e. p [I|S]. Such probabilities are shown in Table 1, strati-
fied by the other three risk factors considered to be relevant [age at 
diagnosis, presence of perianal disease, and disease phenotype]. The 
highest value [83%] was observed for patients who were 40 years 
old or younger at diagnosis, had perianal disease, and a penetrating 
disease behaviour [B3]. The lowest value [35%] was observed for 
patients who were 40 or younger at diagnosis, had no perianal disease, 
and presented the least aggressive phenotype [B1]. These results were 
accounted for in the construction of the final risk matrices.
3.3.1. Disabling disease
The risk for CD patients of facing disabling disease, taking into 
consideration the relevant factors determined previously, is stated 
in Table  3. Patients undergoing early surgery [Group S] had a 
lower probability of facing disabling disease than patients in the 
other two groups. For the other three risk factors considered, one 
could detect an increased risk when patients were 40  years old 
or younger at diagnosis, had perianal disease, and a penetrating 
disease behaviour [B3]. The highest risk was observed for patients 
included in Group SI, with perianal disease, penetrating disease 
behaviour [B3], and older than 40 years at diagnosis: 94% [88–
98%]. The lowest risk was observed for Group S patients, who 
had no perianal disease, non-structuring/non-penetrating disease 
behaviour [B1], and who were 40 or younger at diagnosis: 27% 
[21–36%].
3.3.2. Reoperation
The risk for CD patients of undergoing more than one surgery 
[reoperation] during the course of the disease, taking into considera-
tion the relevant factors determined previously, is stated in Table 4. 
Patients who had an early start of immunosuppression therapy had 
a lower probability of reoperation than those who had an early 
surgery. Moreover, younger age at diagnosis and perianal disease 
increased the risk of reoperation, whereas a non-structuring/non-
penetrating [B1] disease behaviour decreased it. The lowest prob-
ability of reoperation was observed for patients in Group I  who 
were older than 40 years at diagnosis, had no perianal disease, and 
a non-structuring/non-penetrating [B1] disease behaviour: 0.4% 
[0.2–0.9%]. The highest probability of reoperation was observed for 
patients who had undergone an early surgery and later entered into 
an immunosuppression therapy [Group SI], were diagnosed before 
or at 40, and had perianal disease and a structuring [B2] disease 
behaviour: 54% [26–73%].
3.4. Model validation
The Bayesian prognostic models and the resulting risk matrices 
were validated following two different approaches: an internal 
one, which consisted of two different tests [leave-one-out and ten 
times 2-fold cross-validation]; and an external one, following the 
analysis of a prospectively recruited validation cohort. ROC analy-
ses were performed independently for the derivation cohort and for 
each of the validation sets of data, and the respective AUCs, along 
with their 95% CIs, are illustrated in Figure 2. As was desirable, 
the AUC values of the validation cohort nearly overlapped those of 
the derivation cohort, and the AUC values of the generated sets of 
data for the internal validation were rather similar to the later ones. 
Furthermore, the overall discrimination power was high for both 
outcomes [78% for disabling disease and 86% for reoperation, using 
the derivation cohort]. Based on this, the following cut-offs were 
Behavior
Disabling
Event Location
Perianal
L4 Event
Reoperation
Behavior
Location
PerianalGender Gender
54% - Female
46% - Male
54% - Female
46% - Male
48% - I
35% - SI
17% - S0
Age
79% - <=40
21% - >40
88% - No
12% - Yes
82% - No
18% - Yes
10% - L2
43% - L3
47% - L1
74% - No
26% - Yes
36% - B2
32% - B3
32% - B1
Age
79%- <=40
21%- >40
36% - B2
32% - B3
32% - B1
48% - I
36% - SI
17% - S0
10% - L2
43% - L3
47% - L1
74% - No
26% - Yes
64% - Yes
36% - No
L4
88%-No
12%-Yes
Figure 1. Bayesian network representing the relationships between each outcome [disabling disease and reoperation] and each demographic and clinical 
variables, and relationships between predictive factors. The bars within each variable represent the prior marginal probabilities for each variable’s category. 
Arrows represent association between variables, but do not convey any causal relationship, the association between the outcomes and each of the remaining 
variables being imposed on the model.
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determined: values above 75% [for disabling disease] and above 
19% [for reoperation] were considered to be positive test results, i.e. 
to predict the occurrence of the respective outcome.
Table 5 presents the performance of the chosen cut-offs for each 
outcome in the derivation and validation cohorts. The CIs for each 
of the performance measures computed overlapped between the two 
cohorts [with only two exceptions], further validating our model. 
Overall, the application of the cut-offs to the validation cohort 
resulted in 94 % [83–98%] specificity and 89% [70–97%] PPV for 
disabling disease, and 96% [78–100%] sensitivity and 98% [90–
99%] NPV for reoperation.
3.5. Derivation vs. validation cohorts
The validation cohort consisted of 129 patients who were prospec-
tively enrolled in this study, and whose demographic and clinical 
characteristics are depicted in Table 6. The derivation and validation 
cohorts were shown to be similar for all variables analysed, with the 
exception of the presence of perianal disease [26% in the derivation 
cohort vs. 13% in the validation cohort, p = 0.003] and stratifica-
tion in the three different patients’ groups considered [p < 0.001]. 
To exclude the hypothesis that these differences could significantly 
impact the validation analysis, a new set of comparisons was carried 
out: the performance of the determined cut-offs was computed for 
the validation cohort stratified according to the presence of perianal 
disease [see Supplementary Table S1] and the patient’s group [see 
Supplementary Table S2]. The performance measures were similar 
[i.e. the 95% CIs overlap], with a few noted exceptions that occurred 
in performance measures that were less relevant for the correspond-
ing outcome.
4. Discussion
Because CD is a disabling disease that has a significant negative 
impact on the patient’s quality of life, the construction and valida-
tion of predictive models that can anticipate negative outcomes is 
a cornerstone for preventive therapeutics, allowing physicians to 
adjust the medication in a prophylactic fashion, instead of doing 
so as a reaction to a flare. A few attempts to analyse risk factors 
from a prognosis perspective have been done in the past, but they 
usually involved results from genetic or serologic tests,24,25 which 
are both expensive and time-consuming. Our study is, to our best 
knowledge, the first one to build and validate risk models for CD 
outcomes—disabling disease and reoperation—based solely on clini-
cal and demographic variables, which have the key advantage of 
Table 4. Risk matrix showing probability [%] of reoperation during the course of the disease.
Perianal Disease
No Yes
B1 B2 B3 B1 B2 B3
Age at diagnosis ≤40 9% [6–13%] 42% [36–51%] 37% [29–51%] 22% [10–32%] 44% [23–50%] 48% [23–36%] Group S
>40 6% [3–8%] 19% [15–26%] 20% [15–31%] 11% [4–17%] 26% [9–44%] 28% [13–36%]
≤40 1% [0.5–2%] 9% [5–14%] 3% [2–6%] 1% [0.5–3%] 11% [3–24%] 4% [2–7%] Group I
>40 0.4% [0.2–0.9%] 5% [3–8%] 2% [1–3%] 0.7% [0.2–1%] 6% [2–14%] 2% [1–4%]
≤40 21% [14–32%] 49% [42–58%] 41% [32–56%] 30% [12–45%] 54% [26–73%] 51% [28–59%] Group SI
>40 9% [6–15%] 26% [21–34%] 20% [15–32%] 14% [5–23%] 31% [11–50%] 28% [13–35%]
Patient’s therapeutic group: S = surgery; SI = surgery and immunosuppression 6 months after surgery; I = immunosuppression.
Reading example: A patient 40 years old or younger at diagnosis, without perianal disease, and B1 phenotype had the probability of reoperation ranging 
between 1% (if he or she had immunosuppression in the first 6 months after diagnosis [Group I]) and 21% (if he or she had surgery in the first 6 months after 
diagnosis and immunosuppression thereafter [Group SI]). But if the patient had perianal disease, the probability of reoperation increased to 30% if a surgery 
occurred during the first 6 months after diagnosis and the patitent had immunosuppression 6 months after surgery [Group SI].
Colour scheme: White = ≤10%; green = 11–19%; yellow = 20–49%; orange = 50%-74%; red = ≥75%.
Table 3. Risk matrix showing the probability [%] of having disabling disease during the course of the disease.
Perianal Disease
No Yes
B1 B2 B3 B1 B2 B3
Age at diagnosis ≤40 27% [21–36%] 60% [57–66%] 64% [62–65%] 72% [59–78%] 77% [67–87%] 85% [74–94%] Group S
>40 31% [17–39%] 43% [36–50%] 60% [49–62%] 66% [50–73%] 73% [58–83%] 76% [59–87%]
≤40 55% [43–69%] 71% [67–79%] 77% [75–80%] 82% [75–90%] 90% [83–96%] 92% [84–97%] Group I
>40 45% [34–60%] 62% [58–72%] 69% [67–72%]  75% [67–86%] 86% [77–94%] 88% [78–96%]
≤40 53% [42–66%] 71% [67–79%] 76% [74–77%] 81% [74–89%] 90% [83–96%] 91% [83–97%] Group SI
>40 63% [52–75%] 78% [75–84%] 82% [81–84%] 86% [81–92%] 93% [88–98%] 94% [88–98%]
Patient’s therapeutic group: S = surgery; S1 = surgery and immunosuppression 6 months after surgery; I = immunosuppression.
Reading example: A patient 40 years old or younger at diagnosis, without perianal disease, and disease phenotype B1 had a probability of disabling disease 
ranging between 27% (if he or she had a surgery [Group S]) and 55% [if in the first 6 months after diagnosis he or she had immunosuppression]. But if the 
patient had perianal disease, the probability of disabling disease increased: 72% with a surgery in the first 6 months after diagnosis [Group S] and 82% if  
immunosuppression [Group I] was conducted.
Colour scheme: White = ≤10%; green = 11–19%; yellow = 20–49%; orange = 50%-74%; red = ≥75%.
6 C. C. Dias et al.
 by guest on January 11, 2017
http://ecco-jcc.oxfordjournals.org/
Downloaded from 
6. PREDICTION
84
being easily and quickly acquired. The final results were arranged 
into color-coded and user-friendly matrices that constitute a prelimi-
nary but useful tool that can be used by physicians in the therapeutic 
decision-making process.
The overall disabling rate was 64%, ranging from 19% in Group 
S0 patients to 78% for Group SI patients, values that are lower than 
those previously published.6,8 However, our definition of disabling 
disease was stricter than that used in those studies, as variables 
such as ‘need for immunosuppression’ or ‘need for anti-TNF’ were 
not interpreted as disabling. In fact, the notion of disabling disease 
published by Beaugerie et al. has suffered a few modifications with 
the advent of new therapeutic strategies, namely the acceleration of 
step-up and the implementation of top-down treatments. We have 
taken these factors into account, and adjusted the concept of disa-
bling disease to the present context. Moreover, one should keep in 
mind that the concept of disabling is different from that of disabil-
ity. In fact, the disability index published by Peyrin-Biroulet et al.26 
is a multidimensional approach to disabling events, encompassing 
body function and structure, activities, participation, and environ-
mental factors. As our main aim was to predict the disabling events 
from the clinical and demographic context of the patient, we have 
chosen to use the concept of disabling instead of the disability index 
mentioned above.
The need for more than one surgery [reoperation] occurred in 
18% of all patients, a value that ranged from 40% in Group SI 
to 3% in Group I.  In our study, a cumulative risk of reoperation 
for Group S0 ranged between 1% and 15% at 5 and 30 years of 
follow-up, respectively. For patients in Group SI, the probability 
ranged from 0% to 41% for 5 and 30 years of follow-up, while for 
Group I the cumulative probability ranged between 0% and 3% for 
5 and 30 years of follow-up, respectively. These values were lower 
than those found by Frolkis et al.,27 but our cohort had a subgroup 
of patients who had a more aggressive treatment from diagnosis, 
namely immunosuppression within 6 months after diagnosis. The 
ability to anticipate flares and to establish preventive therapeutic 
strategies are invaluable steps for better disease management and a 
rational utilization of the available resources, especially in the case 
of a highly disabling and chronic disease such as CD. In this context, 
the Pocer study was a seminal work, establishing that retreatment 
according to the clinical risk of recurrence, with an early colonos-
copy and treatment step-up if needed, was better than conven-
tional drug therapy alone for the prevention of postoperative CD 
Disabling Disease ROC Curves Reoperation ROC Curves
1.
0
0.
0
0.0 0.2 0.4 0.6
1 − specificity
0.8
derivation sample AUC = 79%, 95%CI = [75%,83%]
leave−1−out AUC = 71%
10 x 2−fold cross−validation avg AUC = 71%
(min AUC = 68%, max AUC = 74%)
validation sample AUC = 78%, 95%CI = [69%,86%]
1.0
0.
8
0.
6
0.
4se
ns
iti
vi
ty
0.
2
1.
0
0.
0
0.0 0.2 0.4 0.6
1 − specificity
0.8
derivation sample AUC = 86%, 95%CI = [82%,89%]
leave−1−out AUC = 80%
10 x 2−fold cross−validation avg AUC = 79%
(min AUC = 78%, max AUC = 82%)
validation sample AUC = 86%, 95%CI = [80%,93%]
1.0
0.
8
0.
6
0.
4se
ns
iti
vi
ty
0.
2
Figure 2. Receiver operating characteristic analyses and area under the curve values for the outcomes of disabling disease and reoperation in the derivation and 
validation cohorts, as well as for the internal validation procedures.
Table 5. Performance of risk matrix in derivation and validation cohort for disabling disease and reoperation (% [CI 95%]).
Disabling [>75%] Reoperation [>19%]
Derivation Validation Derivation Validation
Sens 53% [47–58%] 31% [21–42%] 91% [85–97%] 96% [78–100%]
Spec 74% [68–80%] 94% [83–98%] 66% [61–71%] 61% [50–70%]
PPV 78% [73–83%] 89% [70–97%] 37% [31–43%] 37% [26–49%]
NPV 47% [41–53%] 47% [37–57%] 97% [95–99%] 98% [90–99%]
Accuracy 60% [55–64%] 55% [46–64%] 70% [66–74%] 67% [59–75%]
LR+ 2.04 [1.55–2.68] 5.23 [1.66–16.47] 2.67 [2.29–3.09] 2.43 [1.89–3.13]
LR– 0.63 [0.57–0.72] 0.73 [0.63–0.85] 0.14 [0.07–0.27] 0.07 [0.01–0.46]
Odds post test+ 3.67 [2.80–4.80] 8.00 [2.72–23.44] 0.59 [0.48–0.72] 0.58 [0.41–0.84]
Odds post test– 1.14 [1.02–1.29] 1.13 [0.91–1.38] 0.03 [0.01–0.06] 0.02 [0.00–0.11]
Sens: sensibility; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR: negative likelihood ratio.
Development and Validation of Risk Matrices for Crohn’s Disease 7
 by guest on January 11, 2017
http://ecco-jcc.oxfordjournals.org/
Downloaded from 
6.1. DEVELOPMENT AND VALIDATION OF RISK MATRICES FOR CROHN’S DISEASE
OUTCOMES IN PATIENTS SUBMITTED TO EARLY THERAPEUTIC INTERVENTIONS.
85
recurrence.28 The rationale for our study was different, and so were 
the variables and the outcomes analysed, namely by including the 
impact of early strategies [immunosuppression and/or surgery] in the 
CD development. However, it is our belief that combining the results 
of an early endoscopic examination—after the Pocer study—with 
our risk matrices could greatly improve the predictive ability and 
increase the chances of effectively adjusting the medication in a pre-
ventive fashion.
The variables considered in the risk matrices were included after 
a significant result in logistic regression analysis [behaviour, patient 
group, and perianal disease] or because they have been previously 
described as predictive factors [age at diagnosis].4,6,8 The disabling 
disease risk matrix showed that patients who were 40 years or less 
at diagnosis, have perianal disease, an aggressive disease phenotype, 
and who are medicated with immunosuppressors [either before any 
surgery or after an initial one] have a higher risk of undergoing the 
disabling events considered. The need for a reoperation, on the other 
hand, is more likely to occur in patients diagnosed at 40 or less, who 
have perianal disease, an aggressive disease phenotype, and who 
underwent an early surgery upon diagnosis. These results are in line 
with past research, supporting the accuracy of our matrices.4 The 
embedded models’ discriminative power ranges between 78% for 
disabling disease and 86% for reoperation. These values are higher 
than those presented by Siegel et al.,23 a study that involved more 
variables, some of which of a genetic nature; therefore, our study 
opens new windows of opportunity for simpler yet usable models in 
clinical practice. The cut-offs established in our study for detecting 
disabling disease and reoperation [75% and 19%, respectively] were 
shown to have quite good performance, presenting a positive post-
test odds of 8.00 [2.72–23.44] for disabling disease, and a negative 
post-test odds of 0.02 [0.00–0.11] for reoperation.
The BMs and risk matrices built in this study were validated 
using internal leave-one-out and crossed validations, as well as an 
independent and prospectively recruited validation cohort. The ROC 
curves for disabling disease and for need for reoperation were simi-
lar for the derivation and the validation cohorts. The differences 
between the derivation and the validation cohorts—present in the 
occurrence of perianal disease and formation of groups based on 
early therapeutic decisions—were thoroughly investigated. Whereas 
differences regarding the occurrence of perianal disease did not 
seem to impact the results, those concerning unbalanced groups of 
patients may convey a slight but undefined bias in the overall predic-
tive quality of the models. In fact, in the derivation cohort, Group SI 
had a lower discriminative ability for reoperation, whereas Group I 
had a higher discriminative ability for the same outcome, the unde-
fined nature of bias coming from both the groups having had a lower 
frequency in the validation cohort when compared with the deriva-
tion cohort.
This study had a few limitations that we acknowledge as fol-
lows: the retrospective nature of the derivation cohort, the inability 
to provide a close set of treatment strategies for all patients [due 
to lack of data], the smaller follow-up time for Group I, and the 
absence of data regarding patients’ smoking habits. Nevertheless, we 
believe we have limited these drawbacks by: [i] monitoring the inclu-
sion with a data entry monitor; [ii] precisely defining the inclusion 
and exclusion criteria before study start; and [iii] building a web 
platform for study purposes that automatically sends missing data 
reports. Regarding smoking status, the lack of this variable in the 
case report of many patients prevented its use. However, we have 
tested the models, including the smoking status whenever possible, 
and the results were similar to those we have obtained without this 
variable [data not shown].
As a global conclusion, we may say that our study added impor-
tant knowledge to the state of the art regarding CD development—
namely unveiling important risk predictive factors, including the 
impact of early therapeutic strategies in the disease development. 
Moreover, that knowledge is delivered in the form of an intuitive 
and user-friendly bedside predictive tool, which can be used by any 
Table 6. Comparison between derivation and validation cohort.
Derivation [n = 489] Validation [n = 129] p-value
n [%] n [%]
Gender 0.831
Male 225 [46%] 58 [45%]
Location 0.817
L1. Ileal 232 [47%] 64 [50%]
L2. Colonic 45 [9%] 13 [10%]
L3. IleoColonic 212 [43%] 52 [40%]
Upper tract involvement [L4] 0.714
Yes 55 [11%] 16 [12%]
Disease behaviour 0.266
B1. Non-structuring /non-penetrating 158 [32%] 49 [38%]
B2. Structuring 176 [36%] 37 [29%]
B3. Penetrating 155 [32%] 43 [33%]
Perianal disease 0.003
Yes 125 [26%] 17 [13%]
Age at diagnosis 0.945
≤40 years 388 [79%] 1028 [79%]
>40 years 101 [21%] 27 [21%]
Disabling disease 314 [64%] 78 [61%] 0.432
Reoperation 89 [18%] 25 [19%] 0.759
Patients group <0.001
S0 80 [17%] 53 [41%]
SI 175 [35%] 30 [23%]
I 234 [47%] 46 [36%]
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physician to quantify the likelihood of disabling events or the need 
for reoperation. The fact that no genetic or serologic tests results 
are included allows an immediate reading of this tool, allowing the 
early adjustment of medication and contributing to a prophylactic 
approach concerning CD’s negative outcomes.
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Abstract 
 
Introduction:  
Crohn’s disease (CD) is a chronic inflammatory bowel disease known to carry 
a high risk of disabling and many times requiring surgical interventions. The 
computation of prognosis models is a key step towards a better 
comprehension of the disease and a more efficient management of its 
symptoms. This article describes a decision-tree based approach that defines 
the CD patients’ risk or undergoing disabling events, surgical interventions and 
reoperations, based on a particular combination of clinical and demographic 
variables. 
Material and methods: 
This multicentric study involved 1547 CD patients retrospectively enrolled and 
divided into two cohorts: a derivation one (80%) and a validation one (20%). 
Decision trees were built upon applying the CHAIRT algorithm for the selection 
of variables. 
Results: 
Three-level decision trees were built for the risk of disabling and reoperation, 
whereas the risk of surgery was described in a two-level one. A receiver 
operating characteristic (ROC) analysis was performed, and the area under 
the curves (AUC) revealed that the decision trees were able to predict 
disabling, surgery and reoperation with a probability of 72%, 80% and 69%, 
respectively. Risk cut-off levels were defined and shown to be useful for the outcomes 
assessment: risk levels above 75% for disabling had an odds test positivity of 4.06 [3.50-4.71], 
whereas risk levels below 34% and 19% excluded surgery and reoperation with an odds test 
negativity of 0.15 [0.09-0.25] and 0.50 [0.24-1.01], respectively. Globally, patients with B2 
or B3 phenotype had a higher proportion of disabling disease and surgery, 
while patients with later introduction of pharmacological therapeutic (1 months 
after initial surgery) had a higher proportion of reoperation. 
 Conclusions: 
Demographic and clinical variables can be used to accurately assess the CD 
patients’ future risk of disabling, surgery and reoperation. The decision-tree 
based approach used in this study has shown to be a valid and useful 
approach to depict such risks.  
 
Keywords: Disabling disease, reoperation, Crohn’s disease. Risk matrices
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Introduction 
 
Crohn’s disease (CD) is a chronic inflammatory bowel disease for 
which no definitive treatment has been described. As so, clinicians approach 
the disease attempting to control the symptoms, avoiding disease 
complications and improving patients’ quality of life (1). The most frequent CD 
complications are related to an uncontrolled inflammation of the bowel, which 
may cause obstruction and perforation of the small intestine or of the colon, 
abscess, fistulae and/or intestinal bleeding. The occurrence of these events 
may require a surgical intervention, which ends up being a common strategy 
in CD management. In fact, previous studies have reported that around 50% 
of all CD patients will eventually undergo bowel surgery within 10 years after 
the diagnosis, whereas 80% will eventually require a surgery throughout the 
entire disease course (1,2). Moreover, recurrence is extremely frequent, and 
the rate of reoperations in previous studies ranged from 40% to 80% (2,3).  
As for the concept of disabling, this term was introduced by Beaugerie 
et al. in 2006 (4) and by Loly et al. (5) in 2008: both groups evaluated the 
impact of the disease using clinical and measurable criteria. These studies 
reported a proportion of disabling disease between 85% and 58%, 
respectively. Five years after the initial study on this topic, Yang et al. (6) 
presented a new report that settled the proportion of disabling at 80%. 
However, this last study used a slightly different definition of disabling 
disease. In fact, given the rapid evolution of disease control strategies, there 
is currently no consensus on the concept of disabling disease. 
The definition of a strong and accurate prognosis model is a key step 
towards a better disease control and a higher quality of life in CD patients. In 
this context, this study aimed to unveil the differential impact of several clinical 
and demographic variables on the CD patients’ risk of surgery, disabling and 
reoperation, using a decision trees-based strategy.  
 
Material and Methods  	
Derivation and validation cohort 
This manuscript describes a multicentric retrospective cohort study including 
1547 CD patients recruited from six Portuguese inflammatory bowel disease 
(IBD) specialist hospitals. Patients were included if 1) had a definitive 
diagnosis of CD; 2) had at least three years of follow-up; 3) had at least one 
consultation with a physician involved in this study during 2014 or 2015; and 
4) had performed at least an X-ray computed tomography (CT) or a magnetic 
resonance imaging (MRI) during the follow-up. A hold-out strategy was 
followed to enable a generalized validation of the prognostic models: the 
cohort was randomly split into two groups. The first one comprised 80% of 
patients and constituted the derivation cohort; the held-out remaining 20% of 
patients were considered to be the validation cohort. 
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Clinical and demographic variables  
All data was retrieved from GEDII (Grupo de Estudos de Doenças 
Inflamatórias Intestinais, the Portuguese IBD group) database (7) and 
included clinical and demographic variables, the dates in which the patients 
were submitted to bowel surgeries or started immunosuppression, and their 
classification regarding steroid dependence and refractoriness. The definition 
of steroid dependence was the inability to reduce steroids below the 
equivalent of 10 mg per day, prednisolone within 3 months of starting steroids 
without recurrent active disease, or disease relapse within 3 months of 
stopping steroids. Steroid resistance was defined as the presence of active 
disease despite a prednisolone dose of up to 0.75 mg kg−1 per day over a 
period of 4 weeks (8).  The presence and timing of immunosuppressive 
medication was stratified in four categories: 1) no pharmacological treatment; 
2) pharmacological treatment both before and after the first surgery (started 
within the first month after surgery); 3) pharmacological treatment only after 
the surgery (starting more than 1 month after the first surgery); and 4) 
pharmacological treatment only before the first surgery.   
 
Outcomes analyzed 
Three different outcomes were analyzed in this study: 
a) disabling disease, defined as a composite endpoint characterized by 
the presence of at least one of the following events: more than one 
abdominal surgery or two hospital admissions in the follow-up period; 
steroid dependence or steroid refractoriness; need for switching the 
first immunosuppression or anti-TNFα; and the appearance of new 
clinical events after the index episode (stenosis, anal disease or 
penetrating disease); 
b) surgery, defined as the need for a surgical intervention (abdominal 
surgery only for CD); 
c) reoperation, defined as the need for more than one surgical 
intervention (abdominal surgery only for CD). 
 
Statistical analyses 
The results of the statistical analysis performed during this study are 
summarized into decision trees, which are a graphical representation of a 
possible combination of variables based on specific conditions. It uses a 
divide-and-conquer strategy to solve a decision problem, which works by 
dividing a complex problem into simpler problems, recursively applying the 
same strategy. The different solutions of sub problems are then combined in 
the form of a tree to produce a solution for the original problem. Each split in 
the tree (a node) is produced by specifying the percentage of the outcome 
present in each of the categories of one independent variable (the one that 
has the highest impact at that level), while the final leaves convey an estimate 
of the outcome for the subgroup of patients that recursively traversed the tree 
along that path. Therefore, each path in the tree (from root to leaf) represents 
an exclusive decision rule associated with an estimate for the outcome. 
Whereas most decision trees supporting clinical decision problems are expert-
based following a deductive reasoning, inductive learning the decision tree 
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from data, e.g. using recursive partitioning, is a valid method to generate a 
data-driven decision model (9). In order to determine the relationship between 
clinical/demographical factors and outcomes, decision tree classifiers were 
built from the derivation cohort, applying the CHAID algorithm (10), which is 
based upon corrected (Bonferroni post-hoc test) chi-squared significant 
testing. The following variables were analyzed for the outcomes disabling and 
surgery: gender, smoking habits, age at diagnosis, location disease, behavior, 
upper tract involvement (L4) and perianal disease. The presence and timing 
of medical therapeutics were also included when considering the outcome 
reoperation. The decision tree parameters were validated on the 
independently held-out validation cohort. The predictive quality of the leaves 
was evaluated on both cohorts estimating the proportion of the outcome for 
each of the derived rules.  
To assess the discriminative ability of the trees for each outcome, specific 
cut-off values were chosen after analyzing the ROC curves in the derivation 
cohort. For disabling disease, a rule-in approach was applied aiming at a high 
positive predictive value (around 80%). For surgery and reoperation, a rule-
out approach was applied aiming at a high negative predictive value (also 
around 80%). The derived trees (defining exclusive decision rules) were 
evaluated in both cohorts for the estimation of sensitivity, specificity, accuracy, 
predictive values, likelihood ratios and post-test odds. 
Variables were described through absolute (n) and relative (%) frequencies. 
The comparison between derivation and validation cohort was made applying 
a Chi-Square test. All reported p-values were two-sided, for a significance 
level of 5%. All data were arranged, processed and analyzed with SPSS® 
v.24.0 (Statistical Package for Social Sciences). 
 
Results 	
Population baseline characteristics and measured outcomes 
The derivation cohort consisted of 1245 CD patients, the majority of them 
female (54%), non-smokers (53%) and diagnosed as young adults (17 to 40 
years old, 69%) (Table 1). Disease location and behavior were classified 
according to the Montreal classifications (11): 16% had colonic disease and 
only 12% presented upper tract involvement. Concerning behavior, 46% had 
a non stricturing/non penetrating phenotype, whereas 26% had perianal 
disease. Disabling disease occurred in 68% of patients, 47% underwent 
bowel surgery, and 38% (among the latter) needed reoperation. 
 
Disabling disease 
 Disabling disease occurred in 68% of the derivation cohort patients. The 
induced decision tree, computed from all independent variables with the 
exception of the presence and timing of pharmacological therapy (as this 
variable is itself involved in the disabling definition), resulted in a three-level 
model (Fig. 1). The first level was defined by the behavior phenotype, a two-
way split that separated the risk for disabling of B1 (54%) apart from that of 
B2 and B3 phenotypes (80%). The second level consisted in the presence of 
perianal disease. Location and gender defined the third level for patients that 
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had the B1 phenotype and the absence or presence of perianal disease, 
respectively. The set of rules defined by this tree can be summarized by the 
different risk levels (32% to 90%) reported in Table 2. Globally, patients with 
phenotypes B2 or B3 have a higher risk of disabling disease, while for 
phenotype B1, gender plays an important role, with female patients having a 
higher risk than males. 
 
Surgery 
The outcome surgery affected 47% of the derivation cohort patients. The 
induced decision tree, computed using the same variables as those used for 
the disabling decision tree, resulted in a two-level model (Fig. 2). As for the 
disabling, the first level was defined by disease behavior, although in this case 
a three-way split separated the surgery risk of all phenotypes:  16% for B1, 
68% for B2, and 75% for B3. The second level of the model included 
information on upper track involvement (L4) (for patients with the B2 
phenotype) and gender (for patients with the B3 phenotype). The set of rules 
hereby defined represent different risk levels (17% to 81%), which are 
depicted in Table 2. Globally, patients with phenotype B3 have a higher risk of 
surgery than patients with B1 behavior phenotype, increased for B3 male 
patients compared to females. 
 
Reoperation 
The rate of reoperation was defined among those patients that underwent 
bowel surgery: 38% required additional surgical interventions. The induced 
decision tree, computed using all variables described before and including the 
timing and presence of pharmacological therapeutics, resulted in a three-level 
model of variables (Fig. 3). The first level was defined by the presence and 
timing of the anti-TNF introduction, separating those that started anti-TNF 
more than one month after surgery (53% of reoperation risk) from all the 
others (29% of reoperation risk). The second level included behavior for the 
former (stratified in B1 vs. B2/B3) and presence and timing of AZA 
introduction for the later  (discriminating between patients that have either 
never been medicated or been medicated only before surgery from the 
remaining). The third level encompassed the disease location, separating L1 
from L2 and L3. The defined set of rules resulted in different risk levels (13% 
to 58%) that are listed in Table 2. Globally, patients with later introduction of 
pharmacological therapeutic (1 month after initial surgery) had a worse 
outcome, i.e, have a higher probability of reoperation than the remaining 
patients.  
 
Model Validation 
The validation cohort consisted of 302 patients and was similar to the 
derivation cohort concerning the frequency of the analyzed variables and 
outcomes (Table 1). The risk of each outcome following the decision rules 
extracted from the trees in the derivation and validation cohorts are 
represented in Figure 4. The proportion of the outcomes is similar in both 
cohorts, and their confidence intervals are overlapping, therefore attesting the 
robustness of the decision rules. 
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Receiver operating characteristic (ROC) analysis were performed 
independently for the derivation and validation cohorts and the respective 
AUC values were similar in and had overlapping 95% CI for disabling and 
surgery, but not for reoperation (Fig. 5). Moreover, the AUCs were rather 
heterogeneous for the different outcomes: the derivation cohort presented an 
AUC of 72% for disabling, 80% for surgery and 69% for reoperation. 
The derivation cohort ROC curves were used to establish cut-offs able to 
assess the likelihood of the occurrence of each outcome. Positive results 
were defined for risk levels above 75% concerning disabling disease, above 
34% concerning surgery, and above 19% concerning reoperation. These cut-
offs enabled the computation of a simplified set of rules that are listed in Table 
2. The performance parameters of the chosen cut-offs considering each 
outcome are depicted in Table 3 for the derivation and the validation cohorts. 
Most of the 95% CI overlapped between both cohorts, once again validating 
the initial model. Overall, the application of the cut-offs to the validation cohort 
resulted in 81% [74%-86%] PPV for disabling disease, 87% [80%-92%] NPV 
for surgery, and 67% [57%-75%] for reoperation. 
 
Discussion  
Given the impact and frequency of recurrences among CD patients, the 
development of prognostic models is a cornerstone to guide physicians in 
their therapeutic choices and to improve patients’ well-being. The most 
important characteristics of these models are their user-friendliness and 
readability, allowing a fast and effortless readout during patient encounters or 
upon the need to decide on a therapeutic approach.  
This cohort presented a disabling rate of 68%, a similar value to that depicted 
in previous studies of different Portuguese cohorts (12,13). However, other 
authors have reported higher disabling rates (4–6). This difference is likely 
due to the fact that the disabling definition used in this study is stricter than 
that used in previous ones, namely by excluding the need of 
immunosuppression or anti-TNF as criteria. In our opinion, the introduction of 
pharmacological therapy not qualify as disabling, given the top-down and 
accelerated step-up strategies currently followed to approach CD. 
Surgery, on its turn, affected 47% of the patients in the derivation cohort. This 
value is lower than that presented by Bernal et al. (2), which could be related 
to the fact that the cohort analyzed in that study was composed of older 
patients (data collected since 1955). The rapid evolution of CD therapeutics 
and the current strategies used to approach the disease, together with the fact 
that our cohort included patients that have been more recently diagnosed, 
explains our lower surgery rate. Moreover, a recent meta-analysis has 
reported a 47% risk of surgery within 10 years after diagnosis (14), thereby 
supporting the results described here. Reoperation, on the other hand, 
affected 38% of the patients who underwent a first surgery, a rate similar to 
that presented in a recent meta-analysis that settled the 10-years risk of 
reoperation at 33% (15).  
The results from this study are depicted in three decision trees that represent 
the risk for each of the outcomes described above taking into specific 
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combinations of clinical and demographic variables. These decision trees 
were validated in an independent cohort by; a) comparing the proportion of 
the outcome in each derived rule; and b) comparing the diagnostic 
performance parameters using specific risk cut-off levels. The proportion of 
each outcome following the decision rules in the different cohorts was similar. 
Moreover, the comparison of the diagnostic performance parameters revealed 
that the decision trees had a good prognostic ability of concerning disabling 
disease and surgery: the validation cohort had a positive post-test odds for 
disabling disease of 4.24 [3.09-5.81], and a negative post-test odds for 
surgery of 0.15 [0.09-0.23]. Reoperation, on the other hand, appeared to a 
harder outcome to predict, presenting a less favorable performance among 
the validation cohort patients. This might indicate that other factors – besides 
those that have been considered – need to be included in the model. 
Nevertheless, the negative post-test odds of the validation cohort were 0.5 
[0.24-1.01], and therefore this model might still be useful to detect patients 
with a lower risk of reoperation. 
The variables used in the decision tree were chosen by applying the CHAID 
algorithm, which is similar to the chi-square with Bonferroni correction post 
hoc test. The final selection of variables was the same as that used in 
previous studies that employed different selection methods, therefore 
attesting the robustness of the computed decision trees (2,4–6,16–18). The 
decision tree analysis has a some advantages over others that are more 
widely used (e.g. logistic regression). An undeniable strength of this method is 
its graphical representation, which allows a quick and intuitive reading. On the 
other hand, decision trees are rather flexible in the way that they do not 
assume any data distribution. Another advantage is the attribute selection, 
which restricts the variables in the model to those that are non-redundant. The 
interpretability of the trees is also one their strong points – complex decisions 
can be approximated by simple or local decisions. Finally, decision trees allow 
an easy comparison of patients’ subgroups, as decision rules can be created 
directly from the tree.  
Globally, patients with B2 or B3 phenotype had a higher proportion of disabling disease and 
surgery, while patients with later introduction of pharmacological therapeutic (1 months after 
initial surgery) had a higher proportion of reoperation. Although retrospectively run, with 
retrospectively defined outcomes, this study presents an analysis of a large 
multicentric cohort formaly validated by the application of the derived results 
in a validation cohort.  
In conclusion, we have shown that variables such as disease behavior, 
upper gastrointestinal involvement, gender, perianal disease, location and 
medical therapeutics affect the risk of disabling disease, surgery and 
reoperation in CD patients. Moreover, these variables impact the 
aforementioned outcomes at different levels, having different weights in sub-
groups of patients with different variables’ combinations. Our results are 
represented in three graphical and user-friendly bedside tools that can be 
used by the physicians to assess the risk of disabling, surgery and 
reoperation in CD patients, therefore supporting the decision making process 
regarding therapeutic strategies. A disabling risk above 75% allows the 
prediction of disabling events with a PPV of 81% and an odds post-test 
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positivity of 4.24, whereas a surgery risk inferior to 34% allows the exclusion 
of future surgeries with a NPV of 87% and an odds post-test negativity of 
0.15. The reoperation was the hardest outcome to predict, although a risk 
below 19% could be useful for excluding future events (NPV: 87 and odds 
post-test negativity: 0.5). 
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 Table 1- Baseline characteristics and comparison between the derivation and the validation 
cohorts. 
 Derivation 
(n=1245) 
Validation 
(n=302) 
p-value 
Gender     0,409 
Male 577 (46%) 132 (44%)  
Age at diagnosis     0,682 
A1 - <=16 years 138 (11%) 37 (12%)  
A2- 17-40 years 865 (69%) 212 (70%)  
A3- >40 years 242 (19%) 53 (18%)  
Location     0,246 
L1 - Ileon 542 (44%) 120 (40%)  
L2 – Colonic 200 (16%) 44 (15%)  
L3 - IleoColonic 503 (40%) 138 (46%)  
Upper tract involvement (L4) 152 (12%) 27 (9%) 0,111 
Behaviour      0,431 
B1 - Non-Stricturing/non-penetrating 572 (46%) 146 (48%)  
B2 - Stricturing 308 (25%) 64 (21%)  
B3 - Penetrating 365 (29%) 92 (30%)  
Perianal disease 327 (26%) 80 (26%) 0,937 
AZA     0,403 
No AZA 794 (64%) 199 (66%)  
AZA before and after surgery (<1 month) 79 (6%) 16 (5%)  
Aza only after surgery (>1 month ) 270 (22%) 70 (23%)  
Aza before surgery 102 (8%) 17 (6%)  
Anti TNF     0,835 
No anti TNF 943 (76%) 234 (77%)  
anti TNF before and after surgery (<1 month) 44 (4%) 9 (3%)  
anti TNF only after surgery (>1 month) 224 (18%) 53 (18%)  
anti TNF before surgery 34 (3%) 6 (2%)  
Disabling disease 849 (68%) 206 (68%) 0,995 
Surgery 579 (47%) 135 (45%) 0,573 
Reoperation  220 (38%) 45 (33%) 0,313 
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Table 2- Decision rules and proportion and confidence intervals of outcomes observed  
Disabling Disease 
 Proportion of outcome  For cut-off of 75% 
B1 & No Perianal & L1 31.5% [24.4%-38.6%] 
46.8% [42.0%-51.6%] 
B1 &  No Perianal & L2/L3 56.7% [50.6%-62.8%] 
B1 & Perianal & Male 66.7% [55.8%-77.6%] 66.7% [55.8%-77.6%] 
B1 & Perianal & Female 82.7% [74.5%-90.9%] 82.7% [74.5%-90.9%] 
B2/B3 & No Perianal 76.4% [72.7%-80.1%] 
79.9% [76.8%-82.8%] 
B2/B3 & Perianal 90.2% [87.8%-94.6%] 
Surgery 
 Proportion of outcome For cut-off of  >34% 
B1 16.6% [13.5%-19.7%] 16.6% [13.5%-19.7%] 
B2 & No L4 72.0% [66.4%-77.6%] 
68.2% [62.3%-73.1%] 
B2 & L4 51.7% [38.44%-64.6%] 
B3 & Male 81.2% [75.3%-87.1%] 
75.1% [70.4%-79.2%] 
B3 & Female 69.7% [63.3%-76.2%] 
Reoperation 
 Proportion of outcome For cut-off of > 19% 
TNF after surgery (> 1 month) & B2/B3 57.9% [50.9%-64.9%] 
52.7 % [46.2%-59.1%] 
TNF after surgery (> 1 month) & B1 23.5% [9.3%-37.8%] 
TNF (without, before or before and after 
surgery) & AZA (without or only before 
surgery) & L1 
13.3% [6.6-%-20.0%] 13.3% [6.6%-20.0%] 
TNF (without, before or before and after 
surgery)  & AZA (without or only before 
surgery) & L2/L3 
28.9% [18.7%-39.1%] 28.9% [18.7%-39.1%] 
TNF (without, before and before or after 
surgery)  &  (AZA after or before and 
after surgery) 
37.0% [30.3%-44.3%] 37.0% [18.7%-39.1%] 
Logical operators: & (AND) ; White - <=10%; green – 11-19%; Yellow – 20%-49%; Orange – 50%-74% 
and red>=75% 
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Table 3 – Performance of risk matrix in derivation and validation cohort for disabling disease and reoperation (% [CI 95%])  
 Disabling 
>75% 
Surgery 
>34% 
Reoperation 
>19% 
 Derivation Validation Derivation Validation Derivation Validation 
Sens 71 
[68-74] 
67 
[61-74] 
84 
[80-86] 
86 
[78-91] 
94 
[89-97] 
87 
[73-94] 
Spec  62 
[57-74] 
65 
[55-75] 
72 
[68-75] 
76 
[69-82] 
24 
[19-28] 
13 
[7-23] 
PPV 80 
[77-83] 
81 
[74-86] 
72 
[68-75] 
74 
[66-81] 
43 
[39-48] 
33 
[8-21] 
NPV 50 
[45-55] 
48 
[40-58] 
83 
[80-86] 
87 
[80-92] 
87 
[78-92] 
67 
[57-75] 
Accuracy       
LR+ 1.89 
[1.66-2.16] 
1.97 
[1.47-2.65] 
2.94 
[2.60-3.34] 
3.59 
[2.71-4.74] 
1.23 
[1.15-1.32] 
1 
[0,67-1,15] 
LR- 0.46 
[0.41-0.51] 
0.49 
[0.40-0.60] 
0.23 
[0.19-0.28] 
0.19 
[0.12-0.28] 
0.25 
[0.14-0.43] 
1,00 
[0,41-2,43] 
Odds post test+ 4.06 
[3.50-4.71] 
4.24 
[3.09-5.81] 
2.56 
[2.25-2.92] 
2.90 
[2.18-3.85] 
0.75 
[0.66-0.86] 
0,5 
[0,37-0,67] 
Odds post test- 0.99 
[0.90-1.08] 
1.05 
[0.87-1.26] 
0.20 
[0.16-0.24] 
0.15 
[0.09-0.23] 
0.15 
[0.09-0.25] 
0,5 
[0,24-1,01] 
Sens: Sensibility; Spec: Specifity; PPV: Positive Predictive value; NPV: Negative Predictive value; LR+: Positive Likelihood ratio: LR-: 
Negative Likelihood ratio 
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Figure 1- Decision tree for disabling disease 
 
Figure 2- Decision tree for surgery 
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Figure 3- Decision tree for reoperation 
 
 
 
  
6. PREDICTION
104
	 17	
Figure 4- Proportion and 95% confidence interval of outcome in derivation and 
validation cohort 
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Figure 5- AUC  
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Figure 5- AUC  
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7. Discussion and recommendations
Being a chronic disease, and with non-curative therapeutic approaches, the prognosis of inflammatory
bowel disease has a huge importance for both the patients and the clinicians. Given this, it is important to
develop models which can predict the major outcomes with only few factors and as soon as possible. One of
the most important groups of factors are clinical and demographical because they are easy to collect and do not
depended on external methods, such as genetic or serologic ones. In recent years, different disease outcomes
have been studied, namely disabling disease and reoperation for Crohns disease and colectomy for ulcerative
colitis, and different factors were identified to be related with those outcomes. In this thesis, two systematic
reviews with meta-analysis were developed to identify outcomes, and clinical and demographical factors which
can predict those outcomes. In ulcerative colitis, the major event that may significantly affect the patients in
terms of quality of life and mortality is colectomy [Baumgart and Sandborn, 2007]. The probability of having
an abdominal surgery in these patients is around 25% in the first 10 years of the disease but half of them occur
in the first year after diagnosis and colectomy rate is around 10%. Factors such as gender, smoking habits,
disease extent, need for corticosteroids and hospitalization are all associated with colectomy [Dias et al., 2015].
7.1 Disabling disease
In Crohns disease, disabling disease was studied and factors such as age at diagnosis, perianal disease, location
and initial use of steroids were isolated as independent prognostic factors [Dias et al., 2013]. However, the
concept of disabling disease, introduced by Beaugerie et al.[Beaugerie et al., 2006] in 2006, is not consensual;
in fact, disabling is a dynamic concept, which necessarily changes with the evolution of medical techniques and
the different strategies followed to achieve disease control. Beaugerie et al.´s definition is the presence of at
least one of the following criteria: two steroid courses required and/or steroid dependency; further hospitalisa-
tion after diagnosis or complications of the disease; chronic symptoms; immunosuppressive therapy; intestinal
resection or surgical operation for perianal disease. This definition was used by Lolly et al. [Loly et al., 2008],
in 2008 but, in 2011, Yang et al. [Yang et al., 2011] presented a study of disabling disease with the definition
not including chronic symptoms. In our studies, we have chosen to use a stricter definition of global disabling
disease, defining precise criteria: abdominal surgery, hospital admissions, course of steroids/year, steroid de-
pendence or refractoriness, need to switch immunosuppressors or anti-TNF, and the appearance of new clinical
events (abscesses, fistula, anal disease, stenosis). This change was motivated by the new concept of early
starting immunosuppression, within a window of disease opportunity, instead of using it as the end of route.
From our original studies of independent cohorts of Crohn´s patients, some clinical/demographical factors,
as well as the impact of early approaches (surgery or immunosuppression), were identified as relevant for the
studied outcomes.
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The rate of disabling disease events were considerably high and did not differ between the two therapeutic
choices (surgery: 77%, or immunosuppression: 76%, p=0.770). Concerning the surgical group there were
no differences among patients with different immunosuppression starting points in the occurrence of disabling
disease (p=0.372). The same scenario was observed in the immunosuppression group with no difference in
the rate of disabling disease (p=0.487). When analysing the time to disabling disease adjusted to all variables
(gender, age at diagnosis, location, behaviour, upper tract involvement and perianal disease) there were also
no differences between the two groups (HR=0.963 [0.771-1.202]). This study shows that neither early surgery
nor early immunosuppression can prevent the occurrence of disabling events in CD patients.
When we studied only patients with a surgical intervention, disabling disease was observed in 75% of
the patients. Factors such as location (colonic disease: OR=2.615 [1.125-0.078]), upper tract involvement
(OR=2.593 [1.125-6.078]) and a longer time elapsed from diagnosis to first surgery (13-36 months: OR=2.754
[1.538-4.934] and 36 months: OR=2.114 [1.318-3.235] presented a higher risk of disabling disease. Overall,
the timing of therapeutic strategies affects the CD outcomes and an early surgery (within six months after
diagnosis) can decrease the occurrence of disabling events.
Different prognostic models for disabling disease were derived using only clinical/demographical data. In
the first one, Bayesian networks were used, achieving an AUC of 78% for the prognosis of disabling disease.
Age at diagnosis, perianal disease, behavior and early therapeutic decision were found to be significant factors
and used to create user-friendly matrices depicting the probability of having disabling disease, exhibiting good
rule-in performance for the most important criteria: positive post-test odds=8.00 [2.72-23.44]. This value
gives us improved safety in applying the matrices, since the odds of having disabling disease, having a positive
test, are extremely high. A second model was developed, inducing a decision tree from the cohort data. The
induced decision tree resulted in a three-level model of variables: first level included behavior phenotype, a
two-way split with the risk of disabling for B1 (54%) apart from that of B2 and B3 phenotypes (80%); the
second level considered the existence of perianal disease; location and gender were then included at the third
level. Overall, patients with phenotypes B2 or B3 have a higher risk of disabling disease, while for pheno-
type B1, gender plays an important role, with female patients having a higher risk than males. Again this
model exhibited good rule-in performance, with positive post-test odds of 4.24 [3.09-5.81]. The variables
chosen by both methods were the same used in previous studies, showing the robustness of these algorithms
[Beaugerie et al., 2006, Loly et al., 2008, Yang et al., 2011] and with good performance in the validation co-
horts.
7.2 Surgery and Reoperation
Surgery has also an important impact in patients quality of life. Fifty percent of patients undergo surgery in
the initial 10 years after diagnosis of CD [Carter et al., 2004, Peyrin-Biroulet et al., 2010], whereas a total of
80% is estimated to need surgery during the course of the disease [Moss, , Cosnes et al., 2002]. An induced
decision tree, computed with all variables, resulted in a two-level model of variables: the first one included
behavior phenotype, with different risk levels for B1 (16%), B2 (68%) and B3 (75%); the second level included
information on upper track involvement (L4) and gender, i e, patients with a B3 phenotype have a higher risk
of surgery than those with a B1 behavior, and this risk is further aggravated in male B3 patients. This model
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exhibited good rule-out performance, with negative post-test odds for surgery of 0.15 [0.09-0.23], i.e. when
the model predicts the absence of need for surgery, the odds of actually needing it are very low.
Recurrence, including reoperation, is also extremely frequent and affects 40% to 80% of CD patients
[Bernell et al., 2000, Olaison et al., 1992]. Some clinical/demographical factors, as well as the impact of early
approaches (surgery or immunosuppression), were identified and evaluated.
Concerning the impact of early approaches, our results show differences between surgery and immunosup-
pression approaches, and also relevant is the different time point at which the patients start immunosuppression
therapy. When we studied only patients with the first abdominal surgery after diagnosis, the achieved rate
of reoperation of 33% was the same as the value presented in a recent meta-analysis [Frolkis et al., 2014]
for the 10-years risk of reoperation. Multiple risk factors patient-related, disease-related and surgery-related
have already been identified and used to predict this outcome, but the literature is not consensual on this
issue [Vaughn, 2014]. In our study, some risk factors were identified, namely age at diagnosis, disease pheno-
type, perianal disease and the introduction of pharmacological medication. A few studies have been published
associating the introduction of medical therapeutics, namely immunosuppression, with reoperation. Immuno-
suppression was considered to be relevant in the CD management particularly when introduced before or after
surgery as a prophylactic therapy [Vaughn, 2014]. Our study was not entirely conclusive in this regard, but
highlighted the increased risk for patients beginning medical therapeutics only one month after surgery.
Different prognostic models for reoperation were also derived using only clinical/demographical data. In
the first one (using Bayesian networks) achieved an AUC of 86% for the prognosis of reoperation. Age at
diagnosis, perianal disease, behavior and early therapeutic decision were found to be significant factors and
used to create user-friendly matrices depicting the probability of needing reoperation, exhibiting good rule-out
performance for the most important criteria: negative post-test odds=0.02 [0.00-0.11]. This value gives us
improved safety in applying the matrices, since the odds of needing reoperation, having a negative test, are
extremely low. A second model was developed, also inducing a decision tree from the cohort data. The induced
decision tree, computed with all variables plus therapeutics used during the disease, resulted in a three-level
model of variables: first one included the moment of anti-TNF therapeutics, singling out those with more
than 1 month after surgery (53% risk) from the remaining (29% risk); the second level included behavior
(stratified in B1 vs B2/B3) and immunosuppression therapeutics, discriminating between those without or
only before surgery, and the remaining; the third level considered disease location (L1 vs L2/L3). Overall,
patients with a later introduction of pharmacological intervention (1 month after initial surgery) had a worse
outcome, i.e, they have a higher probability of undergoing more than one surgery during the disease course.
However, reoperation stood out as a harder outcome to predict, perhaps signalling a need for other factors
to be included in the model, although negative post-test odds of 0.5 [0.24-1.01] suggests the model might
nonetheless be useful to rule out patients.
7.3 Recomendation
Overall, clinical and demographical factors should be used more frequently in the prognosis of IBD because
they are easier to collect than serologic or genetic ones. Factors such as age at diagnosis, behavior, perianal
disease, and location are important predictors for negative outcomes and should, as soon as possible, be known.
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Concerning interventions, immunosuppression, as the first therapy after diagnosis, is effective in preventing
future surgeries, being its efficiency higher upon an early start. On the other hand, patients undergoing an early
surgery after diagnosis have an increased tendency to be re-operated, even with a concomitantly early start of
immunosuppression therapy. Given this, predictive models for CD prognosis could enhance the initial approach
and, therefore, improve the clinical outcome. Likewise, models for ulcerative colitis must be developed using
the same strategies and data. Finally, software or paper tools that could bring such models into bedside
application are welcome and should be pursued, while cost-effectiveness studies should be run to evaluate the
impact of such models/tools in clinical practice and in the prevention of new cases with negative prognosis.
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Abstract— Crohn's disease is one type of inflammatory bowel 
disease whose incidence is currently increasing, and may affect 
any part of both the small and large intestine, possibly 
irritating deeper layers of the organs. Being a chronic disease, 
neither treatment nor surgery actually heals the patients. Thus, 
focus has been given to identifying good prognostic models 
based on clinical factors since they are more easily included in 
daily practice. The aim of this work is to provide an initial 
study on the adequacy of a Bayesian network model to enhance 
the prognosis prediction for patients with Crohn's disease. 
Multicentric study data of patients with surgery or 
immunosuppression in the six month after diagnosis was used 
to derive a Bayesian network, focusing on the prognosis and 
the analysis of factors interaction, including clinical features, 
disease course, treatment, follow-up plan, and adverse events. 
Two models were evaluated (naïve Bayes and Tree-Augmented 
Naïve Bayes) and also compared with logistic regression, using 
cross-validation and ROC curve analysis. Preliminary results 
showed competitive accuracy (above 75%) and discriminative 
power (above 70%). The generated models presented 
interesting insights on factor interaction and predictive ability 
for the prognosis, supporting their use in future clinical 
decision support systems. 
Keywords: prognosis; Crohn’s disease; clinic decision 
support; Bayesian network models 
I.  INTRODUCTION  
Inflammatory bowel disease (IBD) is a chronic and 
progressive disease, subject to relapse and possibly 
disabling, with unknown etiology. Nonetheless, the 
interaction between genetic and environmental factors is also 
believed to play a role in both the etiology and pathogenesis 
of the disease, which can occur at any time in life but is 
usually diagnosed between the second an third decade of life 
[1]. 
The clinical course is usually characterized by 
intermittent relapses, with half the patients expressing a mild 
disease with low levels of relapse. The more aggressive cases 
usually require surgery [2] but, being a chronic disease, 
neither treatment nor surgery actually heals the patients, 
yielding frequent medical visits and hospitalizations, which 
in turn creates uncertainty about the professional and social 
future of patients and their families [3].  
This is particularly true since in the last decades the 
medical treatment options have been dramatically 
changed. Other strategies are now approaching, namely 
accelerate step-up and top down treatment]. The top-down 
strategy is based on the very early use of intensive therapy 
(immunosuppressive and/or biologics) to maintain a good 
quality of life from the first flare-up of the disease and 
prevent any irreversible consequences [4]. Therefore, it 
is now crucial to identify simple clinical criteria at 
diagnosis to predict CD outcome. 
Besides the classical approach of controlling the 
symptoms, recent studies have been focusing on quality of 
life improvement and hospitalization and surgery reduction. 
Since the treatment plan clearly affects the disease course, 
focus has been given to identifying good prognostic models 
based on genetic/serological and clinical/demographic 
factors, especially the latter since they are more easily 
included in daily clinical practice [5], [6]. 
But the studies developed to improve the prognosis have 
been struggling as the different published studies show 
heterogeneous results, likely the result of using different 
methodologies and/or applying different criteria for selection 
and evaluation. In addition, predicting the prognosis is a task 
of considerable uncertainty, so the development of predictive 
models also requires research. Although prognostic models 
are utterly required, they are, unfortunately, not widely 
studied. Moreover, the complicated nature of real-world 
biomedical data has made it necessary to look beyond 
traditional biostatistics [7]  without losing the necessary 
formality. For example, naive Bayesian approaches are 
closely related to logistic regression [8]. Bayesian statistical 
methods allow taking into account prior knowledge when 
analyzing data, turning the data analysis into a process of 
updating that prior knowledge with biomedical and health-
care evidence [9], which offers a general and versatile 
approach to capturing and reasoning with uncertainty in 
medicine and health care [7]. On a general basis, a Bayesian 
network represents a joint distribution of one set of variables, 
specifying the assumption of independence between them, 
with the inter-dependence between variables being 
represented by a directed acyclic graph [10], and their 
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applicability to other clinical domains – with high levels of 
uncertainty – has been already widely studied [11] and 
present thus a valuable approach for studying disabling in the 
context of Crohn’s disease. 
The aim of this work is to initiate the study of developing 
Bayesian networks for the predictive prognosis of patients 
with Crohn’s disease.  
II. MATERIAL AND METHODS 
Multicentric study data of Crohn’s patients with surgery 
or immunosuppression in the first six months after diagnosis 
with more than 18 years old and at least 3 years of follow 
were included. A total of 591 patients were included (out of 
668 patients collected). Seventy-seven patients were 
excluded because of missing values.  
A. Studied variables and outcomes 
Data collection included the characterization of patient 
and illness (data of diagnosis, data of surgery or 
immunosuppression, gender, age at diagnosis, disease 
location, behavior and presence of perianal disease), follow-
up data (total number of surgeries and hospitalization; 
treatment, namely corticoids, immunosuppressives or ANTI-
TNF and adverse events - stenosis, abscess, perforation and 
anal disease).  The variable event was calculated after data 
collection to express the happening of surgery, surgery in the 
first 6 months after diagnosis and immunossupressives up to 
2 months after surgery, surgery and immunossupressives 
more than 2 months after surgery and immunossupressives in 
the first 6 months after diagnosis.  
The main outcome of this study was disabling disease 
defined by the presence of at least one of the following 
criteria: more than one surgery (excluding the first); more 
than two hospitalizations (excluding the first); two steroids 
course requirements per year, steroids dependency, steroids 
refractory; need to switch immunosuppressives or Anti-TNF 
therapy; adverse events.   
B. Model building and evaluation  
Logistic regression was applied to all studied variables to 
predict disabling. Additionally, two Bayesian network 
classifiers were built – Naïve Bayes (NB) and Tree 
Augmented Naïve Bayes (TAN) – which differ on the 
number of conditional dependences (besides the outcome) 
allowed among variables (NB: zero dependences; TAN: one 
dependence), in order to choose the structure which could 
better represent the problem. 
To assess the general structure and accuracy of learned 
models, stratified 10-fold cross-validation was repeated 10 
times, estimating accuracy, sensitivity, specificity, precision 
(positive and negative predictive values) and the area under 
the ROC curve, for all compared models. 
Logistic regression was applied with R package stats 
[12], Bayesian network structure was learned with WEKA 
software [13], Bayesian network parameters were estimated 
with R package gRain [14], and ROC curves were computed 
with R package pROC [15]. 
 
TABLE I.  MAIN CHARACTERISTICS OF PATIENTS WITH CROHN’S 
DISEASE INCLUDED IN THE STUDY. 
 n (%) 
Event   
E1 – surgery 87 (15%) 
E2 – surgery and IMUNO<2 months 42 (7%) 
E3 – surgery and IMUNO>2 months 194 (33%) 
E4 - imuno 268 (45%) 
Gender   
Male 279 (47%) 
Female 312 (53%) 
Age at diagnosis   
A1 (<=16 years) 34 (6%) 
A2 (17-39 years) 425 (72%) 
A3 (>=40 years) 132 (22%) 
Location   
L1 – Ileal 274 (46%) 
L2 – Colonic 58 (10%) 
L3 – Ileocolic 259 (44%) 
L4 upper   
No 528 (89%) 
Yes 63 (11%) 
Behaviour   
B1 – Non structuring/non penetrating 176 (30%) 
B2 – Structuring 212 (36%) 
B3 - Penetrating 203 (34%) 
Perianal disease   
No 440 (74%) 
Yes 151 (26%) 
Disabling disease   
No 158 (27%) 
Yes 433 (73%) 
 
III. RESULTS 
The main characteristics of patients are shown in Tab. I.  
Forty five percent of patients made immunossupressives in 
the first 6 months after diagnosis and only 15% had surgery. 
Fifty three percent were female and only 6% had less than 16 
years old. Concerning location 46% had ileal disease and 
34% had penetrating disease.  We observed that 73% of 
patients had disabling during the course of the disease.  
A. Bayesian network model qualitative analysis 
Fig. 1 and 2 show the resulting qualitative models, 
where we can better inspect the additional dependencies 
introduced by the TAN model. It is interesting to note the 
association between behavior and perianal disease, location, 
age and event. Perianal disease was also associated with 
gender while event was associated with L4. 
Disabling
Gender L4 Behaviour Perianal Event Location Age
 
Figure 1.  Naïve Bayes 
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Figure 2.  Tree-Augmented Naïve Bayes 
B. Bayesian network model in-sample analysis 
 Fig. 3 and 4 present the in-sample ROC curves for NB 
and TAN models, respectively, where no specific cut off 
rises from the curves’ shape. Resulting AUC were 78.1% 
(NB) and 79.5% (TAN).  
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Figure 3.  In-sample ROC curve for Naïve Bayes 
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Figure 4.  In-sample ROC curve for Tree-Augmented Naïve Bayes 
 
C. Evaluation with cross-validation 
Aggregated results from 10 times 10-fold cross 
validation for both models are presented in Tab. II. Both 
classifiers presented good accuracy levels (>75%) and 
discriminative power (AUC > 70%). TAN approach 
presented a lower ability to identify patients with disability 
(91% vs 95%), although expressing similar precision during 
prediction (81% vs 79%). On the other hand, regarding 
patients without disabling, TAN revealed higher ability to 
identify them (40% vs 32%) at the cost of a lower precision 
for these cases (62% vs 70%). 
TABLE II.  CROSS-VALIDATION RESULTS FOR PREDICTING DISABLING 
IN CROHN’S DISEASE, USING LR, NB AND TAN MODELS. 
 LR 
% [CI95%] 
NB 
% [CI95%] 
TAN 
% [CI95%] 
Accuracy 76.18 
[75.21,77.16] 
78.09 
[77.12,79.06] 
77.31 
[76.32,78.3] 
Sensitivity 83.38 
[82.20,84.45] 
94.85 
[94.20,95.50] 
90.83 
[89.99,91.66] 
Specificity 56.60 
[54.24,58.96] 
32.37 
[30.21,34.52] 
40.40 
[38.18,42.61] 
Precision (PPV) 84.18 
[83.33,85.03] 
79.34 
[78.30,80.38] 
80.67 
[79.62,81.71] 
Precision (NPV) 55.81 
[53.83,57.78] 
70.17 
[66.78,73.57] 
61.90 
[59.01,64.8] 
AUC 76.64 
[53.83,77.91] 
76.35 
[74.98,77.73] 
74.33 
[72.83,75.83] 
 
IV. DISCUSSION 
The main contribution of this work is the preliminary 
study for the development of graphical representation models 
of uncertain knowledge existent in the characterization of 
disabling disease.  
From the qualitative models presented earlier, several 
associations improved the naïve approach. The disease 
behavior (whether it is penetrating or presenting stenosis or 
neither) appears to be directly associated with perianal 
disease (better for patients with perianal disease, which is, in 
turn, associated with male gender), location of the disease, 
event (also associated with L4) and age at diagnosis (worse 
behavior for older patients). This representational strategy 
allows an easy visualization of the model, reinforcing the 
experts with the possibility of a supported decision, not only 
by risk factors or discriminating cut points, but mostly 
supported in the interdependences of studied variables and 
their causality. 
From the quantitative analysis, the most relevant aspect 
of the proposal is that no significant decrease in predictive 
accuracy rises from the enhancement of graphical analysis of 
factor dependences, enabling a sound inspection by the 
clinical experts. Furthermore, we may note that the Tree-
Augmented Naïve Bayes might have over-adjusted to the 
training cohort (i.e. higher in-sample AUC), losing some 
generalization ability (i.e. lower quality on cross-validation), 
but this is yet to be confirmed with further validation with 
independent cohorts. 
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V. CONCLUSIONS 
This study showed a preliminary approach of Bayesian 
networks for prognosis in Crohn’s disease. These results 
show good performance indications, reinforcing the path of 
developing probabilistic graphical models for future 
inclusion in clinical decision support systems. 
Future directions include the analysis of expert-designed 
causal models, hill-climbing greedy strategies for structure 
learning, and temporal Bayesian networks for the modeling 
of temporal interdependences useful for mid- and long-term 
prognosis of Crohn’s disease course. 
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Abstract— Crohn's disease is one type of inflammatory 
bowel disease whose incidence is currently increasing, 
subject to relapse and disabling, with unknown etiology, and 
usually diagnosed between the second and third decade of 
life. The aim of this work is to develop a Bayesian network 
tool to predict disabling and reoperation in patients with 
Crohn’s disease subject to early surgery or 
immunosuppressors intake. Multi-centric study data from 
patients with surgery or immunosuppression in the first six 
months after diagnosis was used, focusing on the prognosis 
and the analysis of factors’ interaction. Patients were grouped 
by the index episode: immunosuppressors intake, and surgery 
(stratified considering the use or not of immunosuppressors 6 
months after surgery). Patient group was associated with 
disease behavior, upper gastrointestinal tract location (L4) 
and age at diagnosis, while disease extent was associated to 
perianal disease. For disabling, association between perianal 
disease and gender and location was also found. Association 
between gender and L4 was also found for reoperation. The 
cross-validated discriminative power of the models were high 
for both disabling (above 70%) and reoperation (above 80%). 
The generated models presented interesting insights on factor 
interaction and predictive ability for the prognosis, 
supporting their use in future clinical decision support 
systems. 
Keywords: prognosis; Crohn’s disease; clinic decision 
support; Bayesian network models 
I.!  INTRODUCTION  
Crohn’s disease is a chronic illness with unknown etiology 
usually diagnosed during the second and third decade of life. 
The interaction between genetic and environment factors had 
a important role in the etiology of the disease [1]. 
The disease could had along periods of remission but the 
more aggressive cases requires more aggressive interventions 
like surgery [2] but, being a chronic disease, neither treatment 
nor surgery actually heals the patients, yielding frequent 
medical visits and hospitalizations, which in turn creates 
uncertainty about the professional and social future of patients 
and their families [3].  
The treatment of Crohn’s disease has changed in the last 
decades. Strategies like step-up or top down treatments have 
been more frequently chosen. The top-down strategy is 
based on the very early use of intensive therapy 
(immunosuppressive and/or biologics) to maintain a good 
quality of life !"#$%&'(%!)"*&%!+,"(-./%#!%&'(%0)*(,*(%,10%/"(2(1&%,13%)"reversible consequences [4].  
In our day the principal focus of treatment has been the 
improvement of quality of life, reduction of surgeries or 
hospitalization, besides the sole control of symptoms. Since 
the treatment plan clearly affects the disease course, focus has 
been given to identifying good prognostic models based on 
clinical/demographic factors since they are more easily 
included in daily clinical practice [5], [6]. 
However, prognostic studies show heterogeneous results, 
likely as a result of using different methodologies and/or 
applying different criteria for selection and evaluation. In 
addition, predicting the prognosis is a considerably uncertain 
task, so the development of predictive models also requires 
research. Also, traditional biostatistics is no longer enough to 
cope with the real-world biomedical data and it is necessary 
to look to other techniques [7]. Bayesian networks are a good 
choice since they deal well with prior knowledge, collected in 
published evidence included in quality literature or in primary 
or secondary data sources, and transform the data analyses in 
a process of updating the prior knowledge with available 
evidence at inference time [9], dealing better than other 
models with the uncertainty in the data. Bayesian networks are 
represented by a qualitative model (which describes the 
relations among variables) and a quantitative model (which 
gives the joint probability of all variables) which allows the 
inspection of marginal probabilities for each variable’s state, 
and their use in the computation of a posteriori probabilities 
for single patients at inference time [10]. 
A preliminary study on the problem constituted a proof-
of-concept for the use of Bayesian network classifiers as 
prognostic predictor model for disabling of prognostic 
prediction of disabling [15]. However, a thorough follow-up 
clinical appraisal of those results revealed that the analysis of 
immunosuppressive therapy prior to six months after surgery 
was misleading, so a new definition of groups should be 
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considered. Also, an additional important outcome should be 
modelled, as clinicians usually consider the risk for 
reoperation as a decisive factor for defining the best 
intervention for those patients. 
The aim of this work is to develop Bayesian networks for 
the predictive prognosis of patients with Crohn’s disease 
subject to early surgery or immunosuppression, namely 
targeting disabling disease and reoperation. 
 
II.! MATERIAL AND METHODS 
Multi-centric study data of Crohn’s patients with surgery 
or immunosuppression in the first six months after diagnosis 
with more than 18 years old and at least 3 years of follow were 
included. A total of 489 patients were included (out of 668 
patients collected). Hundred and seventy-nine patients were 
excluded because of missing values.  
A.! Studied variables and outcomes 
This study was a retrospective study and the collected 
variables included: characterization of patients (gender), 
disease (data of diagnosis and intervention (surgery and/or 
immunosuppressors, location with or not upper 
gastrointestinal tract, behavior and perianal disease), and 
follow up data (namely number of surgery and 
hospitalizations, treatments and adverse events). Patients 
were grouped by the index episode: immunosuppressors 
intake, and surgery (stratified considering the use or not of 
immunosuppressors 6 months after surgery). 
The two main outcomes were disabling (defined by the 
presence of at least one of the following criteria: more than 
one surgery, excluding the first; more than two 
hospitalizations, excluding the first; two steroids course 
requirements per year, steroids dependency, steroids 
refractory; need to switch immunosuppressors or Anti-TNF 
therapy; adverse events) and reoperation (defined by the deed 
of second surgery). 
  
B.! Model building and evaluation 
Following the preliminary study presented previously [15], 
Tree Augmented Naïve Bayes (TAN) models were derived 
using all studied variables to predict disabling and 
reoperation. To assess the general structure and accuracy of 
learned models, stratified 10-fold cross-validation was 
repeated 10 times, estimating accuracy and the area under the 
ROC curve. 
WEKA software [12] was used to learn the Bayesian 
network structure. gRain [13] and pROC [14] R packages 
were also used to estimate de parameters of the networks and 
ROC curves, respectively. 
III.! RESULTS 
The main characteristics of patients are shown in Tab. I.  
Forty-eight percent of patients took immunosuppressors in the 
first 6 months after diagnosis and 36% had surgery with 
immunosuppressors 6 months after surgery. Forty-six percent 
were male and 21% had more than 40 years old at diagnosis. 
Concerning location 47% had ileal disease and 32% had 
penetrating disease.  We observed that 64% of patients had 
disabling during the course of the disease and 18% needed a 
second surgery.  
TABLE I. ! MAIN CHARACTERISTICS OF PATIENTS WITH CROHN’S 
DISEASE INCLUDED IN THE STUDY (N=489). 
 n (%) 
 
Event   
S0 surgery 80 (16%) 
SI surgery and immuno > 6 mo after surgery 175 (36%) 
I immunosuppression 
 234 (48%) 
Gender   
Male 225 (46%) 
 
Age at diagnosis   
A1 & A2 (<40 years) 388 (79%) 
A3 (>=40 years) 101 (21%) 
 
Location   
L1 Ileal 232 (47%) 
L2 Colonic 45 (9%) 
L3 Ileocolic 212 (43%) 
 
L4 upper   
Yes 55 (11%) 
 
Behavior   
B1 Non structuring/non penetrating 158 (32%) 
B2 Structuring 176 (36%) 
B3 Penetrating 155 (32%) 
 
Perianal disease   
Yes 125 (26%) 
 
Disabling disease 
 
314 
 
(64%) 
Reoperation 
 
89 
 
(18%) 
 
 
 
A.! Bayesian network model qualitative analysis 
The qualitative models were show in Fig 1 and 2.  Patient 
group was associated with disease behavior, upper 
gastrointestinal tract location (L4) and age at diagnosis, while 
disease extent was associated to perianal disease. 
For disabling, association between perianal disease and 
gender and location was also found. Association between 
gender and L4 was also found for reoperation.  
B.! Bayesian network model validation 
 Fig. 3 presents the in sample, leave-one-out and 10 times 
10-fold cross validation ROC curves for disabling and 
reoperation models, respectively. Resulting validation AUC 
were between 72% and 73%. (for disabling) and between 
79% and 80% (for reoperation).  
266
B.1. DISABLING AND REOPERATION IN PATIENTS WITH CROHN´S DISEASE SUBJECT
TO EARLY SURGERY OR IMMUNOSUPPRESSION: A BAYESIAN NETWORK PROGNOSTIC
MODEL. DISEASE.
133
IV.! DISCUSSION 
The main contribution of this work was the development 
of prognostic models for disabling disease and reoperation. 
This models were developed after a preliminary study [15] 
done for the adequacy of these techniques into this problem, 
where comparison with other methods, namely logistic 
regression, has been assessed. Other clinical problems were 
also already addressed in the past with good performance, 
easy interpretation and friendly representations [7], [8], [11]. 
From models presented in Fig. 1 and 2 it was possible to 
infer some known clinical associations. In both outcomes, 
patient group was associated with disease behavior (whether 
it is penetrating or presenting stenosis or neither), upper 
gastrointestinal tract location (L4) and age at diagnosis, while 
disease extent was associated to perianal disease. These 
global dependencies show a common thread for knowledge 
representation in Crohn’s disease management, specifically 
tune for each outcome considering the added associations 
between perianal disease and gender and location (found for 
disabling) and the association between gender and L4 (found 
for reoperation).  
This knowledge representation allows an easy 
visualization of the model, supporting the experts’ decision 
beyond the use of risk factors and discriminative cut points, 
into a support on the interdependences of studied variables 
and their induced causality. 
From the quantitative analysis, and following the 
discussion from previous preliminary study - which showed 
that no significant decrease in predictive accuracy rises 
(beyond the naïve Bayes approach) with the enhancement of 
graphical analysis of variables’ dependences - the Tree 
Augmented Naïve Bayes proved to be an accurate prognostic 
model, usable in clinical settings, even though it might (as 
expected) slightly over fit the training cohort (i.e. higher in-
sample AUC), losing some generalization ability (i.e. lower 
quality on cross-validation). Further analysis shall confirm 
such suspicions using independent cohorts. 
V.! CONCLUSIONS 
The cross-validated evaluation of the Bayesian network 
classifiers derived in this study resulted in high accuracy and 
discriminative power for both disabling (above 70%) and 
reoperation (above 80%) outcomes in Crohn’s disease 
patients subject to early surgery or immunosuppression. The 
generated models presented interesting insights on factor 
interaction and predictive ability for the prognosis, 
supporting their use in future clinical decision support 
systems. 
Current path of research includes the definition of 
clinically usable decision support tools, based on the hereby 
derived Bayesian network classifiers and temporal Bayesian 
networks for the modeling of temporal interdependences 
useful for mid- and long-term prognosis of Crohn’s disease 
course, taking into account the specific modeling of 
immunosuppressors intake. 
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Figure 1. ! Modeling disabling in Crohn’s disease patients subject to early surgery or immunosuppression – Tree Augmented Naïve Bayes 
 
Figure 2. ! Modeling reoperation in Crohn’s disease patients subject to early surgery or immunosuppression – Tree Augmented Naïve Bayes 
 
Figure 3. ! In sample , leave-one-out and 10 cross validation ROC curves of TAN models for disabling and reoperation outcomes. 
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C. Using the Bayesian net

C. Using the Bayesian net
CrohnBayes Online Clinical Decision Tool
This appendix presents screenshots of CrohnBayes (Figure C.1), an online clinical decision tool for direct
Bayesian network inference, which queries the models built in this thesis, providing the user with:
Figure C.2 an estimate of the risk for a subgroup of patients, or a patient with missing observations.
Figure C.3 an individualized risk estimate for the patient, having all included variables been observed.
CrohnBayes was developed with the invaluable help of Raphael Oliveira and Pedro Pereira Rodrigues.
The most recent (beta) version of the tool is available for academic review at
http://servicosforms.gim.med.up.pt/form test/crohnbayes.html
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Figure C.1: CrohnBayes: Online clinical decision tool
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Figure C.2: CrohnBayes: Example of use with missing observations
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C. USING THE BAYESIAN NET
Figure C.3: CrohnBayes: Example of use with all included variables
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